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A bstract
The am ylo id  precursor p ro tein  (APP) has been extensively stud ied  in re la tion  to  
A lzheim er's  disease, b ut th e  physiological function  o f th e  p ro te in  has y e t to  be d e te rm in e d . 
O ne possible ro le fo r APP m ay be to  p ro tect cells against th e  d e trim e n ta l effects o f excess 
copper. In th e  cu rren t study I have investigated w hich regions o f th e  APP m olecule  
p artic ip ate  in th is p u ta tive  fu nctio n . I have used both D u l4 5  and SH-SY5Y m am m alian  cell 
system s to  exp lo re  this question , re lating  th e  g enera ted  results to  both cancer and  
A lzheim er's  Disease. Initial studies using w es te rn  b lo tting  show ed th a t a range o f prostate  
cancer cell lines express APP, and th a t increased APP expression levels m ay represent a m ore  
advanced stage o f cancer progression. Exogenous copper a lte red  th e  expression levels o f  
APP in D u l4 5  cells, im m e d ia te ly  indicating th e  in tricate re lationship  b e tw ee n  APP and  
copper. Subsequently, using M TS assays, I found th a t APP can indeed enhance cell v iab ility  in 
th e  face o f copper, in both  o f th e  cell systems stated above. This role is isoform  d ep en d en t, 
being specific to  th e  APP 6 9 5  isoform , w hich is p red o m inantly  found in th e  brain. N -te rm in a l 
copper binding and copper binding w ith in  th e  A(3 region o f th e  APP ho loprote in  appeared  to  
be a prerequis ite  fo r this action. The in trace llu lar dom ain  was also requ ired  in o rd er to  
enhance cell v iability , and th e  im p ortan ce o f this region was assigned to  specific tyrosine  
residues w ith in  th e  dom ain . APP over-expression in D u l4 5  cells also appeared  to  induce a 
partia l ep ithe lia l to  m esenchym al trans ition  o f th e  cells. A long w ith  suggesting a possible 
physiological function  fo r APP, these data suggest th a t p rostate  cancer ep ithe lia l cells 
m etastasising to  th e  brain m ight utilise APP to  p ro tect th em  against th e  increased copper  
levels found  in this organ.
2
The Am yloid  Precursor P rotein  and Cell V iab ility  in Diseases o f th e  Ageing B ra in ..........................1
A b s tra c t..................................................................................................................................................................................2
Table o f C o n te n ts ..............................................................................................................................................................3
List o f fig u re s ....................................................................................................................................................................... 9
List o f T a b le s .................................................................................................................................................................... 12
A ckn o w led g em en ts ....................................................................................................................................................... 13
1. L ite ra tu re  R e v ie w ............................................................................................................................................ 14
1.1 . In tro d u c tio n .......................................................................................................................................................15
1.2. A lzheim er's  D is e a s e ..................................................................................................................................... 15
1 .2 .1 . Incidence and a e tio lo g y ...................................................................................................................15
1 .2 .2 . P atho logy................................................................................................................................................. 17
1 .2 .3 . Diagnosis and tre a tm e n t ..................................................................................................................19
1.3 . Prostate C ancer................................................................................................................................................20
1 .3 .1 . Incidence and a e tio lo g y ...................................................................................................................21
1.3 .2 . P a th o lo g y ................................................................................................................................................22
1.3 .3 . Diagnosis and tre a tm e n t ................................................................................................................. 23
1.4 . The am ylo id  precursor p ro tein  (APP)....................................................................................................24
1.4 .1 . APP s tru c tu re ........................................................................................................................................25
1 .4 .1 . APP proteo lysis..........................................................   26
1 .4 .2 . Am ylo idogenic processing.............................................................................................................. 26
1 .4 .3 . N o n-am ylo idogen ic  processing.................................................................................................... 28
1.5 . Lipid rafts and APP proteo lysis ................................................................................................................32
1.6 . The physiological role o f APP and its m e ta b o lite s ..........................................................................32
1 .6 .1 . Functions o f th e  APP h o lo p ro te in ............................................................................................... 33
1 .6 .2 . Functions o f th e  APP cytosolic d o m a in .....................................................................................35
1 .6 .3 . Functions o f sA PPa............................................................................................................................. 39
1 .6 .4 . Functions o f sAPPP............................................................................................................................. 41
1.6 .5 . Functions o f th e  soluble A IC D ....................................................................................................... 42
1 .6 .6 . Functions o f (3-amyloid p ep tid es ..................................................................................................43
1.7 . APP and m etals - c o p p e r............................................................................................................................. 43
1.7 .1 . C opper binding to  th e  APP ec to d o m ain ................................................................................... 44
1.7 .2 . C o p per-m ed iated  APP expression...............................................................................................45
1 .7 .3 . C o p per-m ed iated  APP p ro teo lys is ..............................................................................................4 6
3
1 .7 .4 . APP and copper hom eostas is ........................................................................................................ 47
1 .7 .5 . APP and th e  reduction  o f d ivalen t c o p p e r.............................................................................. 49
1 .7 .6 . C opper in A3 a g g re g a tio n ............................................................................................................... 51
1.8 . APP and m etals -  iro n .................................................................................................................................52
1 .8 .1 . Iron in th e  expression and proteolysis o f A P P ...................................................................... 52
1 .8 .2 . APP and th e  m etabolism  o f i r o n ..................................................................................................53
1 .8 .3 . Iron and th e  A 3 p e p tid e ................................................................................................................... 53
1 .9 . The roles o f APP and copper in A lzheim er's  d is ea se .................................................................... 53
1 .9 .1 . M echanism s o f A 3 -m ed ia te d  n eu ro tox ic ity ...........................................................................54
1 .9 .2 . C opper and A lzheim er's  disease p ath ogenes is ....................................................................55
1 .1 0 . The roles o f APP and copper in c a n c e r ............................................................................................... 56
1 .1 0 .1 . APP and c a n c e r ................................................................................................................................56
1 .1 0 .2 . APP and prostate  c a n c e r............................................................................................................. 60
1 .1 0 .3 . C opper and cancer pathogenesis ............................................................................................ 61
1 .1 1 . Aims o f th e  cu rren t p ro je c t...................................................................................................................... 65
2. M a te ria ls  and M e th o d s ...................................................................................................................................... 6 8
2 .1 . M a te r ia ls ........................................................................................................................................................... 69
2.2 . M o le cu la r b io lo g y .........................................................................................................................................70
2 .2 .1 . P reparation  o f agar p la te s .............................................................................................................. 70
2 .2 .2 . Bacterial tra n s fo rm a tio n .................................................................................................................70
2 .2 .3 . Bacterial suspension cu ltures........................................................................................................70
2 .2 .4 . DNA p u rifica tio n ..................................................................................................................................70
2 .2 .5 . S pecto p ho to m etric  quantification  o f D N A ............................................................................71
2 .2 .6 . Agarose gel e lectro p ho res is .......................................................................................................... 71
2 .2 .7 . S ite-d irected  m utagenesis polym erase chain reaction (P C R ).......................................... 72
2 .2 .8 . Restriction enzym e digests /  DNA lin ea riza tio n ................................................................... 73
2 .2 .9 . E thanol prec ip itation  o f plasm id D N A .......................................................................................73
2.3 . M am m a lian  cell c u ltu re ...............................................  74
2 .3 .1 . G ro w th  incubations........................................................................................................................... 74
2 .3 .2 . Freezing dow n cell stocks............................................................................................................... 74
2 .3 .3 . Cell co unting ..........................................................................................................................................74
2 .3 .4 . T ransient transfection  using lip o fe c ta m in e ...........................................................................75
2 .3 .5 . Stable transfection  using lip o fe c ta m in e ................................................................................. 75
2 .3 .6 . Stable transfection  o f D u l4 5  cells using n u c le o fe c tio n ................................................... 76
4
2 .3 .7 . Stable transfec tio n  using e le c tro p o ra tio n ................................................................................76
2 .3 .8 . Small in te rfe rin g  RNA (siRNA) transfection  o f D u l4 5  ce lls ...............................................77
2.4 . P rotein  analys is ................................................................................................................................................79
2 .4 .1 . P repara tion  o f concentra ted  conditioned  m ed iu m  sam ples and cell ly s a te s  79
2 .4 .2 . Bicinchoninic acid (BCA) pro te in  as s a y ...................................................................................... 80
2 .4 .3 . Sodium  dodecylsu lphate - polyacrylam ide gel electrophoresis (SDS-PAGE) 82
2 .4 .4 . Im m u n o b lo tt in g .....................................................................................................................................83
2 .4 .5 . Im m u n o b lo ttin g  Stripping and re -prob ing  W este rn  B lo ts................................................ 84
2 .4 .6 . A m ido  black s ta in in g ........................................................................................................................... 84
2 .5 . Lipid ra ft is o la tio n ......................................................................................................................................... 85
2 .6 . Cell v iab ility  and m orphology analysis ................................................................................................. 85
2 .6 .1 . M e th a n e th io s u lfo n a te  (M TS) cell v iab ility  assay...................................................................85
2 .6 .2 . Cell m orphology docum en tation  using optical m icroscopy..............................................8 6
2 .7 . Im m obilized  m eta l chela te a ffin ity  chrom atography ( IM A C ).................................................. 8 6
2 .8 . Statistical an a ly s is ..........................................................................................................................................87
3. C haracterisation  o f constitu tive  w ild -typ e  APP expression and proteolysis in cell lines 8 8
3 .1 . In tro d u c tio n ......................................................................................................................................................89
3 .2 . APP expression and p ro teo lys is ..............................................................................................................89
3.3 . The e ffec t o f d ih ydro tes tos terone on APP expression and proteolysis in LNCaP cells
.................................................................................................................................................................................95
3 .4 . a -secretase ex p res s io n ............................................................................................................................... 98
3 .4 .1 . A D A M 1 0  expression ......................................................................................................   98
3 .4 .2 . A D A M 17  expression ..........................................................................................................................99
3 .4 .3 . The e ffe c t o f d ih ydro tes tosterone on A D A M 10  and A D A M 17 expression in 
LNCaP c e lls ............................................................................................................................................................... 100
3 .5 . S u m m a ry .............................................................................................................................................. 102
4. The effects o f co p per on endogenous APP expression and proteolysis in p rostate  cancer 
ep ithe lia l c e lls .............................................................................................................................................................. 103
4 .1 . In tro d u c tio n ........................................................................................................................................104
4 .2 . The e ffec t o f copper on LNCaP cell v ia b ility ....................................................................... 104
4 .3 . The e ffec t o f copper on th e  expression and shedding o f endogenous APP in LNCaP
cells.................................................................................................................................................................................... 106
4 .4 . The e ffec t o f copper on PC-3 cell v ia b ility ........................................................................... 110
4 .5 . The effect o f copper on th e  expression and shedding o f endogenous APP in PC-3
cells....................................................................................................................................................................................H I
5
4 .6 . The e ffec t o f copper on D u l4 5  cell v ia b ility ....................................................................................113
4 .7 . The e ffec t o f copper on th e  expression and shedding o f endogenous APP in D u l4 5
cells..................................................................................................................................................................................... 114
4 .8 . S u m m a ry ........................................................................................................................................................... 117
5. The e ffe c t o f fu ll-len g th  APP construct expression on D u l4 5  cell v iab ility  in th e  presence o f
co p p e r............................................................................................................................................................................... 119
5 .1 . In tro d u c tio n ..................................................................................................................................................... 120
5 .2 . Endogenous APP transcrip t analysis in D u l4 5  cells......................................................................120
5 .3 . O ver-expression o f APP isoform  constructs in D u l4 5  ce lls ...................................................... 123
5 .4 . The e ffec t o f APP isoform  over-expression on D u l4 5  cell v iab ility  in th e  presence o f
c o p p e r..............................................................................................................................................................................125
5 .5 . The e ffec t o f ab lating  endogenous APP expression on D u l4 5  cell v iab ility  in th e
presence o f c o p p e r .................................................................................................................................................... 128
5 .6 . S u m m a ry ........................................................................................................................................................... 130
6 . The APP cytosolic dom ain  is a prerequis ite  fo r enhanced D u l4 5  cell v iab ility  in th e  
presence o f c o p p e r ....................................................................................................................................................132
6 .1 . In tro d u c tio n .....................................................................................................................................................133
6.2 . The expression and proteolysis o f APP cytosolic dom ain m u ta n t constructs in D u l4 5
cells.....................................................................................................................................................................................133
6 .3 . The effects o f APP cytosolic dom ain  m utations on th e  viability  o f D u l4 5  cells in th e
presence o f c o p p e r ....................................................................................................................................................137
6.4 . APP regulates th e  ra ft association o f c a v e o lin -1 ...........................................................................137
6 .5 . P otentia l in trace llu lar signalling pathw ays influenced by APP o ver-ex p ress io n  142
6 .6 . S u m m a ry ........................................................................................................................................................... 145
7. The APP ectod o m ain  and enhanced D u l4 5  cell v iability  in th e  presence o f c o p p e r  147
7 .1 . In tro d u c tio n .....................................................................................................................................................148
7 .2 . The expression and proteolysis o f th e  APP copper binding dom ain  construct in D u l4 5
cells.................................................................................................................................................................................... 149
7 .3 . The e ffec t o f E l copper binding dom ain  m utations on th e  viability  o f D u l4 5  cells in
th e  presence o f c o p p e r............................................................................................................................................152
7 .4 . The role o f th e  soluble APP ectodom ain  in prom oting  D u l4 5  cell v iab ility  in th e
presence o f copper; stable o ver- expression o f s A P P a ........................................................................... 154
7.5 . The role o f th e  soluble APP ectodom ain  in prom oting  D u l4 5  cell v iab ility  in th e
presence o f copper; inh ibition  o f endogenous ectodom ain  g e n e ra tio n ......................................... 158
7 .6 . The role o f th e  soluble APP ectodom ain  in prom oting  D u l4 5  cell v iab ility  in th e
presence o f copper; th e  e ffec t o f recom binant sAPP[3............................................................................ 163
7.7 . S u m m a ry ........................................................................................................................................................... 165
6
8 . APP-induced m orphological changes in D u l4 5  c e lls ............................................................................167
8 .1 . In tro d u c tio n ................................................................................................................................................... 168
8 .2 . The e ffe c t o f APP6 9 5  over-expression  on D u l4 5  cell m o rp h o lo g y .......................................168
8 .3 . APP695-induced m orphological changes in D u l4 5  cells are n ot associated w ith  
neuro en do crin e  d if fe re n tia t io n ........................................................................................................................... 168
8 .4 . APP695-induced m orphological changes in D u l4 5  cells are associated w ith  ep ith e lia l- 
to -m esen ch ym al tra n s it io n .....................................................................................................................................172
8 .5 . APP-induced ep ith e lia l-to -m esen ch ym al trans ition  in D u l4 5  cells is isoform  specific 
..............................................................................................................................................................................174
8 .6 . The APP6 9 5  cytosolic dom ain  is involved in ep ithe lia l-to -m esen ch ym al trans ition  in 
D u l4 5  ce lls ......................................................................................................................................................................177
8 .7 . The E l co p per b inding dom ain  is a prerequis ite  fo r APP695-induced ep ith e lia l-to -  
m esenchym al trans itio n  in D u l4 5  c e lls ..........................................................................................................178
8 .8 . A tte m p te d  artific ia l induction o f ep ith e lia l-to  m esenchym al trans ition  by enhancing  
endogenous APP express ion ..................................................................................................................................180
8.9 . S u m m a ry ......................................................................................................................................................... 183
9. The role o f copper b inding in APP proteolysis and th e  viability  o f SH-SY5Y cells...................184
9 .1 . In tro d u c tio n ...................................................................................................................................................185
9 .2 . The expression and proteolysis o f APP6 9 5  copper binding m utan ts  in SH-SY5Y cells 185
9 .3 . The effects o f APP 6 9 5  co p per binding m utants on th e  viability  o f SH-SY5Y cells in th e  
presence o f c o p p e r .................................................................................................................................................... 189
9 .4 . The expression and proteolysis o f APP7 7 0  copper binding m utan ts in SH-SY5Y cells 190
9 .5 . The effects o f APP 7 7 0  co p per binding m utants on th e  viability  o f SH-SY5Y cells in the  
presence o f c o p p e r ....................................................................................................................................................194
9 .6 . APP binds co p per desp ite  m u ta tio n  o f th e  E l o r A(3 copper binding d o m a in s  195
9 .7 . S u m m a ry ......................................................................................................................................................... 196
10. Discussion................................................................................................................................................................199
10 .1 . In tro d u c tio n .................................................................................................................................................. 200
10 .2 . Characterisation  o f co nstitu tive  w ild -typ e  APP expression and proteolysis in cell lines 
 200
10 .3 . The effects o f co p per on endogenous APP expression and proteolysis in prostate  
cancer ep ithe lia l ce lls ................................................................................................................................................2 0 2
10 .4 . The e ffec t o f fu ll-len g th  APP construct expression on D u l4 5  cell v iab ility  in th e  
presence o f  c o p p e r ................................................................................................................................................... 203
10 .5 . The APP cytosolic dom ain  is a prerequis ite fo r enhanced D u l4 5  cell v iab ility  in th e  
presence o f c o p p e r ................................................................................................................................................... 204
10 .6 . The APP ec tod o m ain  and enhanced D u l4 5  cell v iability  in th e  presence o f copper 207
7
10 .7 . APP-induced m orphological changes in D u l4 5  c e lls .................................................................... 210
10 .8 . The role o f copper b inding in APP proteolysis and th e  v iab ility  o f SH-SY5Y cells  212
10 .8 . Future d irec tio n s ............................................................................................................................................215
10 .9 . S u m m a ry ........................................................................................................................................................... 216
R e fe re n c e s ......................................................................................................................................................................2 1 8
8
ILIsc o*i iiigui 0s
Figure 1.1. The pathological hallm arks o f A lzheim er's  d isease............................................................... 18
Figure 1.2 . UK prostate  cancer statistics fro m  2 0 0 8 -2 0 1 0 ....................................................................... 21
Figure 1.3. Schem atic o f APP fu nctio n al dom ains and copper binding sites.....................................26
Figure 1.4 . Proteolysis o f th e  am ylo id  precursor p ro tein  via th e  am ylo idogenic and non-
am ylo idogenic processing p a th w a ys .................................................................................................................... 27
Figure 1.5. Schem atic o f th e  y-secretase m ed ia ted  cleavage o f APP................................................... 29
Figure 1.6. Protein  binding in teractions o f th e  am ylo id  precursor p ro te in  in trace llu lar
d o m a in ................................................................................................................................................................................ 36
Figure 3 .1 . APP expression levels in cell lysates..............................................................................................91
Figure 3.2 . sAPPa shedding in to  conditioned  cu lture m e d iu m ............................................................... 92
Figure 3 .3 . sAPPP in conditioned  cell cu lture m e d iu m ................................................................................ 9 4
Figure 3 .4 . The e ffe c t o f DHT on APP expression in LNCaP cells............................................................ 95
Figure 3 .5 . The e ffe c t o f DHT on sAPPa shedding fro m  LNCaP cells.................................................... 96
Figure 3 .6 . The e ffe c t o f DHT on sAPP(3 release from  LNCaP cells........................................................ 97
Figure 3.7 . A D A M 10  expression in cell lysates................................................................................................99
Figure 3 .8 . A D A M 17  expression in cell lysates............................................................................................. 100
Figure 3 .9 . The e ffec t o f DHT on A D A M 1 0  expression in LNCaP cells............................................... 101
Figure 3 .10 . The e ffe c t o f DHT on A D A M 1 7  expression in LNCaP cells.............................................101
Figure 4 .1 . The e ffec t o f copper on LNCaP cell v iab ility ...........................................................................105
Figure 4 .2 . The e ffec t o f copper on APP expression in LNCaP cells.................................................... 107
Figure 4 .3 . The e ffe c t o f copper on soluble APP production fro m  LNCaP cells.............................109
Figure 4 .4 . The effect o f copper on PC-3 cell v iab ility ...............................................................................110
Figure 4 .5 . The e ffec t o f copper on APP expression in PC-3 cells....................................................... 112
Figure 4 .6 . The e ffec t o f copper on soluble APP production from  PC-3 cells.................................112
Figure 4 .7 . The e ffec t o f copper on D u l4 5  cell v iab ility ........................................................................... 113
Figure 4 .8 . The e ffec t o f copper on APP expression in D u l4 5  cells................................................... 115
Figure 4 .9 . The e ffec t o f copper on soluble APP production fro m  D u l4 5  cells............................116
Figure 5 .1 . Endogenous APP transcrip t expression in D u l4 5  cells......................................................122
Figure 5 .2 . Schem atic showing th e  APP isoform  constructs used in th e  cu rren t s tu d y 123
Figure 5 .3 . APP isoform  over-expression in D u l4 5  cells..........................................................................124
Figure 5 .4 . Soluble APP produced by D u l4 5  cells over-expressing APP isoform
constructs....................................................................................................................................................................... 125
Figure 5 .5 . The effects o f APP isoform  construct over-expression on D u l4 5  cell v iab ility  in th e
9
presence o f co p p e r.................................................................................................................................................... 127
Figure 5 .6 . APP expression and proteolysis in siRNA transfec ted  D u l4 5  cells.............................. 129
Figure 5 .7 . V iab ility  o f siRNA transfec ted  D u l4 5  cells..............................................................................130
Figure 6.1. Schem atic representing  APP in trace llu lar dom ain  m u ta n t constructs...................... 134
Figure 6 .2 . APP in trace llu lar dom ain  m u ta n t over-expression in D u l4 5  cells..............................135
Figure 6 .3 . Soluble APP g enera tion  by D u l4 5  cells over-expressing APP in trace llu lar dom ain
m u ta n ts ............................................................................................................................................................................136
Figure 6 .4 . The effects o f APP in trace llu lar dom ain  m u ta n t over-expression on D u l4 5  cell
viab ility  in th e  presence o f co p p er......................................................................................................................138
Figure 6 .5 . Analysis o f p ro tein  d istribution  in sucrose gradients p rep ared  from  D u l4 5  cells
transfec ted  w ith  e ith e r vector alone, w ild -typ e  APP6 9 5  or APP695A IC D .............................................139
Figure 6 .6 . Analysis o f APP d is tribution  in sucrose gradients p repared  fro m  D u l4 5  cells
transfec ted  w ith  e ith e r vecto r alone, w ild -typ e  APP6 9 5  or APP695A IC D .............................................140
Figure 6.7 . Analysis o f caveolin-1 d is tribution  in sucrose gradients prepared  fro m  D u l4 5  cells
transfec ted  w ith  e ith e r vecto r alone, w ild -typ e  APP6 9 5  o r APP695A IC D .............................................141
Figure 6 .8 . ERK1 expression in D u l4 5  cells over-expressing APP in trace llu lar dom ain
m u tan ts ............................................................................................................................................................................143
Figure 6.9. ERK1 expression in D u l4 5  cells over-expressing APP isoform s.................................... 144
Figure 7.1 . Schem atic representing  th e  APP N -te rm in a l copper b inding dom ain  d efic ien t
construct.........................................................................................................................................................................149
Figure 7 .2 . APP N -te rm in a l copper binding dom ain  m u tan t over-expression in D u l4 5
cells.....................................................................................................................................................................................150
Figure 7.3 . Soluble APP g enera tion  by D u l4 5  cells over-expressing th e  APP6 9 sACuBD
construct.........................................................................................................................................................................151
Figure 7 .4 . The e ffe c t o f APP695ACuBD m u ta n t over-expression on D u l4 5  cell v iab ility  in th e
presence o f co p p e r................................................................................................................................................... 153
Figure 7 .5 . D etec tion  o f th e  soluble APP7 7 0  construct using th e  anti-FLAG an tib o d y ..............155
Figure 7 .6 . D etec tion  o f th e  soluble APP7 7 0  construct using th e  an tibo d y 2 2 C 1 1 ......................156
Figure 7.7 . Lack o f soluble APP7 7 0  degradation  by D u l4 5  cell lysates..............................................157
Figure 7 .8 . Inh ib ition  o f APP a-secretase activ ity by G 12 540 23 X  in w ild -typ e  APP695-
transfec ted  D u l4 5  cells........................................................................................................................................... 159
Figure 7 .9 . The e ffec t o f APP a-secretase inhibition on th e  viab ility  o f APP695-transfec ted  
D u l4 5  cells in th e  presence o f co p per............................................................................................................. 160
Figure 7 .10 . Inh ib ition  o f APP (3-secretase activ ity by (3-secretase inh ib ito r IV in D u l4 5  cells.... 
 162
10
Figure 7.11. The effect o f APP (3-secretase inhibition on the viability of APP695-transfected
D u l4 5  cells in th e  presence o f co p p e r..............................................................................................................163
Figure 7 .1 2 . D etec tion  o f soluble APP derivatives in conditioned  m edium  from  m ock- and
APP6 9 5 (3 -transfec ted  HEK cells............................................................................................................................... 164
Figure 7 .1 3 . The e ffe c t o f reco m b inant sAPP(3 on th e  v iab ility  o f D u l4 5  cells in th e  presence
o f co p p e r..........................................................................................................................................................................165
Figure 8 .1 . APP695- induced m orphological changes in D u l4 5  cells................................................... 169
Figure 8 .2 . Decreased NSE expression and secretion in APP695-transfec ted  D u l4 5  cells 171
Figure 8 .3 . APP695-transfec tio n  is associated w ith  ep ithe lia l-to -m esen ch ym al trans ition  in
D u l4 5  cells..................................................................................................................................................................... 173
Figure. 8 .4 . The e ffe c t o f APP isoform s on EM T in D u l4 5  cells.............................................................175
Figure. 8 .5 . The e ffec t o f APP C -term inal constructs on EM T in D u l4 5  cells.................................176
Figure. 8 .6 . The e ffe c t o f APP E l dom ain  copper binding ab lation  on EM T in D u l4 5  cells ...179
Figure 8 .7 . The e ffec t o f NGF-(3 on APP expression and proteolysis in D u l4 5  cells................... 181
Figure 8 .8 . The e ffe c t o f HGF on APP expression in D u l4 5  cells..........................................................182
Figure 9 .1 . Schem atic representing  APP6 9 5  copper binding m u ta n t constructs..........................186
Figure 9 .2 . APP6 9 5  copper binding dom ain  m u ta n t over-expression in SFI-SY5Y cells..............187
Figure 9 .3 . Soluble APP gen era tion  by SH-SY5Y cells over-expressing th e  APP 6 9 5  copper
binding constructs...................................................................................................................................................... 188
Figure 9 .4 . The e ffe c t o f APP6 9 5  copper binding m u ta n t over-expression on SH-SY5Y cell
v iab ility  in th e  presence o f co p p e r..................................................................................................................... 187
Figure 9 .5 . Schem atic representing  APP7 7 0  copper binding m u tan t constructs..........................191
Figure 9 .6 . APP7 7 0  copper binding dom ain  m u tan t over-expression in SFI-SY5Y cells..............192
Figure 9 .7 . Soluble APP g enera tion  by SH-SY5Y cells over-expressing th e  APP7 7 0  copper
binding constructs...................................................................................................................................................... 193
Figure 9 .8 . The e ffe c t o f APP7 7 0  co p per binding m u ta n t over-expression on SH-SY5Y cell
v iab ility  in th e  presence o f co p p er..................................................................................................................... 195
Figure 9 .9 . Binding o f APP constructs to  m etal a ffin ity  spin co lum ns............................................... 197
Figure 10 .1 . NED in D u l4 5  cells............................................................................................................................211
11
List of Tables
Table 1.1. The physiological processes associated w ith  APP ad ap to r p ro te in s ..............................38
Tab le 1.2. Tissue copper levels in cancer........................................................................................................... 62
Tab le  1.3. Serum  copper levels in cancer........................................................................................................... 63
Tab le 2 .1 . The com position o f resolving gels used in SDS-PAGE............................................................ 81
Tab le  2 .2 . The com position o f stacking gel used in SDS-PAGE................................................................ 81
Tab le 2.3 . Prim ary an tibody d ilu tio ns ................................................................................................................. 83
Tab le  5 .1 . RT-PCR prim ers em ployed  in th e  cu rren t study.....................................................................121
12
Acknowledgem ents
I w ou ld  like to  th an k  m y supervisor Dr. Ed Parkin fo r his help and support th ro u g h o u t m y  
PhD, particu larly  fo r his tim e  spent reading and correcting this thesis. I w ou ld  also like to  
th an k  o ur previous lab group m em bers, Edd and Cath, fo r teach ing  m e th e  ropes in th e  lab 
and fo r alw ays being th e re  w h en  I needed help, e n te rta in m e n t o r som ething  to  bang m y  
head against! I w ou ld  also like to  th an k  m y fe llo w  PhD students, w ho  provided support, 
distraction, tran sp o rt, food  and friendships w hich I co u ld n 't have done w ith o u t. Finally, I 
w ould  like to  th an k  th e  B iotechnology and Biological Sciences Research Council fo r fund ing  






The am ylo id  precursor p ro tein  (APP) is a ubiquitously expressed p ro te in  o f unknow n  
physiological fu nctio n . The p rotein  is singularly m ost noted  fo r its role in th e  pathogenesis o f  
th e  n eu ro d eg en era tive  condition A lzheim er's disease (AD) (1) and, m ore recently, in th e  
d eve lo p m e n t o f various cancers, notably p rostate  cancer (2). In th e  case o f th e  la tte r  
disease, a lthough it is rare, cancerous cells can m etastasize to  th e  brain (3). In th e  cu rren t 
study, th e  role o f APP in p rom oting  cell v iab ility  in th e  brain in both  o f th ese diseases o f  
ageing is exam ined .
1.2. Alzheimer's D isease
A lzheim er's  disease (AD) is th e  m ost com m on fo rm  o f d em en tia , th e  la tte r o f w hich  
is defined  by cognitive im p a irm en t w hich in terferes w ith  daily life (4). AD w as first described  
by th e  G erm an psychiatrist and neurophysiologist Alois A lzheim er, in 1906 . The disease is 
m ost com m only diagnosed in people over 65 years o f age, a lthough th e  less-prevalent early- 
o nset AD can occur much earlie r in life (5).
1.2.1. Incidence and aetiology
Ferri e t  al. (6 ) es tim ated  th a t 24 .3  m illion people have d em e n tia  w o rld w id e  and th a t  
th e re  are 4 .6  m illion new  cases every year. In th e  UK alone, th e  cost o f  d em en tia  is th ou gh t  
to  be £23  billion p er year (7). AD is believed to  account fo r 50 -60 %  o f d em en tia  cases (5), 
w ith  ap p ro xim ate ly  5 0 0 ,0 0 0  people suffering fro m  th e  disease in th e  UK (8 ). Population  
based studies in Europe have suggested th a t th e  prevalence o f AD in people  above th e  age o f 
65 is 4 .4%  (4).
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In itially , th e  sym ptom s o f AD m ay be m istaken as natural signs o f aging. H ow ever, 
a fte r  tim e , th e  severity  o f th e  condition becom es ap p aren t. M ild  cognitive im p a irm en t (M C I) 
is th e  te rm  w hich  describes these initial sym ptom s (5). Progression fro m  M CI to  AD takes  
place a t a ra te  o f ap p ro x im ate ly  10 -15%  per year. The fo rem o st sym ptom  o f AD is a 
progressive loss o f episodic m em o ry  (4). This m ay th en  be accom panied by language and 
visuospacial deficits and th e  im p a irm en t o f executive functions. As th e  disease progresses 
fu rth e r, behavioural d isturbances are o ften  developed, and to w ard s th e  end o f th e  disease  
process, patien ts  lose th e  ab ility  to  stand, reverting  to  a vegetative  sta te . The average  
dura tio n  o f AD b etw ee n  diagnosis and death  is 8 -1 2  years. Astonishingly, th e  tim e  lapse 
b e tw ee n  th e  pathophysiological beginnings o f AD and onset o f sym ptom s is app ro xim ate ly  
2 0 -3 0  years (9).
The p red o m in an t risk fac to r fo r developing AD is age. O f those individuals aged 60 - 
6 5 ,0 .0 8 %  develop  th e  disease each year, w hereas th e  incidence ra te  fo r those over th e  age 
o f 85 is 6 .48%  per year (10 ). This association o f AD w ith  age m ay be due to  a life tim e  
exposure to  d iffe ren t risk factors; possibly a com bination o f genetic  susceptibility, biological 
factors and en viron m enta l exposures.
The fam ilia l fo rm  o f AD (FAD) is th o u g h t to  account fo r less than  3% o f all AD cases 
and is inh erited  in an au tosom al d om in an t fashion (11). FAD is also know n as early -o n set AD, 
as th e  onset is likely to  be b efo re  th e  age o f 65. M u ta tio n s  in th e  am ylo id  precursor pro tein  
(APP) (chrom osom e 21 ), presenilin 1 (chrom osom e 14) and th e  presenilin 2 (chrom osom e 1) 
genes, have been im plicated  in FAD (5).
The apo lip op ro te in  E4 (ApoE4) allele has been im plicated as a risk fac to r fo r la te -
o nset AD (LOAD), w ith  each inherited  copy o f th e  allele low ering  th e  age o f disease onset by
alm ost 10 years (12 ). Possessing one ApoE4 allele increases th e  risk o f developing LOAD
ap p ro x im ate ly  th ree -fo ld , and hom ozygosity fo r th e  allele increases th e  risk o f developing AD
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by up to  fifte e n  tim es (13 ). O th e r genetic  links have been im plicated  as risk factors fo r LOAD, 
such as those genes encoding various am ylo id  degrading enzym es (14 ), but none o f these  
factors are  as closely linked to  th e  risk o f developing th e  disease as th e  ApoE4 alle le .
In ad d ition  to  g enetic  factors, th e re  are also m any o th e r risk factors fo r AD. E levated  
blood pressure in m idd le  age, d iabetes, pred iabetes, hyperinsu linem ia, cerebrovascular 
disease, severe atherosclerosis, cardiovascular disease and c igarette  sm oking have all been  
linked to  an e leva ted  risk o f AD (4). Conversely, an ti-hypertens ive calcium channel blocking  
drugs, light to  m o d e ra te  alcohol consum ption, low  serum  cholestero l, cholestero l low ering  
drugs and a d ie t o f m o re  fish, vegetab les and low  saturated  fa t m ay decrease th e  risk o f 
develop ing  th e  disease (4). T h e re  is also evidence th a t an inte llectua lly  active lifestyle m ay  
p ro tec t against AD th rough  increasing neural and cognitive reserve w hich affords th e  brain  
m ore chance o f coping w ith  th e  pathological effects o f th e  condition.
1.2.2. Pathology
The brain o f an AD p a tien t exhibits global atrop h y i.e. a reduction in overall size, but 
p articu larly in th e  h ippocam pus and tem p o ra l lobes (4). The tw o  m ain pathological hallm arks  
o f AD are  ex trace llu la r am ylo id  plaques and in tracellu lar neurofibrilla ry  tangles (NFTs)
(Fig.1 .1).  The m ain  co n stituen t o f am yloid plaques is th e  1-43 am ino acid, am ylo id  beta  (A(3)- 
peptides. The m ost p reva len t form s o f A3 in th e  brain are A 3 i-40and A p i.42w ith  th e  A 3 i-4 2 - 
p eptide th o u g h t to  be th e  p rim ary  neurotoxic species in AD (15). Indeed som e FAD 
associated PS1 and PS2 m u tatio ns exert th e ir  effects by increasing th e  A 3 i-4 2 :A3 i-4o 
production  ra tio  (16 ). The core o f am yloid plaques consists o f A3 fibrils ab o u t 7 -1 0  nm in 
length alongside n o n -fib rilla r form s o f A3, o ften  in association w ith  m etals such as zinc, 
copper and iron (1 7 ,1 8 ) .  This core is surrounded by dystrophic dendrites and axons, 




Figure 1.1. The pathological hallmarks of Alzheimer's disease. The image shows A(3 plaques and NFTs in 
the cerebral cortex. Taken from  Blennow et al. (5).
with a diameter of approximately 200 pm which can initiate inflammation o f the surrounding 
area (19).
NFTs are comprised of a hyperphosphorylated form of the microtubule associated 
protein tau (Fig. 1.1), which forms paired helically twisted protein filaments (PHFs) confined 
to  the cell cytoplasm (20). Phosphorylation of tau inversely correlates w ith its attachment to 
microtubules, so when it becomes hyperphosphorylated, it dissociates from the 
microtubules completely and instead forms NFTs. The presence of hyperphosphorylated tau 
in the neurons decreases the efficiency of axonal transport, which results in synaptic defects 
and memory impairments (21). However, NFTs are believed to have a lesser involvement in 
AD than A(3 pathology (22).
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1.2.3. Diagnosis and treatment
In itial AD diagnosis relies on th e  exclusion o f o th e r possible causative conditions. As 
such, th e  p atien t's  m edical h istory is first consulted and ro u tin e  blood tests are p erfo rm ed  
in o rd er to  ensure th a t th e re  are no o th e r underly ing  problem s (4). Physical and neurological 
exam inations are  p erfo rm ed  to  ensure th a t th e  p atien t is not suffering fro m  an a lte rn a tive  
fo rm  o f d em e n tia . Follow ing this, neuro im aging  techniques such as positron em ission  
to m o g rap h y  (PET), com puterised  to m o grap hy (CT) or m agnetic resonance im aging (M R I) are  
o ften  used to  analyse th e  brain and identify  any gross m orphological changes. The  
psychiatric and cognitive p erfo rm an ce o f th e  p a tien t are th en  evaluated  using th e  criteria  o f 
th e  N ational In s titu te  o f Neurological and C om m unicative Diseases and Stroke and th e  
A lzheim er's  Disease and R elated Disorders Association (N INCDS-ADRDA), to  aid diagnosis (5). 
C u rren tly  th e  m ost d e fin ite  m etho d  o f diagnosis is post-m o rtem  neuropatho logy, but even  
this does not give a defin itive  diagnosis, because as m any as 20 -40%  o f non-AD sufferers  
have enough plaques and NFT's to  satisfy th e  AD diagnostic criteria . Researchers are  hopefu l 
th a t, in th e  fu tu re , Ap, to ta l tau  and phosphorylated  tau levels in th e  CSF and perhaps even  
plasm a m ight be used as re liable b iom arkers fo r AD (rev iew ed  in (23)).
C urrently , acety lcho linesterase (AchE) inhibitors are th e  m ost w id e ly  used tre a tm e n t  
fo r AD. These inhibitors inh ib it th e  degradation  o f th e  cholinergic n eu ro tran sm itte r, 
acety lcholine (Ach), but ten d  to  tre a t th e  sym ptom s ra th er th an  deal w ith  th e  underlying  
cause o f th e  disease (4). H o w ever, th e y  can be beneficial in im proving th e  cognitive, 
behavioural and functional deficits associated w ith  AD fo r a lim ited  period o f tim e . Four 
AChE inhibitors thus fa r are licensed as a tre a tm e n t fo r AD; donepezil, rivastigm ine, 
galan tam in e, and in som e countries tacrine.
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M e m a n tin e , a n o th e r th e ra p e u tic  used in th e  tre a tm e n t o f AD, targets  N - m ethyl-D - 
asparta te  (N M D A ) receptors (24 ). These receptors are activated  by am ino  acids such as 
g lu tam ate , and kill th e  cell th rough excess calcium  influx; a process know n as excitotoxic ity . 
M e m a n tin e  is a n on -co m p etitive  N M D A  recep to r antagonist and prom otes cell survival.
The m a jo rity  o f fu tu re  AD th era p e u tic  possibilities rely on e ith e r th e  inhib ition  o f A p - 
p ep tid e  fo rm atio n  o r th e  post-fo rm atio n  dissolution o f A p-o ligom ers a n d /o r  aggregates. 
Thus, these m ethods include anti-fib rillisa tion  agents, P- and y- secretase inhibitors, y- 
secretase m odulators , a-secretase stim ulators, APP targe tin g  antibod ies, m eta l a tte n u atin g  
com pounds, gene th era p y , p -sheet b reaker peptides and AP aggregation targe tin g  antibod ies  
(5, 2 4 -2 7 ). H o w ever, as Ap targe tin g  th erapeutics  have thus fa r lacked success, a huge 
am o u n t o f research is still being carried o u t in regards to  tau  and N F T s  in AD, so 
th erapeutics  ta rg e tin g  tau  kinases and phosphatases and th e  clearance o f 
h yperphosphoryla ted  tau  are prom ising fu tu re  th e ra p e u tic  strategies fo r AD (28).
Therapeutics th a t ta rg e t th e  sym ptom s o f AD have also been suggested, such as 
behaviour m odify ing drugs, an ti-in flam m ato ry  drugs, antioxidants, as trocyte-m odulating  
agents, caspase inhibitors and neurotrophins (5, 24 , 29, 30).
1.3. P rosta te  Cancer
Prostate cancer (PCa) develops in th e  p rostate , a gland in th e  m ale  reproductive  
system responsible fo r th e  production o f sem inal flu id . This cancer can m etastasize prim arily  
to  th e  surrounding bones and lym ph nodes, but in rare cases it also m etastasises to  d istant 
organs such as th e  brain.
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Incidence and aetiology
Prostate cancer (PCa) accounts fo r one quarter o f all male cancer cases in the UK, 
and is therefore the most common cancer in men (31) (Cancer research UK, 2010). 
Approximately 36,000 men are diagnosed w ith the disease each year in the UK, and in 2008 
913,000 men worldw ide were diagnosed w ith PCa.
■■■Male Rates ■  Male Cases
04 09 14 19 24 29 34 29 44 49 54 59 64 69 74 79 84
Age at Diagnosis
Figure 1.2. UK prostate cancer statistics from 2008-2010. Average num ber o f new cases per year and age 
specific incidence rates is shown. Taken from  Cancer research UK (31).
The strongest, yet unavoidable, risk factor fo r PCa is also age, w ith the risk increasing
at 50 and remaining elevated until the age of 85 years and beyond [Fig. 1.2) (32). However,
there is also a genetic element to  the disease (33). If a male has a first degree relative who
developed PCa before the age of 50, his chances of developing a carcinoma himself are
increased two-three fold. In addition, PCa is strongly associated w ith ethnicity, w ith black
men from North America developing PCa on average ten years earlier than white men (34).
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D iet m ay also play a role in th e  d eve lo p m e n t o f PCa. The strongest link to  d ie t is th a t o f 
anim al fa t consum ption  leading to  an increased risk o f developing th e  disease, possibly 
re la ted  to  fa t  co n ten t affecting  th e  handling o f tes tos teron e w ith in  th e  body (34 ). V egetarian  
m en are th o u g h t to  have up to  a 50%  lo w er risk o f developing PCa co m pared  to  m eat eaters. 
There  are also som e possible p ro tective factors in th e  d ie t, such as v itam in  E, v itam in  A, 
vitam in  C, lycopenes, selenium  and isoflavonoids (34 ). This suggests th a t a varied , h ealthy  
d ie t is likely to  decrease th e  probability  o f developing PCa.
1.3.2. Pathology
The PCa tu m o u r is o ften  an adenocarcinom a, as it arises fro m  th e  ep ith e liu m  o f th e  
glands in th e  p rostate  (33 ). The tu m o u r is typically an irregu lar m icroacinar tu m o u r th a t  
continues to  in filtra te  in to  surrounding norm al glands a t th e  periphery o f th e  mass and into  
th e  surrounding s trom a. If th e  tu m o u r p ro liferates to  substantially p en e tra te  th e  p rostate  
capsule, th e re  is a h igher risk o f tu m o u r progression and th e re fo re  a less favourab le  
prognosis (35 ). The prognosis is also m ore bleak if th e  tu m o u r invades th e  sem inal vesicles 
(36 ). M icrovessel density (M V D ) o f th e  tu m o u r, as a result o f angiogenesis is high in PCa as in 
o th e r form s o f cancer, and once a tu m o u r reaches th e  size at w hich it requires its ow n  blood  
supply a w orse prognosis is likely (37).
Prostatic carcinom as, in th e ir  early stages, seem to  be d ep en d e n t on androgen levels 
fo r th e ir  g ro w th  (38 ). Androgen receptors (ARs) bind sex steroids in th e  prostate  and  
stim u late  transcrip tion  o f specific genes (39). The gene encoding th e  AR consists o f CAG 
repeats, and an association has been identified  b etw een  low er num bers o f these repeats  
and m ore aggressive form s o f PCa.
Prostatic carcinom as release various m arker substances w hilst p ro liferating , tw o  o f 
th e  m ost re levant being prostate  specific acid phosphatase and prostate specific antigen
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(PSA) (40 ). PSA is th e  m ost clinically re levan t o f th e  tw o  and levels in th e  serum  o ften  
negative ly co rre la te  w ith  prognosis (41 ). PSA levels also have a huge role in th e  diagnosis o f 
PCa (42 ). O th e r biological m arkers have also been associated w ith  th e  d eve lo p m e n t o f  
prostatic  carcinom as, such as a reduction in E-cadherin levels (43). E-cadherin is an ep ithe lia l 
adhesion m olecule  and levels can reduce by up to  50%  in cases o f PCa. This, in th eo ry , w ould  
allow  cells to  p ro life ra te  and m etastasise m ore effective ly . Enhanced activ ity o f th e  insulin­
like g ro w th  fac to r signalling system has also been d em o n stra ted  to  b en efit th e  g ro w th  o f 
prostatic carcinom as (40 ). M u ta tio n s  in th e  tu m o u r suppressor, p53, gene are associated  
w ith  th e  onset o f PCa, along w ith  m any o th e r cancers, and p53 reactiv ity  can be a m arker o f 
a particu larly  aggressive fo rm  o f PCa (44).
1.3.3. Diagnosis and treatment
T here  are fo u r key m ethods by w hich PCa is diagnosed (33). Digital rectal 
exam in atio n  is th e  p rim ary m etho d . The prostate  is conveniently  located alongside th e  
rectu m , and th e  presence o f an adenocarcinom a causes a strom al reaction, resulting in a 
hard tu m o u r nodule in th e  posterio r lobe o f th e  prostate , o b litera tin g  th e  usually palpable  
m edian  groove w hich can be fe lt during a digital exam ination. Following this prim ary  
diagnostic p rocedure , a transrecta l u ltrasonography and needle biopsy m ay fo llo w . The m ost 
radical advance in PCa detec tio n  so fa r is th e  m easurem ent o f PSA levels. PSA is a 
glycoprote in  produced by th e  p rostate ep ithe liu m  w hich is involved in th e  liquefaction  o f 
sem en. E levated PSA levels are o ften  associated w ith  PCa, but as PSA levels increase w ith  age 
and flu c tu a te  w ith  in flam m atio n , th ey  are not d irectly indicative o f PCa.
PCa patien ts  are assessed and put into a risk category based on tu m o u r stage (TN M  
category), G leason score and PSA level, w hich aids th e  choice o f tre a tm e n t (34 ). The  
adenocarcinom a o f ap p roxim ately  70%  o f m en diagnosed w ith  PCa is confined to  th e
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prostate  gland w ith  no negative im pact on health  (33 ). This begs th e  question o f w h e th e r  
tre a tm e n t is w o rth w h ile . If th e  tu m o u r is identified  as low -risk, th e re  seem s to  be no b en efit 
in radical tre a tm e n t strategies, as m any m en can die w ith  PCa ra th e r than  fro m  it. H ow ever, 
those localised tu m o urs  w ith  a h igher Gleason score or PSA value w ou ld  be tre a te d  w ith  
p ro statecto m y o r rad io th erap y  to  p reven t fu tu re  m etastasis.
Locally advanced PCa patients, w h e re  th e  tu m o u r has m etastasised w ith in  th e  pelvis 
are usually tre a te d  w ith  rad io th erap y  com bined w ith  androgen ab lation  th e ra p y  (33 ). This is 
effective  fo r those early  stage tu m o urs  w hich still rely on androgens to  p ro life ra te . It can be 
carried o u t by rem oving  th e  supply o f androgens or by blocking AR's, or by a com b inatio n  o f 
th e  tw o . In th e  case o f m etas tatic  PCa, androgen ab lation  is also routine, but only e ffec tive  if 
th e  tu m o u r cells are still d e p en d e n t on androgens fo r survival. As th e  disease progresses, it 
has th e  po ten tia l to  becom e horm o ne re fractory, possibly due to  m utations in ARs. A t this  
stage ch em oth erap y m ight be th e  only option, but w ith  lim ited  success.
Those individuals w ho  m ay have an ex trem ely  high risk o f developing PCa due to  a fam ily  
history o f th e  disease m ay b en e fit fro m  taking  5-a lpha d ihydro testosterone (DHT) reductase  
inhibitors, as th e  p rostate  is d e p en d e n t on DHT to  function  (33).
1.4. The am yloid p recu rso r  p ro te in  (APP)
The pathology and progression o f both A lzheim er's disease and prostate  cancer are  
linked to  th e  m etabolism  o f th e  am ylo id  precursor p ro tein  (APP). The specific links b e tw een  
th e  diseases and APP w ill be discussed in la te r sections in this review , w hilst th e  b elow  
sections w ill deal w ith  th e  general cell biology o f th e  p ro te in .
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APP structure
APP is a typ e  1 integral m em b ran e  protein  consisting o f a small cytoplasm ic dom ain , 
a single helical m e m b ra n e  spanning region, and a large ec todom ain  (45 ). M am m a lian  APP 
exists in th re e  m ain isoform s containing 695, 751  and 77 0  am ino  acids, w ith  APP6 9 5  being th e  
p red o m in a n t isoform  in neurons (45 ). These isoform s are g en era ted  by a lte rn a tive  splicing o f 
exons 7, 8  and 15 in th e  APP  gene (46). The m ain d iffe ren ce b e tw ee n  th e  isoforms is th a t  
APP6 9 5  does not possess th e  Kunitz protease inh ib itor (KPI) dom ain  found in APP75i and  
APP770, w hilst APP7 7 0  contains an add itional OX-2 dom ain  (47 ). The APP ectod o m ain  can be 
divided into  2 d istinct dom ains; th e  E l and E2 dom ains (R eview ed in (48 )), w hich contain  
distinct functional regions {Fig. 1.3).  The E l dom ain  contains th e  g ro w th  fac to r like dom ain  
(o r heparin  binding dom ain; HDB) and th e  copper binding dom ain , w hich are linked to  th e  E2 
dom ain  via an acidic region. The E2 dom ain  consists o f a RERMS sequence and th e  central 
APP dom ain  (containing  a heparan  sulphate proteoglycan-binding  site), w hich in conjunction  
w ith  th e  A(3-peptide region and a ju x tam e m b ra n e  linker com prises th e  'carbohydrate  
dom ain ' o f th e  p rotein  (rev iew ed  in (49 )). In th e  larger APP isoform s, th e  KPI and O X-2  
dom ains are  inserted p rio r to  th e  E2 dom ain  o f th e  p ro te in . The in trace llu lar dom ain  o f APP 
consists o f 47  am ino  acid residues and contains th e  YENPTY m o tif w hich m ay be involved in 
m ediating  th e  endocytosis o f th e  prote in , interactions w ith  binding partners and in itia tion  o f 
dow n stream  signalling cascades through th e  phosphorylation o f its tyrosine residues (48,
50 ).
APP is post-translationally  m odified  in various ways, including N-glycosylation, 0 -  
glycosylation, sialylation, chondro itin  sulphate glycosam inoglycan m odification , sum oylation  
and phosphorylation , and each isoform  m ay contain d iffe ren t levels o f each m odification , 




Site -  
Required fo r Cu 
reduction
Residues 
-  Kunitz protease 







/J \  / jv jy js  /Jv t t t
Residues 































Figure 1.3. Schematic of APP functional domains and copper binding sites. Am ino acid numbering is based 
on the 770 amino acid isoform  (U nipro t KB website, (48)).
1.4.1. APP proteolysis
APP proteolysis can fo llow one of two pathways (Fig. 1.4). The pathway that 
ultimately leads to the toxic entities involved in AD pathogenesis, the amyloid beta (A(3)- 
peptides, is entitled the amyloidogenic pathway, and the alternative pathway, the non- 
amyloidogenic pathway (45).
1.4.2. Amyloidogenic processing
The amyloidogenic pathway involves the cleavage of APP by the (3-secretase, beta- 
site APP cleaving enzyme 1 (BACE1) (51). This cleavage is believed to take place primarily 
through co-localisation of APP and BACE1 in the endosomal compartments, whereas 
relocation of APP to  the cell surface promotes the non-amyloidogenic cleavage of APP
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(reviewed in (52)). The internalization o f APP is dependent on the YENPTY region o f the 
protein in its cytosolic domain, and d isruption o f this internalization process reduces A(3 
production (53). BACE1 cleavage releases a secreted form  o f the APP ectodom ain (sAPP(3), 
leaving a C-term inal fragm ent o f 99 amino acids (C99) attached to  the membrane (45). 
Subsequent cleavage o f C99 by the y-secretase complex, consisting o f presenilin (PS) 1 or 2, 
nicastrin (Net), presenilin enhancer 2 (Pen2), and anterior pharynx defective 1 (Aph-1), 
results in liberation o f A(3-peptides and the APP intracellular domain (AICD).
f    .













Figure 1.4. Proteolysis of the amyloid precursor protein via the amyloidogenic and non-amyloidogenic  
processing pathways. (Jacobsen et al. 2009 (45)).
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BACE1 is an aspartic p ro tease w hich exhibits op tim a l activ ity at an acidic pH akin to  
th a t in th e  endosom al system  and th e  Golgi apparatus (54 ). The active site o f BACE1 resides 
w ith in  th e  lum en o f th e  a fo re m e n tio n e d  vesicles, and th e  enzym e can only cleave  
m e m b ran e -b o u n d  substrates (R eview ed in (55 )). W h en  th e  enzym e is knocked o u t in vivo , Ap 
is no longer g en era ted  and am ylo id  pathology disappears, suggesting th a t BACE1 is th e  
prim ary  P -secretase involved in am ylo id  pathology (R eview ed in (56 )).
The y-secretase com plex is com posed o f PS, Net, Pen2 and Aph-1, w ith  th e  
presenilins acting as th e  catalytic  site o f th e  com plex. In add ition , th e  com plex has a n um ber 
o f po ten tia l regu la to ry  proteins (including T M P 21  and gSAP) w hich m ay influence cleavage o f 
th e  APP m olecule  (57 ).
The y-secretase com plex can selectively and sequentially  cleave a t e-, 6 - and y- sites, 
liberating  a range o f A P -p ep tide  species {Fig. 1.5).  A p proxim ate ly  90%  o f these AP species 
are th e  co m p arative ly  in e rt AP40 typ e , and less than  10%  comprises o f th e  toxic A p42  
species (58 ). T here  are also sm all am ounts o f som e a lte rn a te ly  sized peptides, such as A p37, 
A p38 , A p43 , A p46 , A p 47 , AP48, AP49 w hich exist in vivo, som e o f w hich m ay represent 
in te rm e d ia te  stages o f cleavage pathw ays (58 -60 ).
The y-secretase com plex localises at m em branes both at th e  cell surface and in 
endosom es, a llow ing  it to  co-localise w ith  both th e  a -  and p-secretases in addition to  its APP 
substrate (61).
1.4.3. Non-amyloidogenic processing
W h e n  APP is processed via th e  non-am yloidogenic pathw ay, th e  p rotein  is cleaved
by an a -secretase activ ity  w ith in  th e  AP dom ain, th e re b y  precluding th e  fo rm atio n  o f in tact
A p -peptides . This releases sAPPa into  th e  extracellu lar en v iron m ent, and leaves a C -term inal
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Figure 1.5. Schematic of the y-secretase mediated cleavage of APP. (St. George-Hyslop et al. (57))
y-secretase cleavage of C83 liberates the non-toxic p3 fragment and the AICD into the cell 
cytoplasm. The a-secretase activity takes place in the cell surface plasma membrane when 
the a-secretase co-localises w ith APP (62).
The a-secretase activity involved in the non-amyloidogenic proteolysis of APP is 
constituted by one or more members of the a disintegrin and metalloproteinase (ADAM) 
fam ily of zinc metalloproteinases. ADAMs, like APP, are type 1 membrane proteins and, in 
the ir mature state, are between 70 and 90 kDa in size (63). The ADAMs have a common 
modular ectodomain structure consisting of a cysteine-rich domain which can interact w ith 
cell surface proteoglycans, a disintegrin domain which can bind to  cell adhesion integrin 
molecules, a zinc-binding metalloproteinase domain, a large prodomain that keeps the 
metalloproteinase site of the newly synthesised protein inactive via a cysteine switch, and an 
N-terminal signal sequence. Activation of the ADAMs, which involves the removal of the
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A D A M  prodom ain  by p ro p ro te in  convertase activ ity, takes place in th e  trans-golgi n e tw o rk  
(63 , 6 4 ) .
The A D A M  10  p ro te in  consists o f five d istinct dom ains; a prodom ain , a catalytic  
dom ain  containing a zinc-binding m o tif, a cysteine rich disintegrin dom ain , a tra n s m e m b ran e  
region, and a short cytoplasm ic dom ain , w hich is th o u g h t to  contain  p rotein  binding m otifs  
and nuclear localisation sequences (65 ). The enzym e is produced as an inactive zym ogen, 
w hich en ters th e  secreto ry  p a th w ay  a fte r cleavage o f th e  signalling sequence (66 ). A D A M 1 0  
is w id e ly  expressed in th e  hum an body w ith  a broad expression p a tte rn  in th e  brain (65 , 67), 
and th e  enzym e has a large n u m b er o f substrates (a t least 4 0 ), w ith  m ost being typ e  1 
tran sm em b ran e  proteins such as APP (68).
The original evidence pointing to w ard s A D A M 10  being an APP a -secretase  w as  
provided by Lam m ich e t al. (69 ) w ho  over-expressed A D A M 10  in HEK cells and saw a 4 -fo ld  
increase in sAPPa secretion com pared  to  untransfected  cells. F urtherm o re , A D A M 10  is co­
expressed w ith  APP and BACE1 in hum an cortical neurons (70 ), suggesting th a t th e  enzym e  
m ight w ell be responsible fo r physiologically-relevant processing o f APP in th e  brain. M ice  
over-expressing hum an APP[V7i 7i] crossed w ith  A D A M 10  over-expressing m ice d em o n stra te  
reduced AD pathology and a llev ia ted  sym ptom s (71). They produce less A(3-peptide and have  
a reduced plaque deposition and increased sAPPa production, along w ith  an e levated  
learning and m em o ry  p o ten tia l. In contrast, m ice expressing an A D A M 10  d om in an t-n eg ative  
m u tan t (E384A  in th e  zinc-binding m o tif) crossed w ith  th e  APP[V717i] transgenic line, exhib ited  
increased A(3 production, e levated  plaque deposition and vascular pathology along w ith  
defects in lo n g te rm  p o te n tia tio n  and cognition. Finally, w hen  A D A M 10  expression is 
knocked o u t o r dow n in p rim ary  neuronal cultures, th e  a-secretase processing o f APP is 
reduced, suggesting th a t A D A M  10 is indeed th e  prim ary a-secretase in th e  brain (R eview ed  
in (72 )).
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A D A M 17  is also know n as tu m o u r necrosis fa c to r -a  converting  enzym e (TACE) and 
C D 156q and has a structure th a t is ex tre m ely  sim ilar to  A D A M IO , w ith  th e  sam e dom ains  
and a sim ilarly w id e  substrate specificity (73 ). Using TACE knockout m ice, Buxbaum  e ta l .  (74 )  
found  th a t A D A M 17  was a p rim ary a-secretase in th e  phorbol es ter-reg u la ted  cleavage o f  
APP, but not in constitu tive sAPPa release. The p o tentia l role o f A D A M 17  in regu lated  sAPPa  
secretion  is fu rth e r supported by th e  p ro o f th a t A D A M 17  cleaves a synthetic APP p ep tid e  at 
th e  ap p ro p ria te  site, h o w ever th e  cleavage o f fu ll-length  m em b ran e  bound APP by A D A M 17 , 
and th e  kinetics o f th e  cleavage are unconfirm ed. T h e re fo re  it is possible th a t A D A M 1 7  is 
acting indirectly , encouraging a -secretase pro teo ly tic  activ ity  resulting in APP cleavage (75). 
A D A M 1 7  is prim arily  localised to  en d othelia l cells and astrocytes in th e  hum an central 
nervous system (76) and expression studies in prenata l, postnatal and m a tu re  m ice show ed  
only a partia l overlap o f APP and A D A M 17  expression (70 ), suggesting th a t it m ay only have a 
sm all role in a-secretase activity. In CHO cells, th e  use o f TAPI, an A D A M 17  inh ib itor, showed  
th a t phorbol es ter-regu la ted  sAPPa secretion was inhibited  a t th e  cell surface, and partia lly  
inh ib ited  intracellu larly , suggesting A D A M 17  exhibits a dual localisation (77 ).
A range o f ADAM s (ADAM s 8, 9 ,1 0 ,1 2 ,1 5 ,1 7 ,1 9 ,  20, 21 , 28, 30 , and 33 ) have been  
found  to  possess an active protease dom ain  and are involved in ectodom ain  shedding (63 ).
O f these , both A D A M 9 and A D A M 15  have been suggested as p otentia l sheddases o f 
A D A M 1 0  itself (78 ). Three o th e r AD A M  proteins th a t are capable o f exhib iting a-secretase  
cleavage o f APP in vitro  are A D A M 19 , A D A M 33 and A D A M 8 (79 -81 ). H ow ever, even though  
th e re  are a large n um ber o f A D AM s im plicated  in th e  a-shedding  o f APP, it is A D A M 1 0  th a t is 
th o u g h t to  be m ost physiologically re levan t in th e  pathogenesis o f AD.
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1.5. Lipid rafts and  APP proteolysis
Lipid rafts are m e m b ra n e  m icrodom ains rich in cholestero l and sphingolipids, w hich  
can cluster pro teins involved in specific cellu lar processes (82 ). It has been  suggested th a t  
th e  am ylo idogenic processing o f APP p referen tia lly  takes place in th ese  structures. An 
association o f both  APP and BACE1 w ith  lipid rafts has been d em o n stra ted  (83 , 84 ). Also, 
cross-linking APP and BACE1 a t th e  cell surface co-localises these proteins to  lipid rafts w ith  a 
co n co m itan t e levatio n  in A3 production (85). This effect was no longer ap p are n t w hen  lipid  
rafts w e re  d isrupted by cholestero l d ep le tion . The subsequent processing o f APP in lipid rafts  
by y-secretase has also been suggested, based on th e  fact th a t inh ib ition  o f y -secretase  
activ ity  can increase th e  abundance o f APP C -term inal fragm ents in th e  ra ft fraction  (86 ). In 
contrast, th e  non-am ylo idogen ic  processing o f APP is th o u g h t to  occur w ith in  th e  n o n -ra ft 
region o f th e  m e m b ra n e  (R eview ed in (87 )).
As previously discussed, one o f th e  m ost im p o rtan t genetic  risk factors fo r AD is th e  
possession o f th e  ap o lip op ro te in  E (ApoE) e4 allele (88 ). ApoE has a n u m b er o f identified  
functions including roles in cholestero l transpo rt and m etabolism , and recep to r m ed ia ted  
uptake o f lipoprote ins (R eview ed  in (89 )). ApoE has also been shown to  in te rac t w ith  Ap and  
to  co-localise w ith  Ap in lipid rafts in th e  AD brain (9 0 ,9 1 ) .
1.6. The physiological role of APP and its m etabolites
A d e fin ite  physiological function  fo r APP rem ains to  be d e te rm in e d , but th e  protein  
m ight be involved in m any aspects o f general cell m ain tenance and g ro w th , especially in 
neurons (45 ). Equally, th e  physiological role o f APP m ay be m ed ia ted  by e ith e r th e  fu ll-length  
h o loprote in  o r by m eans o f th e  proteo ly tic  fragm ents g en era ted  via th e  am ylo idogenic or 
non-am ylo idogenic pathw ays. Som e p otentia l functions o f th e  p ro te in  are  discussed below .
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1 .6 .1 . Functions of the APP holoprotein
A trip le  knockout in m ice o f APP and th e  APP-like proteins (APLP), APLP1 and APLP2 
resu lted  in 100%  m o rta lity , suggesting th a t APP-like proteins are essential fo r survival a n d /o r  
em bryogenesis (92 ). Knocking o u t th e  APP gene in m ice also results in reduced body and  
brain size, im paired  lo n g te rm  p o ten tia tio n , reduced grip strength , increased corpus 
callosum  deg en eration  and an increase in seizure frequ en cy (93).
It has been proposed th a t APP is a co n trib u to r to  th e  m atura tion  and d iffe ren tia tio n  
o f neurons as it is u p -regu lated  during these processes (R eview ed in (94 )). The sam e authors  
also d em o n stra ted  enhanced an terog rade transpo rt o f APP to  synapses w h e re  levels o f APP 
secretion co rre la ted  w ith  synaptogenesis. APP knockdow n in zebra fish causes defective  
axonal o u tg ro w th , suggesting th a t th e  p rotein  also has a key role in this process (95). 
F urth erm o re , th e  retina o f APP knockout m ice exh ib it reduced neuronal d eve lo p m e n t and 
inner re tinal circuitry but w ith o u t any deleterious effects on visual function  (96 ). This again  
suggests a ro le fo r APP in th e  estab lishm ent o f neuronal netw orks.
A role in neu ro pro tection  has been suggested as an o th er puta tive physiological 
function  o f APP, as a n um ber o f experim ents involving th e  reduction o f APP levels have  
resulted in reduced cell survival and e levated  apoptosis. H ow ever, this e ffe c t was not 
consistent across studies utilizing d iffe ren t m odels (R eview ed in (97 )). The role o f APP in 
n eu ro p ro tec tio n  w ill be discussed in m ore detail in subsequent sections in th e  cu rren t repo rt 
re la ting  to  individual APP m etabolites .
Using q u a n tita tive  im m unofluorescence, Szpankowski e t al. (98 ) d em o n stra ted  th a t  
in m u rin e  h ippocam pal cells, th e  level o f APP co rre la ted  w ith  levels o f th e  kinesin-1 light 
chain and th e  heavy chain o f cytoplasm ic dynein w ith in  axonal vesicles. F urtherm o re , genetic
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reduction  o f APP reduces th e  association o f these m o to r proteins w ith  vesicles carrying APP 
cargoes, suggesting th a t th e  pro te in  m ay regu late  its ow n vesicular axonal transpo rt.
APP has also been associated w ith  th e  g enera tion  and m o dulation  o f synapses. APP 
over-expression experim ents  in vivo suggest th a t th e  p ro te in  can increase activ ity  o f L-type  
calcium  channels w hich , concom itan tly , increases m edium  a fte r hyperpo larisation  (m AHP) 
and low ers excitab ility  o f th e  APP-expressing neurons (R eview ed in (99 )). This function  o f 
APP in th e  m a in ten ance o f neuronal calcium hom eostasis indicates th a t th e  p ro te in  plays an 
in fluen tia l ro le in synaptic transm ission. A role fo r APP has also been suggested in th e  
regu lation  o f dendritic  spine structure  and functions, th e  loss o f which are com m on in 
learning and m e m o ry  deficits (R eview ed in (99 )). Both long te rm  p oten tia tio n  (LTP) and long 
te rm  depression (LTD), w hich underlie  th e  processes o f learning and m em o ry  and requ ire  
synaptic plasticity, have also been shown to  be a ffected  by APP over-expression and  
deficiency (R eview ed in (99 )). Knockdown o f APP, APLP1 and APLP2 in a cell-cu lture  system  
identified  a significant d o w n -reg u la tio n  o f m eth io n in e  adenosyltransferase II alpha (M A T2A ) 
fo llow ing  a com prehensive p ro teo m ic  study (100 ). As M A T2A  is involved in th e  process o f 
n eu ro tran sm itte r m ethy la tion  this study fu rth e r im plicates APP in th e  regu lation  o f synaptic  
function .
APP m ay also play a role in cell adhesion, as it is able to  bind to  collagen I, lam inin  
and glycosaminoglycans (10 1 ) and has been found in adhesion patches associated w ith  
integrins (102 ). An RHDS sequence located w ith in  th e  A(3 dom ain  has been d irectly  
associated w ith  this cell adhesion p ro p erty  (103).
An initial association o f APP w ith  th e  innate im m une system has been suggested by 
Puig e t al. (104 ) w ho  used gut ileum  tissue from  w ild -typ e  and APP knockout m ice to  show  
th a t th e  protein  regu lated  im m une cell phenotype, th e ir secretions and general intestinal 
function .
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APP has also been im plicated  in th e  binding and hom eostasis o f copper. This concept w ill be 
discussed in deta il in la te r sections w ith in  th e  cu rren t review .
1.6.2. Functions of the APP cytosolic domain
A w ea lth  o f data  has been g en era ted  im plicating APP as a cell surface receptor, able  
to  in itia te  dow n stream  signalling cascades via th e  YENPTY m o tif in th e  cytosolic dom ain  o f  
th e  p rotein  (45 ). W h e th e r such cascades are in itia ted  via th e  fu ll-length  holoprote in  
containing th e  cytosolic d om ain , o r via th e  tru n cated  C -term inal fragm ents (p red o m inantly  
C83 and C99), rem ains to  be fu lly  e lucidated .
Firstly, it has been suggested th a t APP m ay act as a G -pro te in  coupled receptor. 
O kam o to  e t al. (1 0 5 ) used a phospholipid vesicle system to  d em o n stra te  th a t N -te rm in a l APP 
ligand binding (in this case, m im icked using th e  22C11 anti-APP N -te rm in a l antibody) 
stim u lated  activation  o f th e  G0 com plex; a process d ep en d e n t on residues H is657-Lys676 in 
th e  cytosolic dom ain  o f APP695. This suggests th a t it is this C -term inal region o f APP which  
associates w ith  th e  G0 com plex. H ow ever, this proposal is controversial, as sim ilar in vivo 
experim ents actually resulted in decreased G0 activation (106 ). Nonetheless, in both cases, 
an in teraction  b e tw een  th e  cytosolic dom ain  o f APP and th e  G0 com plex was dem o n stra ted , 
suggesting th a t th e  role o f APP as a G -prote in  coupled recepto r should be investigated  
fu rth e r.
The G0 com plex is coupled w ith  signalling cascades involved in th e  regulation o f 
calcium channels and apoptosis, and th e re fo re , m ay be a driver o f these activities. Indeed, 
evidence supports a role fo r A P P-G -protein  signalling in apoptosis, as substitutions o f APP's 
V al642  fo r lie, Phe o r Gly results in G -prote in  d ep en d en t apoptosis and ligand ind ep en d en t 
activation  o f G0 (R eview ed in (10 7 )).
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Figure 1.6. Protein binding interactions of the amyloid precursor protein intracellular domain. Proteins 
which in teract w ith  specific regions o f the  in tracellu lar domain are shown, and th e ir  subsequent interacting 
partners and the potentia l physiological consequences o f these interactions are also described. The green 
square isolates the interactions dependent on the release o f the APP C-terminal fragm ent from  the 
membrane into the cytosol (Adapted from  Turner et al. 2003 (107)).
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APP, o r its C -te rm in a l fragm ents can in teract w ith  various ad ap to r pro teins (Fig. 1 .6 ) 
including X l l ,  Fe65, D a b l,  c-Abl, She, JIP-1, Num b and G rb2, som e o f w hich m ay influence  
th e  secretase-m ed ia ted  proteolysis o f APP itself or be involved in o th e r processes such as 
neuronal cell m igration , axonal e longation and dendritic  arborisation (10 8 ). The She and  
G rb2 proteins are SH2 and PTB interacting  adaptors, so APP m ay in itia te  dow n stream  
signalling cascades th rough  th ese adaptors, likely through influencing th e  MAPK/ERK  
p ath w ay  but also possibly th rough  ras, PI3K and JNK signalling pathw ays (10 9 ). The  
a fo re m e n tio n e d  ad ap to r pro teins are involved in th e  induction o f a range o f cellu lar events  
w hich are d eta iled  in Table 1 .1 . This could indirectly involve APP in regu lation  o f all o f these  
cellu lar events, th rough  in itia tion  o f signalling.
Experim ents p erfo rm ed  using Drosophila  sLNV neurons show ed th a t th e  o ver­
expression o f hum an APP stim u lated  axonal extension and arborisation , th e  e ffec t o f w hich  
w as traced  to  th e  YENPTY m o tif in th e  cytosolic dom ain o f th e  p ro te in  (11 0 ). This e ffec t was 
only ap p aren t w hen  th e  cytosolic dom ain  was m em b rane bound and not once th e  soluble  
AICD had been  g en era ted  (11 1 ). Phosphorylation o f APP a t T h r668  (APP695 num bering) can 
stim u late  th e  localisation o f APP into  neuritic -like processes in neuronal and COS-1 cell 
systems, and th e  consequentia l stim u lation  o f process extension (11 2 ). Ando e t al. (113) 
d em o n stra ted  th a t phosphorylated  APP locates to  th e  g row th  cones o f d iffe ren tia tin g  PC12 
cells and th a t d iffe ren tia tio n  w as im paired  w hen  APP phosphorylation w as p reven ted . These  
data ind icate a role fo r phosphorylated  APP in neuronal o u tg ro w th  during d iffe ren tia tio n .
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Adaptor protein Involved in Reference
X l l / M i n t Regulation o f neuronal 
signalling, tra ffick ing  and  
plasticity, and m odulation  o f 
APP processing
Rogelj e t al. 2 0 0 6  (114)
Fe65 Synaptic plasticity Schettin i e ta l.  2 0 1 0  (50)
D a b l Endocytosis, cellu lar grow th , 
p ro lifera tion , hom eostasis
Pilecka e ta l .  2 0 0 7  (115)
c-Abl tyros in e  kinase Regulation o f th e  actin  
cytoskeleton , regulation o f 
th e  cell cycle, regu lation  o f  
th e  ap o pto tic /ce ll cycle 
response to  stress, 
d eve lo p m e n t o f th e  central 
nervous system
S ch latte rer e t  al. 20 11  (116)
She Early cardiovascular 
d eve lop m ent, neuronal 
d iffe ren tia tio n , lifespan  
d eterm in a tio n
W ills and Jones 20 12  (117)
JIP-1 Regulating JNK signalling, 
axonal transpo rt
Koushika S.P. 2 0 0 8  (118)
N um b Cell fa te  d e term in a tio n , cell 
division, endocytosis, cell 
adhesion, cell m igration and 
ubiqu itination  o f substrates
Gulino e t al. 2 0 1 0 (1 1 9 )
G rb2 Cell cycle progression, actin- 
based cell m otility , ep ithe lia l 
m orphogenesis, angiogenesis 
and vasculogenesis
G iubellino e ta l .  20 08  (120)
Table 1.1. The physiological processes associated with APP adaptor proteins.
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1.6.3. Functions of sAPPa
M o st o f th e  d e trim e n ta l effects  seen in APP knockouts can be reversed by 
application  o f sAPPa, suggesting th a t  this fra g m en t carries o u t th e  m a jo rity  o f  th e  functional 
activ ities associated w ith  APP (12 1 ).
sAPPa is th o u g h t to  p ro m o te  n eu rite  o u tg ro w th , synaptogenesis and cell adhesion  
and m ay also be involved in learn ing  and m em o ry  (122 ). The fra g m en t is also involved in cell 
g ro w th , p ro lifera tion  and m igration , and is involved in th e  m igration o f neuronal precursors 
to  th e  cortical p la te  and in th e  regu lation  o f stem  cell d iffe ren tia tio n  (58 ).
Decreasing APP expression in fibroblasts resulted in a reduced gro w th  ra te  th a t  
could be corrected  by th e  add ition  o f reco m b inant sAPPa (123 ). This g ro w th  prom oting  
activ ity  was th o u g h t to  be m ed ia ted  by a p en tap ep tid e  sequence (RERMS) located b etw een  
residues 40 3  and 4 0 7 , inclusive, o f APP (12 4 ). Caille e ta l.  (125) d em o n stra ted , in vivo, th a t  
an sAPPa fusion pro te in  enhanced th e  p ro liferation  o f EGF-responsive progenitors in th e  
subventricu lar zone o f th e  ad u lt brain, and th a t th e  inhibition o f endogenous a -secretase  
activ ity  had th e  opposite e ffec t. The authors proposed th a t these effects w e re  m ed ia ted  by 
sA PPa-enhanced ep iderm al g ro w th  fac to r (EGF) activity. sAPPa also regulates basal cell 
p ro lifera tion  in th e  skin ep iderm is and th e  d iffe ren tia tio n  and pro liferation  o f thyro id  follicle  
ep ithe lia l cells (111 ).
It is th o u g h t th a t th e  activation  o f MAPK/ERK signalling by sAPPa m ight fo rm  th e  
m olecu lar basis by w hich th e  fra g m en t enhances cell p ro lifera tion  (126 ). D em ars e t  al. (127) 
identified  a g ro w th  fac to r-like  activ ity  o f sAPPa in neural progenito r cells, m esenchym al stem  
cells and hum an decidua parieta lis p lacenta stem  cells, w hich acts ind ep en d en tly  o f EGF and 
basic fib rob last g ro w th  fac to r b ut in conjunction w ith  ERK/MAPK signalling pathw ay. This 
sAPP induced pro lifera tion  m ay be m ed ia ted  by its ab ility to  bind to  a proteinaceous
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en d oth e lia l cell surface recepto r w ith in  m em b ran e  ra ft m icrodom ains to  induce an 
in trace llu lar signalling cascade (128 ). A n o th e r fac to r involved in th e  role o f sAPPa as a 
g ro w th  p ro m o te r is likely to  be its possession o f various g ro w th  fac to r like- and heparin  
binding- dom ains.
sAPPa has been shown to  have a n eu ro pro tective  function  by Corrigan e t al. (129 ). 
The authors d em o n stra ted  th a t, com pared  to  w ild -typ e  m ice, APP knockout m ice exhib ited  
g rea te r h ippocam pal dam age and lesion vo lum e w hen  subjected to  m o d era te , contro lled  
cortical im pact injury. The knockout m ice also subsequently d em o n stra ted  increased  
im p a irm en t o f m o to r and cognitive function  and all o f these d etrim e n ta l effects could be 
allev ia ted  by th e  in troduction  o f exogenous sAPPa. A n eu ro pro tec tive  role fo r sAPPa is 
fu rth e r suggested by th e  fac t th a t th e  injection o f this fra g m en t in to  ra t brains fo llo w in g  
tra u m atic  injury enhances m o to r and cognitive function  (97).
sAPPa m ay also be involved in th e  m ain tenance o f synapses. Using an APP knockout 
m ouse m odel, Tyan e t al. 2012  d em o n stra ted  th a t, w hen APP was d ep le ted , spine density  
was decreased and th a t this e ffec t could be partia lly  restored by exogenous sAPPa (130).
The authors also observed a reduction  in apical dendritic  length and arborisation  in th e  
hippocam pus o f aged m ice upon APP knockout, w ith  an accom panied reduction in LTP.
A t th e  m olecu lar level, sAPPa has also been shown to  inh ib it th e  stress-activated JNK 
signalling p ath w ay, preventing  th e  death  o f PC12 cells (131 ), and to  p ro tect neurons against 
th e  effects o f oxygen-glucose d eprivation  (132). The m echanism  o f this action is believed to  
be linked to  th e  ab ility  o f sAPPa to  inh ib it calcium currents and increase potassium  currents  
in o rd er to  stabilize th e  m em b ran e  potentia l o f neurons. sAPPa is also associated w ith  a 
range o f cell survival signalling pathw ays including th e  P I3K /A kt, N F-kB, ERK and p38  
m ito gen-activa ted  pro te in  k inase/M E F2 pathw ays (97). In add ition , th e  en h an cem en t o f a
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range o f gene products associated w ith  n eu ro pro tection  has been linked to  increased sA PPa  
levels including M nSO D , p ero xiredox in -2 , catalase, insulin-like g ro w th  fac to r 2 and insulin­
like g ro w th  factor-b ind ing  p ro te in  2 (97 ).
sAPPa m ay even have th e  ab ility  to  p ro tec t cells against starvation -induced  cell 
death  by disrupting th e  d im eriza tio n  o f th e  APP ho loprote in  itse lf (13 3 ). It has been  
suggested th a t trans d im eriza tio n  o f fu ll-len g th  APP via th e  E l dom ain  m ay tak e  place across 
th e  synaptic cleft and be involved in signal m ed ia tio n , and th a t sA PPa m ight act as a 
co m p etitive  inh ib ito r o f these processes (134 ).
1.6.4. Functions of sAPPp
sAPPd only contains 17 m o re  am ino  acids than  th e  a lte rn a tive  secreted ec todom ain , 
sAPPP, and m ost o f th e  regions a ttr ib u te d  to  its functions are  p resent on both fragm ents. 
H o w ever, sAPPd is decidedly m ore fu nctio n ally  active than  sAPPp, perhaps due to  th e  
heparin  binding dom ain  located a t th e  C -term inal o f sAPPd but not sAPPp (107). 
N evertheless, sAPPp has been specifically im plicated  in a small n u m b er o f physiological 
events.
A knock-in o f a reco m b inant sAPPp protein  in mouse m odels does not rescue th e  
le th a lity  and neurom uscular junction  defects o f a double APP/APLP2 knockout, suggesting  
th a t th e  soluble APPP derivative o f APP does not possess a com parab le protective e ffe c t to  
its d -deriva tive  co u nterp art (13 5 ). H o w ever, in th e  sam e m odels, sAPPp up regulated  
transthyre tin  and Klotho gene expression. Transthyretin  is a carrier o f th e  thyro id  h orm o ne  
thyroxine and is th e re fo re  involved in regu lation  o f m etabolism  (136 ), w hereas Klotho is a 
m em b ran e  bound enzym e w hich has been shown to  extend  ageing, perhaps through  
resistance to  oxidative stress (137 ), re la ting  sAPPP production to  m etabolism  and ageing.
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sAPPP seem s to  be involved in axonal pruning and induction o f neuronal death  
th rough  th e  activation  o f d eath  recepto r 6 and caspase activ ity (13 8 ). The fra g m en t has also 
been shown to  decrease cell g ro w th  in neuronal B103 cells (13 9 ). F urth e rm o re , Freude e ta l.  
(14 0 ) identified  sAPPp as a d river o f hum an em bryonic  stem  cell d iffe ren tia tio n  to w ard s a 
neural cell fa te .
1.6.5. Functions of the soluble AICD
The com bined cleavage o f APP by a -  or |3-secretases and th e  y-secretase com plex is 
th o u g h t to  represen t an 'ou ts id e-in ' signalling p ath w ay re ferred  to  as regu lated  
in tram e m b ra n e  proteolysis (RIP), resulting in th e  in trace llu lar gen era tion  o f th e  soluble AICD  
fra g m en t (141).
A lthough d iffe re n t lengths o f AICD can be gen era ted  depending  on th e  site o f y- 
secretase cleavage, all o f th e  gen era ted  fragm ents possess th e  YENPTY m o tif, enabling  
binding to  ad ap to r proteins such as Fe65 and th e  subsequent en h an ce m en t o f fra g m en t 
stability  (142 ). Through re c ru itm e n t o f th e  histone deacetylase T IP 60 and, potentia lly , 
CP2/LSF/LBP-1, and subsequent nuclear translocation, this com plex can activate  genes such 
as p53, GSK3P, neprilysin, EGFR, KAI, LRP and APP itself (1 2 1 ,1 4 2 -1 4 4 ) . Thus, AICD 
g en era tion  seem s to  be linked to  various cellu lar processes including th e  regulation o f th e  
cell cycle, m etabolism , neuronal cell d eve lopm ent, p ro te in  d egradation , cell p ro lifera tion  and 
lipid hom eostasis (1 2 1 ,1 4 2 -1 4 4 ). Genes involved in calcium regulation  and cytoskeletal 
dynam ics such as transgelin , a2ac tin , and tropom yosin  can also be activated  by this 
m echanism  (1 4 2 ,1 4 3 ) .
The AICD m ay exh ib it a cytotoxic behaviour e ith e r d irectly  o r th rough  th e  
subsequent g enera tion  o f sm aller cytotoxic p ro teo ly tic  fragm ents (rev iew ed  in Zheng and  
Koo (142)).
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1.6.6. Functions of p-amyloid peptides
W hilst, a t high concentrations Ap is toxic to  cells, a t th e  lo w er concentrations found  
in norm al brain tissue th e  peptides m ay actually have beneficial effects (1 4 5 ,1 4 6 ) . Ap 
appears to  provide pro tection  to  neurons a t p icom olar concentrations, p o ten tia lly  through  
m u ltip le  m echanism s involving insulin like g row th  fac to r-1 , P I3K /A kt, ERK1, ERK2 a n d /o r  
pro te in  kinase C signal transduction  pathw ays and transcrip tional regu lation  by cAM P  
response e le m en t-b in d in g  (CREB) protein  (review ed  in (14 6 )). F urtherm ore , th e  inh ibition  o f 
Ap gen era tion  has been shown to  im pair grow th  in a range o f cell lines and this d e trim e n ta l 
effe c t can be reversed, at least in neuronal cells, th rough th e  add ition  o f exogenous AP 
(14 7 ). Furtherm o re , W hitson  e t al. (148) show ed th a t a pep tide consisting specifically o f 
residues 1 -28  o f AP enhanced th e  survival o f h ippocam pal pyram idal neurons in vitro. 
Surprisingly AP has even been linked specifically to  th e  protection  o f cells in vitro  against 
oxidative dam age induced by copper and iron, but not hydrogen peroxide (H 20 2) (149).
A P -peptides m ay also play a ro le in synaptic plasticity as p icom olar levels are capable  
o f enhancing LTP in m ouse hippocam pus (w hereas nanom olar concentrations im pair LTP) 
(15 0 ). These p ro teo ly tic  fragm ents m ay also influence th e  transpo rt and /o r  m etabolism  o f 
lipids th rough  th e ir  ab ility  to  in te rac t co m p etitive ly  w ith  lipid binding sites on ApoE (15 1 ). In 
fact, AP has been shown to  inh ib it cholesterol from  binding to  low  density lipoprote in  (LDL), 
which prevents cholesterol tran sp o rt into cells and th e re fo re  reduces in trace llu lar  
cholesterol levels (152).
1.7. APP and metals - copper
C opper is an essential co m p o nent o f m any enzym es and proteins and vital fo r energy  
m etabolism  (15 3 ). The m etal is w idely  d istributed  around th e  body, w ith  th e  highest 
concentrations found  in th e  kidney and liver, closely fo llo w ed  by th e  brain, suggesting th a t
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copper is o f g rea t im p ortan ce in this la tte r organ (153). H ow ever, w hen  present in excess, 
th e  m eta l is cytotoxic, m aking copper hom eostatic  m echanism s o f p aram o u n t im p ortan ce  
fo r h ealthy cells, especially fo r those cells located in organs containing high levels o f copper. 
O ver th e  last decade it has becom e increasingly ap p aren t th a t APP is closely linked to  th e  
m etabolism  o f copper and m ay have a physiological role in th e  hom eostasis o f th e  m etal 
a n d /o r  th e  p ro tection  o f cells against co p per-m ed ia ted  toxicity  (1 5 4 -1 5 6 ). The links b etw een  
APP and copper are discussed below .
1.7.1. Copper binding to the APP ectodomain
Residues 1 2 4 -1 8 9  o f th e  APP E l dom ain  have been identified  as a copper binding  
dom ain  (E l  CuBD), th e  structure o f w hich has been d eterm ined  using nuclear m agnetic  
resonance spectroscopy. It consists o f an a -h e lix  and a trip le  stranded (3-sheet, im parting  a 
fa irly  rigid structure to  th e  dom ain  (15 4 ). The structure o f th e  E l CuBD is classified as a Type  
2 non-blue Cu(ll) centre , utilising a n u m b er o f nitrogen and oxygen atom s in ion binding. 
Residues H is l4 7 , H is l5 1  and T y r l6 8  have been im plicated in Cu(ll) binding w ith  a Kd o f 10  
n M  w hilst M e t l7 0  is th o u g h t to  be involved in th e  reduction o f Cu(ll) to  Cu(l) in vitro  (157, 
158). The E l CuBD has a surface location, and its structure dem onstra tes a p u ta tive  ab ility  to  
tran s fer copper ions, suggesting a possible role in transfer o f copper ions to  and fro m  o th e r  
proteins (154 ).
Dahm s e t  al. (15 9 ) also identified  a copper binding dom ain  in th e  E2 region o f APP 
(E2 CuBD) in w hich fo u r h istid ine residues (H is313, His382, His432 and H is436) ap p ear to  
coord inate  Cu(ll) co m p etitive ly  w ith  Zn(ll) a t physiological concentrations. Binding o f copper 
w ith in  this E2 dom ain  o f APP causes a large structural con form ational change, suggesting 
th a t copper binding to  th e  m em b ran e  bound holoprote in  m ay im pact on its in teraction  w ith  
o th e r proteins, both in tra - and extra-cellu larly .
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1.7.2. Copper-mediated APP expression
W h en  Lin e t  al. (160 ) tre a te d  PC12 cells w ith  50  and 100  |iM  copper, th e y  noticed an 
increase in APP transcrip tion  levels, w hich decreased w hen  th e  copper concentra tion  was  
raised fu rth e r to  2 0 0  |iM . T re a tm e n t o f these cells w ith  th e  an tiox id an t and m etal chela tor, 
curcum in, resulted in alm ost a co m p lete  prevention  o f th e  copper induced increase in APP 
transcrip tion . The transcrip tional effects o f copper on APP w e re  also reduced using 
alte rn a tive  antiox idants suggesting th a t it was th e  oxidative activ ity  o f copper w hich induced  
APP transcrip tion .
C ater e t al. (16 1 ) found  th a t, in copper defic ien t cells, APP m RNA levels w ere  
reduced w hereas th e  APP pro te in  level was m ain ta ined , suggesting th a t copper deficiency  
m ay increase th e  ra te  o f  APP trans la tion . Sim ilarly, A rm endariz e t al. (162) used cells th a t  
contained  ab n orm ally  high levels o f copper to  d em o n stra te  th a t steady-state APP gene  
expression was up-reg u la ted  by th e  m eta l. This e ffect was also seen w hen  control cells w ere  
tre a te d  w ith  copper, suggesting th a t both endogenous and exogenous copper can regu late  
APP expression. Bellingham  e t al. (163) found th a t cells d ep le ted  o f copper, as a 
consequence o f increased copper efflux, exhib ited  a decline in APP mRNA levels w ith  a 
co ncom itan t decline in APP p ro te in  levels. The authors also identified  th e  site o f a copper 
responsive regu lato ry  e le m e n t w ith in  th e  APP  gene p ro m o te r region b etw een  nucleotides - 
4 9 0  and +104 .
These in v itro  data have been supported by in vivo w ork  p erfo rm ed  by M a o  e t al. 
(16 4 ) in S prague-D aw ley rats. These results also im plicated copper in up regulation o f APP 
expression and p o ten tia lly  3-processing o f th e  protein . The rats w e re  supplied w ith  copper 
enriched drinking w a te r  fo r th re e  m onths, and th e  tre a te d  rats suffered cognitive  
im p a irm en t in com parison to  controls. This cognitive decline was accom panied by increased
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APP and BACE-1 m RNA and pro te in  levels, w hich re tu rned  to  norm al upon cessation o f
tre a tm e n t.
1.7.3. Copper-mediated APP proteolysis
Copper binding to  th e  APP ectod o m ain  m ay also be involved in th e  regu lation  o f its 
proteolysis. Spoerri e ta l.  (165) dem o n stra ted  th a t m u tatio n  o f h istid ine residues 1 4 7 ,1 4 9  
and 151  to  asparagine w ith in  th e  APP E l CuBD decreased production  o f sAPPa, sAPPP and 
Ap. These m utan ts d em o n stra ted  a decreased m aturation  o f th e  h o lo prote in , perhaps due to  
im paired  ER-to-Golgi trafficking, suggesting th a t copper binding a t th e E l CuBD m ay be 
involved in these processes.
The add ition  o f extracellu lar copper (2 -5  p M ) to  SH-SY5Y cells can a tte n u a te  Ap 
production  (166 ) as th e  m etal appears to  disperse APP and y-secretases fro m  lipid rafts and  
p ro m o te  localisation o f th e  fo rm e r to  th e  cell surface through inh ibition  o f flo tillin -2 - 
m edia ted  endocytosis. This prom otes a-secretase as opposed to  p-secretase cleavage o f th e  
p ro te in . It appears th a t th e  reverse m ay be tru e  in th e  A D -afflic ted  brain w h e re  free  copper 
levels are  reduced, prom oting  Ap production and concom itant AP and copper co-localisation  
in lipid rafts (167). Borchardt e t al. (168) also d em onstra ted  th a t copper a tte n u a te d  Ap  
production  in a Chinese-ham ster ovary (CHO) cell m odel, w h e re  copper sup plem en tation  
resulted in decreased AP production and a consequential increase in th e  production o f 
sAPPa and p3 through th e  a lterna tive  processing pathw ay. Conversely, B aum ko tter e t al. 
(13 4 ) suggested th a t copper m ight be involved in th e  d im erization  o f APP leading to  an 
increased generation  o f A p-peptides.
The APP secretase, BACE-1, has been shown to  in te rac t d irectly  w ith  copper via its 
cytoplasm ic dom ain  and, indirectly , th rough interaction  w ith  th e  copper chaperone fo r
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superoxide d ism utase-1 (16 9 ). H ow ever, w h e th e r such interactions result in a ltered  APP 
proteolysis rem ains to  be d e term in ed .
C ater e t al. (16 1 ) also showed th a t hum an fibrob last cells genetica lly  prone to  copper  
accum ulation  p re fe ren tia lly  produced sAPPa, w hereas those prone to  copper deficiency  
prim arily  processed APP via th e  am yloidogenic pathw ay. Copper d efic ien t SH-SY5Y 
neuroblastom a cells also produced e levated  levels o f AP, but did not exh ib it a lterations in 
APP expression levels o r in production  o f th e  a lte rn a te  pro teo ly tic  fragm ents, suggesting th a t  
th e  observed e ffec t m ay have been due to  th e  inhibition o f AP degradation.
An in vivo m odel using transgenic APP23 mice w hich have e levated  APP expression  
levels, d em o n stra ted  th a t increased availab ility o f copper decreased th e  CNS Ap levels and  
plaque burden (1 7 0 ). Transgenic toxic-m ilk (TxJ) and CRND8 mice provide fu rth e r  evidence  
th a t e levated  copper levels m ay a tte n u a te  AP production (171 ). The TxJ m ice express a 
m u tan t ATPase7b w hich favours cellu lar copper accum ulation and CRND8 m ice are an AD  
m odel w ith  a heavy Ap plaque burden. Studies using these transgenic m ice d em o n stra ted  
th a t e levated  in trace llu lar copper levels resulted in a decreased plaque burden and plasma 
AP levels w ith  a conco m itan t increase in survival. H o w ever APP h o lo prote in , sAPPa and AP 
levels in to ta l brain w e re  not significantly d iffe ren t b etw een  control and transgenic m ice. So 
although th e  reduction in p laque burden and plasma AP levels could be due to  a reduced  
production o f AP, it could also be explained by increased clearance o f periphera l AP pools.
1.7.4. APP and copper homeostasis
APP m ay be involved in copper efflux and hom eostasis, as over-expression o f th e  
pro te in  in m ice resulted in reduced brain copper levels and reduced superoxide d ism utase 1 
activ ity, w hich could be corrected  by supplem enting  drinking w a te r  w ith  copper (170). 
Consistent w ith  this e ffect, increased brain copper concentrations have been observed in
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APP knockout m ice (15 6 ). P o st-m ortem  AD brain tissue also show ed reduced copper levels in 
com parison to  controls, possibly due to  enhanced APP levels in th e  d isease-afflicted brain  
(17 1 ).
W h e n  a pep tid e  replicating residues 1 8 -3 5 0  o f th e  APP ex trace llu la r dom ain  was  
over-expressed  in yeast cells, in trace llu lar copper concentrations w e re  reduced by 
ap p ro x im ate ly  40% , suggesting th a t it is this E l CuBD in th e  extracellu lar dom ain  o f APP 
specifically th a t is involved in copper efflux (156). W hen  a sim ilar p ep tid e  containing  
histid ine to  asparagine m utations at positions 1 4 7 ,1 4 9  and 151 (w ith in  th e  E l CuBD) was  
em plo yed , in trace llu lar copper levels w ere  enhanced, im plicating these copper binding  
residues specifically in th e  ab ility  o f APP to  enhance cellu lar copper efflux.
Cerpa e t al. (17 2 ) d em o n stra ted  th a t, w hen a synthetic pep tid e  consisting o f th e  APP 
E l CuBD (residues 13 5 -1 5 6 ), was co-in jected w ith  copper into th e  brains o f m ice, th e  peptide  
p reven ted  th e  norm al neurotoxic effects o f th e  m etal and p revented  th e  associated  
behavioural changes. This suggests th a t th e  APP E l CuBD has a role in pro tection  against 
n eurotoxic copper concentrations. In seem ing contradiction o f this th eo ry , neurons derived  
fro m  APP knockout m ice are less sensitive to  copper toxicity  than  w ild -typ e  neuronal 
cultures, suggesting th a t APP m ay actually p ro m o te  th e  toxic effects o f copper in a tissue/cell 
d ep en d e n t m a n n er (173); a function  w hich has been a ttr ib u ted  to  th e  reduction o f Cu(ll) to  
Cu(l) by th e  cysteine residue o f th e  CuBD (174).
Indeed, over-expression o f APP does appear to  enhance th e  reduction o f 
extracellu la r C u (ll)to  Cu(l) in HEK293 cells (175). Both APP over-expression and provision o f 
A P P 135-155  peptides com prising th e  E l CuBD o f th e  p rotein  by Suazo e t al. (175) assisted 
w ith  Cu uptake into HEK293 cells, p inpointing this region as crucial fo r this function.
H ow ever, those cells over-expressing APP w ere  significantly m ore viable upon exposure to
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exogenous copper, suggesting th a t th e  reduction  and uptake o f copper has a p ro tective  
function , perhaps by creating  a 'co pp er sink' so th a t ROS production cannot take  place.
In T g 2 57 6  m ice, w hich over-express th e  Swedish m u tan t fo rm  o f APP and th e re fo re  
accum ulate A(3 plaques expo n en tia lly  o ver th e ir  lifespan, brain copper levels are reduced by 
~16%  by 16 m onths (17 6 ). This e ffe c t was coupled w ith  reduced zinc, e levated  m anganese  
and unchanged iron levels using age- and sex-m atched controls. Follow -up experim ents  
using TgC lO O .w t m ice, w hich over-express th e  C -term inal 100  am ino  acid residues o f APP, 
including th e  A 3 region, d em o n stra ted  trends o f reduced copper and iron levels, increased  
m anganese and cobalt levels, but unchanged zinc levels. This suggests th a t copper and o th e r  
m etal binding sites w ith in  th e  A3 region o f APP, o r interactions w ith  in trace llu lar ad ap to r  
proteins by th e  APP C -term inus have an im p o rtan t role in hom eostatic  m etal regu lation  by 
th e  p ro te in .
1.7.5. APP and the reduction of divalent copper
The APP E l CuBD binds to  Cu(ll) and reduces it to  Cu(l) in vitro  (177 ). This is likely to  
result in increased neuro tox ic ity  in th e  brain, such as th a t seen in AD, due to  g enera tion  o f 
ROS and induction o f oxidative dam age; an effect th a t has been observed by W h ite  e t al. 
(173 ) in p rim ary neuronal cultures. In fact, Cu(l) has been shown to  d irectly  cause th e  
lipoprote in  peroxidation  and fre e  radical production th a t in itia te  neuronal dam age in vitro  
(17 8 ). The sulphur a to m  o f th e  M e t l7 0  residue in th e  APP E l CuBD moves closer to  bound  
Cu(ll) and aw ay fro m  Cu(l), suggesting th a t this residue has a param o un t role in reduction o f 
copper (158 ). M u lth a u p  e t al. (17 9 ) im plicate th e  generation  o f a d isulphide bridge b etw een  
cysteines 144  and 158  o f APP in th e  reduction o f copper ions. In confirm ation  o f this 
supposition, m u ta tio n  o f C y s l4 4  to  alanine abolishes th e  reducing capacity dem o n stra ted  by 
w ild -typ e  APP (174 ).
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H o w ever, in seem ing contrad iction  to  th e  w o rk  described in th e  previous paragraph, 
Cerpa e ta l.  (17 2 ) d em o n stra ted  th a t th e  in tra -h ip p ocam p al injection o f a pep tid e  com prising  
th e  APP E l CuBD into  rats, p ro tected  against Cu(ll) induced neurotoxic ity . This e ffec t was  
reversed upon m u ta tio n  o f th e  C y s l44  residue, but not th e  H is l4 7 /1 4 9  residues, suggesting  
th a t APP E l CuBD-induced reduction o f Cu(ll) fac ilitates n eu ro pro tection  in rats, w hen  
presented  w ith  exogenous copper. This e ffec t confirm s th e  idea previously presented  by 
Suazo e t  al. (17 5 ) th a t APP m ay bind, reduce and tran sp o rt copper into  cells in o rd er to  
crea te  a sink o f toxic copper w hich can no longer induce ROS production and oxidative  
dam age.
The A p -p ep tid e  itse lf also has m etal reducing po ten tia l, w ith  th e  ab ility  to  rapidly  
reduce Cu(ll) and Fe(lll) to  Cu(l) and Fe(ll), respectively (18 0 ). Ap /C u com plexes can g en era te  
H20 2 fro m  oxygen, w hich contribu tes to  cellu lar toxicity (1 8 1 ,1 8 2 ) .  Zinc binding to  AP, 
displacing Cu(ll), reduces th e  oxidative dam age caused by this p ep tid e , suggesting a specific  
role fo r copper as th e  m etal th a t drives this process. This peroxidase activ ity o f Ap is driven  
by electrons d on ated  by both th e  reduced Cu ion and by th e  T y rlO  residue o f th e  A P-peptide  
(18 2 ). Interestingly , this tyrosine residue is not present in ro d en t APP and these anim als do 
not, inheren tly , d eve lop  AD.
The su lphur a to m  o f M e t3 5  is th o u g h t to  be critical in th e  A p-induced production o f 
H20 2, as transgenic m ice expressing hum an APP lacking M e t6 3 1  (eq u ivalen t to  th e  M e t3 5  o f 
th e  A p -p ep tid e ) do not suffer th e  sam e brain oxidative dam age as th e ir  w ild -typ e  APP 
expressing co u nterp arts  (183 ). H ow ever, w h e th e r o r not this M e t3 5  residue o f th e  AP- 
peptide is responsible specifically fo r copper induced Ap oxidation is still unclear. In fact, 
Ciccotosto e t al. (184 ) d em o n stra te  th a t m u tatio n  o f this residue to  valine does not decrease  
th e  Cu(ll) induced production o f H20 2 in p rim ary m ouse neuronal cortical cells. The residues
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His6, H is l3  and H is l4  are  also p o ten tia l candidates fo r th e  redox activ ity  w hich is in itia ted  
upon binding o f th e  A p -p ep tid e  to  copper ions (185 ).
In seem ing contrad iction  to  th e  fac t th a t Ap enhances copper-induced oxidative  
dam age th rough  th e  reduction  o f m etal ions, AP present in th e  CSF and blood plasm a has 
been shown to  act as an an tiox id an t (186 ). W h en  A p i-4 0  is p resent a t 0 .1 -1  n M  in th ese  
biological fluids, it can inh ib it oxidation o f CSF lipoprote ins and plasm a low  density  
lipoprote in . The A p i-4 2  p ep tide also d em o n stra ted  an an tiox id an t capacity, a lb e it a t a lo w er  
efficacy th an  A p l-4 0 . These data suggest th a t, u nder certain  conditions, AP m ay chela te  
m etal ions preventing  th e ir  reduction and th e  associated production o f toxic oxidative  
species. In support o f th is th eo ry , Feaga e t al. (187) confirm ed  th a t m onom eric  A P -p ep tide  
bound m ore tigh tly  to  Cu(l) th an  Cu(ll), suggesting th a t it possesses th e  ab ility  to  sequester  
this reactive ion.
1.7.6. Copper in Ap aggregation
In add ition  to  th e  copper binding dom ains w ith in  th e  ectodom ain  o f APP, th e  Ap- 
p ep tid e  itself can bind copper, w ith  th e  histid ine residues at positions 6 ,1 3  and 14 th o u g h t 
to  be involved in m etal co -ord ination  (188 ).
The norm al extrace llu la r copper concentra tion  in th e  brain is 0 .2 -1 .7  p M , w hereas  
th e  concentra tion  o f copper in am ylo id  plaques is ~ 4 0 0  p M  (189 ), suggesting th a t th e  m etal 
is involved in p laque fo rm atio n  (190 ). Indeed, in som e in vitro  experim ents th e  in te rac tion  o f 
copper w ith  Ap induces its aggregation, and in vivo copper causes Ap deposition into am ylo id  
plaques (191 ). F urtherm o re , it has been d em onstra ted  th a t th e  tre a tm e n t o f APP Tg2576  
m ice w ith  a co p per/z in c  ch ela to r greatly  im pairs plaque fo rm atio n  and th a t m u tatio n  o f th e  
Ap H is l3  residue reduces th e  propensity o f th e  pep tide to  aggregate (1 9 2 ,1 9 3 ) .  Once
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fo rm ed , A(B com plexes containing copper are also significantly m o re  resistant to  
disaggregation th an  m e ta l-fre e  peptides (194).
F urtherm o re , it is possible th a t regional c o p p e r/m e ta l availab ility  m ay be a 
d eterm in in g  fac to r in term s o f w hich parts o f th e  brain are m ost a ffected  by am ylo id  plaque  
deposition. For exam ple, both th e  cerebe llar cortex and locus ceruleus contain  re la tive ly  high 
copper concentrations (153) and also exhib it high levels o f am ylo id  plaque deposition and  
cell loss in AD (1 9 5 ,1 9 6 ) .
It should also be noted  th a t studies do exist suggesting th a t co p per m ay actually  
discourage th e  aggregation o f A(3 (19 7 ). The ap p are n t contradictions b e tw ee n  these studies  
and those described ea rlie r in this section m ight be explained by th e  propensity o f A(3 to  bind 
copper depending on its aggregation state, w ith  aggregated A (3 (l-4 2 ) having a much stronger 
copper binding strength  than  its m o nom eric  co u n te rp art (198).
1.8. APP and m etals -  iron
In add ition  to  its re lationship  w ith  copper (discussed above), APP is also believed to  
have an in tim ate  relationship  w ith  an o th e r m etal, iron. Som e o f th e  links b e tw ee n  iron and  
APP are discussed below .
1.8.1. Iron in the expression and proteolysis of APP
Iron appears to  be involved in both th e  expression and proteolysis o f APP. The 5'UTR  
region o f th e  APP transcrip t contains an iron-responsive e le m e n t (19 9 ). Additionally , APP 
trans la tion  is influenced by th e  sam e constellation  o f RNA-binding proteins (including th e  
iron-regu latory proteins 1 and 2) w hich control fe rritin  trans la tion , providing fu rth e r  
evidence th a t iron and iro n -re la ted  proteins are involved in th e  regu lation  o f APP transla tion .
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M o re o v e r, Bodovitz e ta l.  (200 ) dem o n stra ted  th a t in HEK293 cells, p roduction o f th e  
n eu ro p ro tec tive  sAPPa increases w ith  iron availab ility, and decreases fo llo w in g  iron  
chela tion.
1.8.2. APP and the metabolism of iron
In HEK293T cells, and in cortical tissue, APP dem onstra tes ferroxidase activ ity  and is 
involved in iron exp o rt (201 ). A blation o f APP in these m odels prom otes iron re ten tio n . In a 
m ouse m odel, APP ab lation  not only increased in tra -n eu ro na l iron levels, but also resu lted  in 
elevated  levels o f oxidative stress, d ep en d e n t on th e  ferroxidase activ ity  o f APP. This 
suggests th a t APP m ed ia ted  iro n -exp ort m ay reduce oxidative stress in th e  AD brain.
1.8.3. Iron and the Ap peptide
Ha e t al. (202 ) dem o n stra ted , using a solid te m p la te  created  by im m obilizing A(3 
oligom ers o n to  an N -hydroxysuccinim ide ester-activated  solid surface, th a t th e  m etal iron  
can also induce th e  aggregation o f Ap. Indeed, iron has been shown to  co-localise w ith  AP to  
fo rm  th e  am ylo id  plaque core in th e  AD brain (203).
A dditiona lly , Tab ner e t al. (204) d em onstra ted  th a t in vitro  th e  in teraction  b etw een  
Ap and iron can result in th e  production o f hydroxyl radicals. This suggests th a t th e  presence  
o f iron in th e  hum an AD brain m ay result in oxidative dam age, and co n tribu te  to  AP induced  
neurotoxic ity .
1.9. The roles of APP and copper in Alzheimer's disease
The am ylo id  cascade hypothesis states th a t an im balance b e tw een  th e  generation  o f 
Ap fro m  APP, and its clearance, is responsible fo r AD pathogenesis (20 5 ). M o re  recently, th e  
specific toxic en tity  in AD has been identified  as o ligom eric Ap, ra th e r th an  th e  am yloid  
plaques, w hich are instead th ou gh t o f as a sink or a 'tom b sto n e ' fo r AP (206 ). These soluble
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oligom ers are spherical in shape, 2 -  6 nm in d ia m e te r and range fro m  d im ers to  24 -m ers  
(20 7 , 20 8 ). Cortical levels o f Ap, including AP oligom ers, corre late  w ith  m e m o ry  im p a irm en t.
1.9.1. Mechanisms of Ap-mediated neurotoxicity
The precise m echanism  o f A p -m e d ia te d  cytotoxic ity rem ains to  be fu lly  established, 
but th e re  are several hypotheses in this respect. Extracellu lar AP oligom ers m ay bind to  
nerve grow th  fac to r receptors on th e  surface o f neurons, triggering cellu lar apoptosis (208). 
They have also been im plicated  in pore fo rm atio n  in th e  plasma m em b ran e  o f cells, w hich  
could lead to  abnorm al ion flo w  and p otentia l cell death  (209 ). Ap oligom ers are also known  
to  bind to  th e  cellu lar prion pro te in  causing synaptic dysfunction (210 ), o r N M D A  receptors  
causing oxidative stress and consequentia l synapse loss (209). The oligom ers also bind insulin 
and Frizzled receptors (208 ). Binding to  th e  insulin receptor im pairs kinase activ ity, resulting  
in insulin recep to r loss from  th e  cell surface. Binding o f th e  oligom ers to  th e  Frizzled recepto r  
can stim u late  tau  phosphorylation, resulting in th e  fo rm atio n  o f th e  o th e r pathological 
hallm ark o f AD, NFTs. All o f these effects u ltim a te ly  lead to  cell death .
In trace llu lar AP oligom ers also have th e  potentia l to  stim u late  cell d eath . A lthough  
Ap oligom ers are not o ften  in trace llu larly  located, th ey  can be im ported  into  th e  cell by 
recep to r-m ed ia ted  endocytosis (21 1 ) and th e  peptides are generated  in th e  first instance by 
B A C E l-m ed iated  cleavage in endosom es (212 ). One th eo ry  as to  how  in trace llu lar Ap  
oligom ers m ight exert th e ir  cytotoxic ity is through th e ir ab ility to  inhibit p ro teasom al 
activ ity, resulting in th e  accum ulation o f unw anted  proteins and, u ltim ate ly , cell d eath  (213). 
Also, in m itochondria, A p-peptides can in te rfe re  w ith  e lectron  transpo rt chain activity, 
resulting in p otentia l neuronal death  and synaptic dysfunction (214).
AP-peptides can g en era te  reactive oxygen species (ROS) w hich can have devastating  
effects on cellu lar hom eostasis through DNA dam age and through lipid and protein
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peroxidation , w hilst sim ultaneously providing th e  o p p o rtu n ity  fo r NFT d eve lo p m en t (214 , 
215). Furtherm o re , in flam m atio n  caused by th e  association o f astrocytes and m icroglia w ith  
th e  AP in am ylo id  plaques can have dual im plications (30 , 214 ). The in flam m ato ry  cells can 
fuel fu rth e r AP deposition  and sim ultaneously trigger ROS stim u lated  neuronal dam age.
1.9.2. Copper and Alzheimer's disease pathogenesis
The link b e tw ee n  ab erra n t copper hom eostasis and AD has been know n fo r som e  
t im e , and m eta-analysis o f data confirm s th a t serum  copper levels in AD patients are , on 
average, h igher th an  h ealthy contro l subjects (216, 217 ). Copper accum ulates in am ylo id  
plaques w ith  high levels o f p -sheet conform ation  AP (218) and th e  surrounding brain tissue 
in AD patients appears to  be dep le ted  o f copper in com parison to  controls (219).
T here  has even been speculation th a t th e  so called AD ep idem ic in deve loped  
countries is due to  leached copper from  w a te r  pipes increasing d ie tary  copper co n ten t and 
driving th e  onset o f th e  disease (220 ). The authors o f th e  study linked copper w ith  
A lzheim er's  disease th rough  various m echanism s. First, ApoE4, w hich im parts an e levated  
risk fo r AD does n ot bind copper, w hereas th e  E2 and E3 isoforms do. This m ay suggest th a t  
th e  inability  o f th e  fo rm e r isoform  to  bind and re locate copper m ight be linked to  disease 
pathogenesis. Second, e levated  copper ingestion in m urine AD m odels increased brain AD- 
like pathology and caused a reduction in cognition. Third, APP, AP, P-secretase and Tau can 
all bind copper and are heavily involved w ith  th e  onset o f AD. Finally, th e  authors noted  th a t  
free  copper levels in th e  blood are inversely associated w ith  cognition in both AD and non- 
AD patients.
As discussed in section 1 .7 .6 . (above), copper has also been shown to  in fluence the  
kinetics o f Ap aggregation, th e  type o f aggregation in te rm ed ia te  fo rm ed , and th e  
precip itation  o f AP aggregations (221). F urtherm ore , th e  binding o f AP to  copper can
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produce reactive oxygen species and dam age plasm a m em branes, th e re b y  co n tribu ting  to  
th e  neuro tox ic ity  caused by th e  peptides (188 ).
Due to  th e  clear invo lvem ent o f copper in AD pathogenesis, various copper 
chelating com pounds have been considered fo r th e ra p e u tic  use. The copper chelators  
tr ie n tin e , pen ic illam ine, b ath o p h en an th ro lin e  and bathocupro ine w e re  shown to  d ep le te  
copper and solubilise A 3 in AD brain tissue (222 ). The m etal chelator, clioquinol, was 
subjected to  a phase II clinical tria l using patients suffering fro m  m o d era te ly  severe AD, 
w h e re  reduced cognitive d e terio ra tio n  and plasm a A 342  levels w e re  observed fo llow ing  
tre a tm e n t (223 ). A n o th er copper chelator, D -pen icillam ine, has been shown to  reduce  
oxidative stress in AD patients but w ith o u t positive effects on cognitive ab ility  (224 ). 
P relim inary tests using th e  m etal chelators cyclen and cyclam have shown th a t in neuronal 
cells these com pounds can reduce th e  toxicity  o f m e ta l-A 3 40  com plexes, likely through  
solubilisation o f aggregates, conversion o f th e  3 -sheet m orphology o f aggregates and 
th rough  inhibition o f H20 2 production (22 5 ). Finally, curcum in and synthetic curcum in  
analogues have also d em o n stra ted  th e ra p e u tic  p o tentia l in term s o f th e ir  ab ility  to  reduce  
A 3 aggregation in vitro  (226).
1.10. The roles of APP and copper in cancer
Although APP is know n prim arily  fo r its role in AD, th e  p rotein  has m o re  recently  
been im plicated  in th e  pathogenesis o f various cancers, as has th e  m eta l, copper. W h e th e r a 
link b e tw een  APP and copper exists in re la tion  to  cancer is m ore speculative.
1.10.1. APP and cancer
APP has been recognised as a con tribu to ry  fac to r in disease progression in a range o f 
cancers including m elanom a, oral squam ous cell carcinom a, pancreatic cancer, colon
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carcinom a, m urine em bryonal carcinom a, neuroblastom a and PCa (2 2 7 -2 3 3 ). In oral 
squam ous cell carcinom a tissues, APP mRNA expression has been found to  be doubled in th e  
m ajo rity  o f m alignant sam ples, com pared  to  non-cancerous m atched tissues (22 8 ). Those  
patients w ith  increased APP m RNA levels exhib ited  a low er survival ra te , possibly due to  th e  
increased ra te  o f tu m o u r g ro w th  driven by APP expression. S im ilarly, APP m RNA expression  
has been found to  be e levated  by 50 -fo ld  in papillary thyro id  carcinom a cells in com parison  
to  th e  ad jacent th yro id  tissue (234 ). Again, higher APP levels w ere  associated w ith  enhanced  
m alignant po ten tia l. A possible explanation  fo r th e  increased APP expression exh ib ited  by 
these m alignancies could involve th e  role o f th e  p53 tu m o u r suppressor gene in th e  
suppression o f APP expression (235 ). If th e  p53 tu m o u r suppressor gene exhibits any  
abnorm alities , as m ay be th e  case in malignancies, it m ay also lose its ab ility  to  suppress APP 
expression, resulting in th e  observed elevations in APP expression. This m ay also explain w hy  
ab erra n t APP expression is not observed in all malignancies. Botelho e ta l.  (227 ), 
d em o n stra ted  th a t, w hen  APP expression was suppressed in a m etastatic  m elanom a cell line, 
pro lifera tion  was im paired  and th e  cells becam e term ina lly  d iffe ren tia ted  and m ore  
susceptible to  ch em oth erap eu tic  in terven tio n .
It is possible th a t th e  enhanced pro liferation  o f cancerous cells caused by APP m ight 
be re la ted  to  th e  ab ility o f th e  p rotein  to  bind heparin  (236 ), collagen (237) or integrins  
(23 8 ), all o f w hich are com ponents o f th e  extracellu lar m atrix . Adhesion has previously been  
shown to  enhance th e  p ro liferation  o f keratinocytes and de-adhesion  to  p ro m o te  
d iffe ren tia tio n  (239). It has been d em onstra ted  th a t APP is over-expressed and can enhance  
ex tram ed u llary  in filtra tio n  o f leukaem ia cells, which decreases survival ra te  (240). This e ffect 
has been a ttr ib u ted  to  a role fo r APP in m igration o f these cells, likely due to  its ab ility  to  
adh ere  to  th e  extracellu lar m atrix . The KPI dom ain (residues 2 8 9 -3 4 5 ) o f APP m ay also 
co n tribu te  to  p ro liferative activity, as neural stem  cells over-expressing sAPP770, as opposed
to  sAPP695( show ed increased pro liferation  (241).
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It w ou ld  seem  th a t th e  soluble APP ec todom ain , sAPPa, is sufficient to  enhance th e  
p ro lifera tion  o f m any cancerous cell lines. In S W 837 hum an colon carcinom a cells, d ow n - 
regu lation  o f APP expression resulted in a reduced p ro lifera tion  th a t could be reversed if 
conditioned  m edia  containing sAPPa was added to  th e  cells (230). If th e  conditioned  m edia  
w as p re -trea te d  w ith  an anti-APP N -te rm in a l an tibody (22C 11) th e  reduced pro liferation  
could n o-longer be negated . The fact th a t th e  antibody 22C 11 binds am ino acids 6 6 -82  at th e  
N -te rm in a l o f APP, suggests th a t th e  ex trem e N -te rm in a l o f APP m ay d irectly  partic ipate  in 
enhancing cell p ro lifera tion  (230 ). This effect was also observed by Ohsawa e t al. (242 ) in rat 
neural stem  cells, w h e re  sAPP695 stim u lated  pro liferation  through th e  p rom otion  o f DNA  
synthesis. Hansel e t al. (243) d em o n stra ted  th a t, in a pancreatic cancer cell line, binding o f 
th e  22C 11 an tibody to  sAPP could reduce pro liferation , and th e  add ition  o f purified  sAPP 
could enhance p ro liferation  o f these cells (243 ). N otab ly a structural analysis o f APP am ino  
acids 2 8 -1 2 3  has shown th a t this region o f th e  protein  has strong structural hom ology to  th e  
cysteine-rich g ro w th  factors, confirm ing th e  th eo ry  th a t this region o f th e  protein  m ay be 
specifically causative o f cellu lar p ro liferation  (244).
In fact, som e lines o f evidence suggest th a t th e  inhibition o f sAPPa generation  m ight 
be a su itab le th e ra p e u tic  in te rven tio n  point fo r th e  tre a tm e n t o f cancer. Evidence exists to  
suggest th a t A D A M 1 0  (the secretase responsible fo r sAPPa generation ) is upregulated  in 
m elanom a m etastasis (245). Furtherm ore , th e  inhibition o f sAPPa production in psoriatic  
keratinocytes, using hydroxam ic-acid-based zinc m eta llop ro te inase inhibitors, has been  
shown to  d ram atica lly  reduce cell p ro liferation; an effect o f w hich could be rescued by th e  
addition  o f exogenous sAPP (246).
T here  is also evidence to  suggest th a t sAPP m ay act as a ligand to  activate signalling 
pathw ays in a trans  fashion, th e re b y  enhancing th e  p ro liferation  o f cancer cells. Using th e  
thyro id  and th yro id  carcinom a cell lines, RFTL- 5 and FTC-133, respectively, Krause e t al.
58
(24 7 ) found th a t insulin and bovine th yro tro p in  (TSH) increased both th e  expression o f APP 
and th e  secretion o f sAPP. They also found th a t pro tein  kinase C (PKC) activation  increased  
sAPP release and postu lated  th a t sAPP activated  a signalling path w ay upon b inding a 
recep to r on th e  surface o f distal cells. Evidence th a t sAPP binds d irectly to  th e  cell surface  
has been g en era ted  using FRTL-5 and PC-12 cells by H offm ann e t al. (248 ). This was achieved  
using a reco m b inant fo rm  o f APP (sAPPrec), w hich enabled visualization o f its localization on 
th e  cell surface. The m olecule to  w hich sAPPrec bound to  at th e  cell surface w as sensitive to  
aldehyde fixation, suggesting a pro teinaceous nature like m any receptors in cell signalling  
pathw ays. These sAPPrec binding proteins w ere  localised in lipid rafts on th e  cell surface, 
w hich is typical o f glycosylphosphatidyl-inositol (G PI)-anchored proteins, suggesting th a t th e  
recep to r m ay be a G PI-anchored prote in .
The APP ec todom ain  m ay also fac ilita te  cancer deve lop m ent th rough  th e  inhibition  
o f apoptosis. W e h n e r e t a l.(249 ) d em o n stra ted  th a t UV-B induced apoptosis in hum an  
keratinocytes was increased by th e  add ition  o f an anti-sAPPa antibody. The authors also 
show ed th a t staurosporine-induced apoptosis could also be a tte n u a te d  by th e  add ition  o f 
reco m b inant sAPPa. This suggests th a t sAPPa m ay act by both inducing p ro lifera tion  and 
inh ibiting  apoptosis to  p ro m o te  cancer cell g row th .
Release o f th e  AICD into  th e  cytoplasm  has also been associated w ith  increased cell 
p ro lifera tion  due to  th e  a ltered  gene expression induced by this pro teo ly tic  fra g m en t o f APP 
(24 7 ). The m RNA expression o f various AlCD-binding proteins (Fe65, ShcA and JIP1) has been  
shown to  increase in thyro id  carcinom a cells com pared to  norm al thyro id  cells. Furtherm ore , 
it has been suggested th a t these proteins aid enhanced sAPP secretion, possibly contributing  
to  signalling via th e  m olecule. H ow ever, in SH-SY5Y cells, over-expression o f th e  AICD 
actually  resulted in reduced p ro liferation  and induced apoptosis (250 ). This e ffec t m ay be 
due to  th e  in teraction  o f AICD w ith  binding partners such as CUX1 and SPT5 to  reduce
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p ro lifera tion . The stim u lation  o f apoptosis by th e  AICD in SH-SY5Y cells has been re la ted  to  a 
d irect in teraction  b e tw ee n  p53 and AICD, prom oting  th e  ap o pto tic  function  o f th e  fo rm e r  
p ro te in  (251 ). Apoptosis has also been associated w ith  caspase-m ediated  cleavage at am ino  
acid 66 4  in th e  AICD and release o f apoptosis inducing APP fragm ents into th e  cytoplasm  
(25 2 ). These co n trad ic to ry  data suggest th a t th e  in terac tion  partners and consequential gene  
activation  and p henotyp ic  effects induced by AICD m ay be d ep en d e n t on location and cell 
typ e , but could play a role in cancerous cell p ro liferation .
Finally, it is possible th a t A(3 m ay inhibit cell p ro lifera tion , such th a t enhanced  
genera tion  o f sAPPa via th e  non-am ylo idogenic path w ay w ith  reciprocally reduced Ap 
production w ou ld  negate  this inh ib itory  e ffec t in cancer cells. Zhao e t al. (253) used hum an  
glioblastom a, b reast cancer and m ouse m elanom a cell lines to  investigate th e  effects o f A3  
on cell p ro lifera tion . Conditioned  m edia from  cells over-expressing APP and containing  
increased levels o f A 3 caused decreased pro liferation  com pared  to  untransfected cell lines. 
F urtherm o re , it was established th a t th e  inhibition o f p ro liferation  was in itia ted  by Ap only, 
and not sAPPa or sAPPp. H ow ever, th e  opposite seem s to  be tru e  in hum an em bryonic stem  
cells in w hich soluble and fib rilla r (b u t n ot o ligom eric) Ap have been shown to  induce cell 
p ro lifera tion , w hilst th e  inh ibition o f p-secretase suppressed pro liferation  (254). The A p i-4 2 -  
pep tid e  also induces th e  p ro lifera tion  o f glial cells (255) and A3, a t nanom olar  
concentrations, s tim ulates th e  g ro w th  o f PC12 cells (256) suggesting a cell typ e -d ep en d en t  
role o f Ap in re la tion  to  th e  stim u lation  or inhibition o f p ro liferation .
1.10.2. APP and prostate cancer
Takayam a e t  al. (2) used chrom atin  im m u noprecip itation  (ChIP) and genom e tiling  
array analysis to  iden tify  APP as a prim ary androgen ta rg e t gene in th e  horm one-sensitive  
PCa cell line, LNCaP. The authors also show ed th a t th e  APP  gene contained androgen
60
recep to r binding sites (ARBS) in its transcrip tional regu lation  region. Androgens w e re  found  
to  enhance both APP m RNA and pro te in  expression in LNCaP cells, and sAPP w as found  to  
enhance cell p ro lifera tion . Furthe rm o re , th e  im p lan ta tio n  o f w ild -typ e  and A PP-dep leted  
LNCaP cells into  nude m ice resulted in significantly reduced tu m o u r fo rm a tio n  in th e  m ice  
im p lan ted  w ith  th e  la tter. The authors also d em o n stra ted  th a t APP im m u n oreactiv ity  in a 
cancerous prostate  corre lated  w ith  a poor prognosis.
Further evidence re lating  APP to  PCa com es from  th e  fact th a t chem ical castration in 
m en w ith  PCa increases plasm a A3 levels, associating tes tos teron e inversely w ith  A 3 (257 ). 
Cell cu lture  systems and ro d en t m odels have also been used to  investigate th e  re lationsh ip  
b etw ee n  androgens and A3, and th e  conclusions draw n appear to  im ply th a t androgens  
negative ly regu late A3 levels (rev iew ed  in Rosario and Pike (258 )).
1.10.3. Copper and cancer pathogenesis
Both serum  and tissue levels o f copper in cancer patients are e levated  (data  
sum m arized  in Tables 1 .2  and 1 .3 ). These a ltered  copper levels can be re la ted  to  disease 
progression and, th e re fo re , prognosis. For exam ple, serum  copper levels o f patients w ith  
h em atological m alignancies e ith e r in a disease progression or relapse phase w ere  e levated , 
w hereas those in a stable disease state o r remission had norm al copper levels (25 9 ). This 
could im p licate  copper as an im p o rtan t diagnostic m arker in cancer. Indeed  copper levels 
have been d e term in ed  as a useful b io m arker in o rd er to  assess th e  response o f tu m o urs  to  
ch em o- and rad io -therap y (260 , 261).
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Cancer Normal patients copper Cancer patients Number o f subjects
levels (pg/g  ± SD) copper levels (pg/g  ± SD) (significance compared
to  control)
Breast cancer 6.13 ± 4 .3 2  (norm al) 
6.51 ± 5 .3 3  (Benign)
11.08 ± 4 .9 8  (Stage I) 
10.10 ± 5 .6 1  (Stage II) 
17.18 ± 11.83 (Stage III)
25
Breast cancer 9.3 ± 2 .3 2 1 .0 ±  10.7 22 (p <  0.0001)
Ovarian cancer 0 .2 -0 .9 0 .4 —2.8 10
Colorectal cancer 1.79 ± 0 .5 7 2.78 ± 0 .84 30 (p <  0 .001)
Breast cancer 2.38 3.25 20
Breast cancer 0.29 (±0.29 ppm 0.89 ± 0.56 ppm 40
Large bowel 1.53 ± 0.35 1.90 ± 0 .6 24 (p < 0 .05)
Stomach 1.44 ± 0.38 2.09 ± 0.52 7 (p < 0 .0 2 )
Ovarian 1.26 ± 0 .4 5 2.16 ± 0 .6 3 5 (p < 0 .0 1 )
Breast 1.58 ± 0 .6 2 1.91 ± 0 .5 6 8
Kidney 1.80 ± 0 .4 2 1.61 ± 0 .2 5 3
Bladder 1.54 2.80 ± 0 .3 2
Testis 1.48 ± 0 .7 1.43 1
Hodgkin’s 1.42 ± 0 .4 4 3.18 1
Total cases 1.42 ± 0 .4 4 2.08 ± 0 .7 6 53 (p <  0 .001)
Breast cancer 1.47 ppm 5.12 ppm 15 (p < 0 .0 1 )
Stomach cancer 1.1 ± 0 .4 1.7 ±0 .1 18 (p < 0 .0 1 )
Ovarian cancer 1.95 ± 0 .64 2 .17 ± 0 .6 4 40
Leukemia 15 ± 4  p g /106 cells 52 ± 16 ng/106 cells 12 (p < 0 .01)
Table 1.2. Tissue copper levels in cancer. Taken from Gupte e t al. (262). In all but 2 studies cancer patients 
have elevated tissue copper levels in comparison to normal patients.
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Cancer Normal patients copper 
levels (pg/dL*5D)
Cancer patients copper 
levels (pag/dL *  SD)





114 *  29 328*74 21 ip <0j01)
Breast cancer 115*20 131 *20 35 ip < 0.01)
Cervical 92.9 129.3 19 (p < 0.001)
Ovarian 92.9 139.5 4 ip < 0.0Q1)
Mon-lHlodgkin',s
lymphoma
120.4*23.3 134.9*42.4 (Stage 1) 
176.1 *  66.3 (Stage II) 
176.9*37.5 (Stage III) 
157.7 *  49.6 (Stage IV)
Breast cancer 122.4*15.8 222.7 * 44.4 (Stage 1) 
203.9* 31.3 (Stage II) 
238.1 *  36.8 (Stage III) 
228.4 *  38.0 (Total)
35
lung cancer 100* 18.2 125 ±20.2 (Stage 1 and II) 
150 *  33.8 (Stage III)
65 ip <0.001)
Prostate cancer 84.1 *6.27 124*8.3 44 ip <0J01)
Reticulo­ 115.8 ±13.9 (males) 228.0 * 52.4 (males) 70 (p < 0.001)
endothelial system 118.9*17.1 (females) 225.4 * 61.8 (females)
(1) Lung cancer 143.0*3.2 188.2* 14.8 (Lung) 20 tp <0.01)
(2) Stomach 
cancer
171.9*7.3 (Stomach) 33 (p <0.01)
(3) Large intestine 164.7* 13.4 (large 
intestine)
22 (p < 0.05)
Co lo rectal cancer 98.8*24.3 165 * 33.9 30 ip <0.001)
Leukemia 86.7*25.3 132.8 *  50.6 (Acute 
leukemia)
129.1 * 49.8 (acute 
lymphoid leukemia) 
139.9* 51.2 (acute non- 
lymphoid leukemia)





8 ip < 0.05)
(1) Oral 66.9 *  22.0 (male) (1) Oral leukoplakia 21
leukoplakia 89.6 * 19.0 (male) 
95.2* 17.0 (female)
25 ip <0.001)
(2) Squamous cell 66.8 *  14.0 (female) (2) Oral cancer 22 ip <0.001)
carcinoma 108.9 * 17.0 (male) 
107.8* 12.0 (female)
20 ip <0.001)
Ovarian cancer 133* 17.0 (Benign,, n» 42) 160 *  17.0 (Stage 1) 
190 ±6.0 (Stage II) 
179 *18.0 (Stage III) 
210 *23.0 (Stage W)
2
4
19 ip <0.001) 
11
Breast cancer 96.5*7.3 (control) n *26 
103.8 ±8.3 (Benign) n *43
125.2* 15.0 25 (D <0.01)
Breast cancer 100.7*40.5 172.8* 12.2 50 ip <0.01)
Table 1.3. Serum copper levels in cancer. Taken from Gupte e ta l.  (262). All studies demonstrate elevated
copper levels in cancer patients.
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As e levated  copper levels have been associated w ith  cancer progression, th e  use o f 
copper chelators in th e  tre a tm e n t o f cancers has been assessed. Trial o f t re a tm e n t using th e  
copper chelator, te tra th io m o ly b d a te , w ith  w om en  possessing a high chance o f breast cancer 
recurrence was carried  out. It d em o n stra ted  th a t if co p per-d ep le tio n  was successful, th e  
n u m b er o f bone m arro w -d erived  en d oth e lia l p rogenitor cells (EPCs) in circu lation was  
m ain ta in ed  below  baseline, reducing th e  risk o f recurrence (263 ). This suggests th a t copper 
m ay assist w ith  th e  survival o f th e  risk enhancing EPCs. N ot only do copper chelators alone  
ap p ear to  have benefits associated w ith  reducing cancer burden, but th ese  chelators can 
also enhance cancer tre a tm e n t w ith  Herpes sim plex virus-derived oncolytic viruses and 
cisplatin (264 , 265).
Interestingly, even though  cancer pathogenesis correlates w ith  e levated  copper 
levels, it has also been associated w ith  decreases in antiox idant activ ity, w ith  catalase and 
superoxide dism utase (SOD) exhib iting decreased activity in colorectal cancer patients (266). 
This e ffec t could im ply th a t th e  reduced activ ity o f SOD m ay be due to  th e  liberation  o f its 
copper cofactor into se rum /tissue, leaving SOD inactive, or th a t e levating  copper levels m ay  
be a physiological m echanism  em ployed  to  try  and enable SOD to  regain its antiox idative  
capacity.
The role o f copper in th e  stim ulation  o f angiogenesis has been know n fo r som e tim e , 
and is com prehensively review ed  in G upte e t a l.(262). How ever, m ore recently , th e  m etal 
has been linked to  th e  stim ulation  o f shedding o f key cell surface proteins involved in cancer 
pathogenesis and to  th e  invasion o f PCa cells. Parr-Sturgess e t al. (26 7 ) d em o n stra ted  th a t 
th e  m etal can stim u late  th e  shedding o f th e  Notch ligand, Jaggedl and th e  cell adhesion  
p ro te in , E-cadherin in th e  PCa cell line, PC3. This e levated  shedding co rre la ted  w ith  an 
enhanced invasive potentia l o f th e  cells.
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W hils t e levated  serum  and tissue copper is associated w ith  various cancers, th e  link 
b etw ee n  d ie tary  in take o f th e  m etal and cancer is less clear. Certain  studies suggest th a t  
enhanced d ie ta ry  copper m ay be beneficial in th e  prevention  o f cancer. M a h a b ir e t al. (268) 
re la ted  an increase in d ie tary  copper to  a reduced risk o f lung cancer in hum ans. 
F urtherm o re , supplem enting  th e  d ie t o f rats w ith  cupric aceta te  has been shown to  prevent 
th e  induction o f h ep ato m a fo rm a tio n  by eth ion ine  (269 ). S im ilarly, tu m o u r incidence and  
burden w e re  increased in a m urine m odel o f intestinal cancer w hen  th e  anim als w e re  fed  a 
copper d efic ien t d ie t (27 0 ). Studies in rats also showed th a t low  copper in take resulted in 
elevated  d im ethylhydrazine -induced colon tu m o u r fo rm atio n , th e  effect o f w hich m ay have  
been due to  th e  reduced activ ity o f Cu an tiox idan t enzym es (271, 27 2 ). Conversely, Senesse 
e t  al. (273) co rre la ted  high levels o f d ie tary  copper w ith  an increased risk o f colorectal cancer 
in hum ans, and N icodem us e t al. (274) found th a t postm enopausal w om en  w ho  had taken  
copper supplem ents w e re  at increased risk o f getting  kidney cancer. T herefo re , th e re  
appears to  be a re lationsh ip  b e tw een  copper intake and cancer risk; how ever this risk is 
likely re lated  to  th e  typ e  and location o f th e  cancer.
1.11. Aims of the cu rren t project
APP and copper, individually, ap p ear to  have pivotal roles to  play in both A lzheim er's  
disease and PCa. H ow ever, w h e th e r these roles are m utually  exclusive or connected in th e  
tw o  conditions is less clear.
The overarching aim  o f th e  curren t pro ject is to  exam ine th e  relationship  b etw een  
APP and copper in tw o  distinct cell models; SH-SY5Y neuroblastom a cells (in re la tion  to  AD) 
and D u l4 5  cells (in re la tion  to  brain m etastatic  PCa). Specifically, th e  effects o f APP o ver­
expression and d ep le tio n  on cell v iability  in th e  presence o f copper are exam ined and th e  
m olecular pre-requis ites underlying such effects are elucidated.
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Firstly, I w ill characterize th e  expression and proteolysis o f APP in a range o f prostate  
cancer cell lines, and in a neuroblastom a cell line. This analysis aims to  d e te rm in e  w h e th e r  
th e re  is a p attern  re lating  APP expression o r proteolysis to  cancer stage. A dditionally , it w ill 
investigate th e  appropriateness o f a range o f cell lines fo r th e  general analysis o f th e  
m olecu lar biology o f APP.
Next, I w ill exam ine th e  e ffec t o f copper on th e  viability  o f these prostate  cancer cell 
lines. I w ill also investigate th e  e ffec t o f copper on APP expression and proteolysis in these  
cell lines. This analysis w ill begin to  investigate th e  relationship b etw een  copper and APP in a 
range o f cell m odels.
Then, using th e  D u l4 5  cell system, I w ill study th e  effect o f fu ll-length  (iso form - 
specific) APP expression on D u l4 5  cell v iab ility  in th e  presence o f copper. Assuming th a t APP 
influences th e  viab ility  o f D u l4 5  cells, I w ill express a range o f APP constructs in this cell line 
in o rd er to  e lucidate w hich regions o f th e  p rotein  are involved in this activ ity. These APP 
constructs w ill investigate th e  roles o f th e  APP cytosolic dom ain, th e  APP a - and (3- 
ectodom ains, th e  N -te rm in a l APP copper binding dom ain, and th e  specific histidine residues  
w ith in  it, in this action.
An add itional aim , w hich arose as th e  pro ject developed, concerns th e  in fluence o f 
APP on D u l4 5  cell m orphology. APP appeared  to  induce a m orphological change in D u l4 5  
cells, and th ere fo re  I also used th e  constructs developed fo r th e  above analysis to  d e te rm in e  
w hich regions o f th e  APP m olecule are involved in this activity.
In o rd er to  consolidate th e  results from  th e  above studies, a sim ilar analysis was  
carried o u t in th e  SY-SY5Y cell system . In add ition , th e  histidine residues located w ith in  an 
additiona l copper b inding region (in th e  E2 dom ain) o f th e  prote in , w ere  exam ined in this cell 
line.
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Such studies o f APP and copper have re levance to  both neuronal v iab ility  in AD and  
th e  survival o f brain m etas tatic  PCa cells.
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2. Materials and Methods
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2.1. M aterials
D u l4 5  cells w e re  a g ift fro m  Alix Bee (U niversity o f Liverpool, UK). PC-3 and SH-SY5Y 
cells w ere  purchased from  th e  Am erican Type C ulture Collection (ATCC). LNCaP cells w ere  a 
g ift fro m  Caroline Dalgliesh (N ew castle  University, UK).
The an ti-p -actin  m onoclonal an tibody, th e  anti-APP C -term inal polyclonal an tibody  
and th e  anti-FLAG M 2  m onoclonal antibody w ere  from  Sigm a-Aldrich (Poole, UK). The an ti- 
APP 6E10 m onoclonal an tibo d y was from  Covance (California, USA). The a n ti-A D A M IO  (C- 
te rm in a l) polyclonal an tibody and th e  an ti-A D A M 17 (am ino acids 8 0 7 -8 2 3  o f hum an A D A M - 
17) polyclonal an tibody w ere  fro m  M erck  (N ottingham , UK). The anti-sAPPP (1A 9) an tibody  
w as kindly provided by Ishrut Hussain (G laxoSm ithKline, H arlow , U.K.). The anti-APP (am ino  
acids 66 -81  o f th e  N -te rm in us on th e  pre-A 4 m olecule) m onoclonal an tibody 22C 11 was from  
M illip o re  (W atfo rd , UK). The an ti-neuron  specific enolase mouse m onoclonal antibody, NSE- 
P2 was from  Abeam  (Cam bridge, UK). The anti-E R K l polyclonal antibody, th e  anti-E -cadherin  
polyclonal an tibody and th e  an ti-v im en tin  polyclonal antibody w ere  from  R&D systems  
(M inneapo lis , USA). The anti-caveo lin  polyclonal an tibody was from  BD biosciences (San 
Jose, California). All Secondary an tibody peroxidase conjugates w ere  fro m  Sigm a-Aldrich  
(Poole, UK).
Unless o therw ise stated  all tissue culture reagents w ere  purchased fro m  Lonza 
(Basel, Sw itzerland), all m o lecu lar biology reagents from  N ew  England biolabs (Ipswich, UK), 
and all o th e r reagents fro m  Sigm a-Aldrich (Poole, UK).
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2.2. Molecular biology
2.2.1. Preparation of agar plates
Both serum  and Agar (7 .5  g) was added to  50 0  ml o f 2% (w /v ) liquid broth  (LB) (low  
salt g ran u la ted ) and th e  solution w as autoclaved . Once th e  agar solution was cooled to  45  
°C, am picillin  w as added to  a final concentra tion  o f 0 .1  m g /m l before pouring th e  plates.
2.2.2. Bacterial transformation
X L -l C o m p ete n t E.coli (Agilent, California, USA) cells w ere  th aw ed  on ice and  
com bined  w ith  DNA at a vo lum e ratio  o f 20:1 (bacteria:D N A ). The m ixture was then  
incubated on ice fo r 30  min before h eat shocking at 42  °C fo r 45  seconds and th en  re turn ing  
to  ice fo r an o th e r 2 m in. LB (9 vo lum es) was added and th e  samples w ere  incubated on a 
carousel fo r l h  a t room  te m p e ra tu re . The samples w ere  then  centrifuged a t 3 5 0 0  g fo r 1 min  
b efo re  rem oving  all but 100  pi o f th e  supernatan t. The bacteria w ere  th en  resuspended in 
th e  rem ain ing  sam ple vo lum e, spread on agar plates and incubated a t 37°C  overnight.
2.2.3. Bacterial suspension cultures
Bacterial suspension cultures w ere  grown in e ith e r 5 ml m in i-cultures o r 50  ml m id i­
cultures. In each case a single bacterial colony was stabbed into th e  cognate vo lum e o f LB 
containing 0 .1  m g /m l final concentra tion  o f am picillin. Cultures w e re  th en  grow n overnight 
on an o rb ita l incub ato r a t 37  °C.
2.2.4. DNA purification
DNA w as ex tracted  and purified fro m  m in i- and midi-suspension cultures using 
QIAGEN Plasmid M in i and M id i kits (Q iagen, Craw ley, UK) according to  th e  m anufacturer's
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instructions. DNA was e lu ted  fro m  m in i- and m id i-p rep  colum ns in final distilled w a te r  
volum es o f 50  and 30 0  p.1, respectively.
2.2.5. Spectophotometric quantification of DNA
DNA concentra tions w e re  d e te rm in e d  using a N anodrop 2000c sp ec tro p h o to m ete r  
reading at a w avelen gth  o f 26 0  nm (Therm o Scientific, St Leon-Rot, G erm any).
2.2.6. Agarose gel electrophoresis
Agarose o r NUsieve GTG agarose (Lonza, Basel, Sw itzerland) (1 -3%  ( w /v ))  was  
dissolved by m icrow aving  in Tris ace ta te  EDTA (TAE) b u ffe r (0 .8  m M  Tris, 0 .4  m M  acetic acid, 
0 .0 2  m M  EDTA, pH 8 .0 ). A fte r cooling to  40°C  in a w a te r bath fo r 30  m in, e th id ium  brom ide  
was added to  a final concentra tion  o f lp g /m l (a lterna tive ly  gels w ere  post-stained w ith  
GelRed (B iotium , Hayw ard, Californ ia). Gels w ere  th en  poured and allow ed to  set fo r at least 
30  min before  transferring  to  a running kit containing TAE. DNA samples w ere  p repared  by 
dilu ting  1 in 6 w ith  6 x loading b u ffe r (0 .25%  (w /v ) brom opheno l blue, 1 m M  EDTA, 30%  (v /v ) 
glycerol, 0 .25%  (w /v ) xylene cyanol FF, pH 8 .0 ). Sam ples w ere  loaded onto  gels alongside an 
ap p ro pria te  DNA standard (e ith e r 1 kB standards (Invitrogen, Paisley, UK) o r 100  bp 
standards (N ew  England Biolabs, Herts, UK)). Gels w ere  run at 90  volts fo r 3 0 -9 0  m in. If post- 
staining was requ ired, th e  gel w as incubated in GelRed solution (1 :5000 , GelRed: TAE) fo r 30  
min a t room  te m p e ra tu re  on a ro tating  p la tfo rm . The results w ere  docum ented  using a 
BioDoc-lt T ransillum inator and Sony V ideo  G raphic P rin ter U P 895M D .
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2.2.7. Site-directed mutagenesis polymerase chain reaction
(PCR)
Prim ers w e re  designed and ord ered  fro m  Sigm a-Aldrich (Poole, UK) and resuspended  
according to  th e  m anu fac turer's  instructions in distilled w a te r. The fo llo w in g  reaction  
m ixture  was th e n  prepared :
DNA (54 .5  n g /p l) - 1  pi
5 x high fid e lity  b u ffe r - 1 0  pi
2 m M  dNTPs - 5 pi
Forw ard p rim er (1 p g /p l) - l p l
Reverse p rim er (1 p g /p l) - l p l
Sterile dH 20 -3 1 .5  pi
Phusion DNA polym erase - 0 .5  pi
The PCR reactions w e re  th en  p erfo rm ed  in a Techne TC -312 th e rm a l cycler (Techne  
Inc, N ew  Jersey, USA) using th e  conditions below :
98  °C
98  °C 30  sec
72 °C 30  sec
72 °C 2 min
72  °C 7 min
10 °C Soak
loop x 16
D p n l (0 .5  |il) w as th en  added to  th e  samples fo llo w ed  by an add itiona l incubation at 
37  °C fo r  1 h.
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2.2.8. Restriction enzyme digests /  DNA linearization
DNA digest reactions w e re  m ade up as show n be low  and incubated  a t 37°C  
overnight:
10  x restriction  enzym e b u ffe r - 5 |il
BSA (10  n g /|il 10 x stock) - 0 . 5 | i l
Restriction enzym e - 1  |il
DNA - 0 .5 -2  \xg
Sterile H20  - m ake up to  50  j l^
2.2.9. Ethanol precipitation of plasmid DNA
The requ ired  am o u n t o f DNA (e ith e r linearized o r non-linearized ) w as com bined w ith  
1 /1 0  vo lum e o f filter-sterilised  3 M  sodium  aceta te  (pH 5 .2 ) and 2 volum es o f cold absolute  
eth an o l. Sam ples w ere  then  m ixed and incubated at -20°C  fo r 1 h. DNA was pelle ted  by 
centrifuging fo r  20 m in at to p  speed in a m icrofuge (4°C). The supern atan t was rem oved and  
3 0 0  ]ul o f cold 80%  (v /v ) ethano l was added to  th e  p e lle t befo re centrifuging once m ore a t 
to p  speed in a m icrofuge (4°C). The su p ern atan t was rem oved fro m  th e  DNA p elle t under 
aseptic conditions and th e  DNA w as resuspended in filte r-s te rilized  distilled w a te r  to  th e  
requ ired  concentra tion .
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2.3. Mammalian cell cu lture
2.3.1. Growth incubations
SH-SY5Y cells w e re  cu ltured  in Dulbecco's m odified  Eagle's m edium  (D M E M )  
su p plem en ted  w ith  25 m M  glucose, 4  m M  L-glutam ine, 10%  (v /v ) fe ta l bovine serum  (FBS), 
penicillin (50  U /m l), strep tom ycin  (50 p g /m l) and fungizone (2 .5  p g /m l). D u -145 , LNCaP and  
PC-3 cells w ere  cultured in Roswell Park M em o ria l Institu te  (R PM I) 1 6 4 0  m edium  containing  
th e  sam e supplem ents. All cells w e re  grown at 37  °C in 5 % (v /v ) C 0 2. For splitting, co n fluen t 
flasks o f cells w e re  trypsinised and centrifuged fo r 3 min (1 5 0 0  g) a fte r first neutralising th e  
trypsin by th e  add ition  o f g ro w th  m ed iu m . The resultant pellets w ere  resuspended routinely  
in 1 ml o f g ro w th  m edium  fo r every subsequent culture to  be seeded.
2.3.2. Freezing down cell stocks
The protocol above (section 2 .3 .1 .) was fo llow ed  but, instead o f seeding cells into a 
fresh flask, th e  p elle t was resuspended in 1.5 ml o f 10%  (v /v ) d im ethyl sulfoxide (D M S O ) 
(m ade up in grow th  m ed iu m ). Sam ples w ere  transferred  to  cryovials and frozen  at -8 0  °C fo r  
app ro xim ate ly  24  h before transferring  to  liquid nitrogen.
2.3.3. Cell counting
The h aem o cyto m eter and cover slip w ere  rinsed in 70  % (v /v ) e th an o l th en  dried. 
The cell suspension w as th en  loaded into th e  V  notch o f th e  h aem o c y to m e te r slide to  load 
th e  sam ple via capillary action; th is was done on both sides o f th e  h aem o cyto m eter. The  
n u m b er o f cells in each counting area was counted and an average taken . The average was 
th en  m ultip lied  by 1 0 ,000  to  give th e  n um ber o f cells per ml.
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2.3.4. Transient transfection using lipofectamine
M am m a lian  cells w ere  grown to  ap p ro xim ate ly  80%  confluence in T75 cm 2 flasks 
b efo re  rem oving  th e  g ro w th  m edium  and replacing w ith  a fresh 10 ml o f O p tiM E M  
(Inv itrogen , Paisley, UK). The cells w ere  th en  placed back in th e  grow th  incubator during  
p rep aratio n  o f DNA: lip o fectam ine com plexes. Ethanol p rec ip itated  non-linearized  DNA (8 
pg) (section 2 .2 .9 .) w as resuspended in 30 jj.1 o f sterile distilled w a te r  and d ilu ted  w ith  4 7 0  pil 
o f O p tiM E M . In a second tu b e , 20 pi lipo fectam ine 20 00  (Inv itrogen, Paisley, UK) was added  
to  4 8 0  pi O p tiM E M . Following 5 min incubation at room  te m p e ra tu re , th e  DNA and  
lip o fectam ine solutions w e re  com bined and incubated fo r a fu rth e r 20  m in at room  
te m p e ra tu re . During th is incubation th e  cells w ere  rem oved fro m  th e  incubator and th e  
O p tiM E M  w as replaced w ith  a fresh 2 ml o f th e  sam e m edium . The DNA: lipo fectam ine  
com plexes w ere  th en  added, drop-w ise, to  th e  O p tiM E M  bathing th e  cells and th e  
transfections w e re  incubated fo r 5 h (37 °C, 5 % (v /v ) C 0 2). D M E M  or RPMI (according to  th e  
cell typ e  used; section 2 .3 .1 .) (5 m l) containing 30  % (v /v ) FBS was th en  added to  th e  flask  
and th e  cells w e re  grow n fo r an add itional 24 h. The m edium  was th en  rem oved and  
replaced w ith  a fresh 10  ml o f co m p lete  g row th  m edium  (section 2 .3 .1 .) before a final 24  h 
incubation period p rior to  assessing protein  expression.
2.3.5. Stable transfection using lipofectamine
The protocol described above (section 2 .3 .4 .) was p erfo rm ed  but using 1 5 -3 0  pg o f 
linearized DNA. Stable transfectants  w ere  th en  selected using 150  p g /m l o r 20 0  p g /m l final 
concentrations o f Hygrom ycin B (Invitrogen, Paisley, UK) forSH-SY5Y and D u l4 5  cells, 
respectively.
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2.3.6. Stable transfection of D u l45 cells using nucleofection
The Am axa cell line nucleofector kit L em ployed  (Lonza, Basel, S w itzerland) consists 
o f tw o  com ponents; cell line nucleofector solution L (2 .25  m l) and su p p lem en t (0 .5  m l). The  
tw o  com ponents w ere  com bined to  fo rm  th e  w orking  reagent. Linearized eth an o l 
prec ip ita ted  DNA (2 .5  pg) (section 2 .2 .9 .) was resuspended in 4  pi o f d istilled w a te r  and  
com bined  w ith  100  pi o f th e  nucleofector kit L w orking  reagent. D u l4 5  cells cu ltured  to  
confluence in 6 -w ell plates w e re  harvested as described in section 2 .3 .1 . and any residual 
g ro w th  m edium  was rem oved fro m  th e  cell pellets using a Gilson p ip ette . The cell p e lle t w as  
th en  resuspended d irectly  in th e  nucleofector kit L w orking  re ag en t/D N A  solution and  
tran s ferred  into an Am axa certified  kit cuvette . The cuvette  was placed in th e  N u cleo fec tor  
2b device (Lonza, Basel, S w itzerland) and program  A-23 was run. The cells w ere  th en  gently  
trans ferred  from  th e  cu vette  into th e  wells o f a 6 -w ell p late containing 2 ml o f p re­
eq u ilib ra ted  (37°C) g row th  m edium . Cells w ere  th en  incubated under norm al g row th  
conditions (37 °C, 5 % (v /v ) C 0 2) fo r 48  h before  stable transfectants w ere  selected using a 
20 0  p g /m l final concentra tion  o f Hygrom ycin B.
2.3.7. Stable transfection using electroporation
Linearized DNA (30  pg fo r SH-SY5Y cells and 20  pg fo r D u l4 5  cells) was e thano l 
p rec ip itated  (section 2 .2 .9 .) and resuspended in 30 pi o f sterile distilled w a te r. A T 7 5  cm 2 
flask o f cells w as th en  harvested (section 2 .3 .1 .) and th e  cell pelle t was resuspended in 80 0  
pi o f O p tiM E M  and trans ferred , along w ith  th e  30  pi o f DNA to  an e lectro p oration  cu vette  
(Fisher, Loughborough, UK). The cuvette  was th en  incubated on ice fo r 10 m in before  
electro p orating  th e  cells in a gene pulser Xcell e lec tro p o ra to r (Bio-Rad, H ertfordsh ire , UK). 
The fo llow ing  e lectro p oration  p aram eters  w ere  utilised:
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SH-SY5Y cells - 'square w ave ' program  
120  V  
25  ms
0 .2  cm cuvette  w id th
D u l4 5  cells - 'square w ave ' program  
20 0  V  
5 0  ms
0 .2  cm cuvette  w id th
Following e lectro p oration , th e  cuvette  was incubated on ice fo r a fu rth e r 10 m in.
The transfected  cells w e re  th en  transferred  to  5 ml o f co m plete  g ro w th  m edium  in a 50  ml 
Falcon tu b e  to  a llow  effective  resuspension by repeated  p ipetting  before adding th e  m ixture  
to  an o th er 10 ml o f co m p lete  g ro w th  m edium  in a T75 cm 2 flask. The cells w ere  then  
incubated u nder norm al g ro w th  conditions (37 °C, 5 % (v /v ) C 0 2) fo r 24 h a fte r which th e  
m edium  was rem oved and replaced w ith  a fresh 10 ml o f co m plete  g ro w th  m edium . The  
selection o f stable transfectan ts  was com m enced 4 8 -7 2  h post-transfection  using 150  p g /m l 
and 200  p g /m l final concentrations o f Hygrom ycin B fo r SH-SY5Y and D u l4 5  cells, 
respectively.
2.3.8. Small interfering RNA (siRNA) transfection of D ul45 cells
D u l4 5  cells w ere  seeded a t 6 .6  x 104 cells per w ell o f a 6 -w e ll p la te  in an tib io tic  and  
fungizone fre e  RPMI containing 10%  (v /v ) FBS and grow n overnight. The g row th  m edium  was  
th en  replaced w ith  2 ml o f U ltra M E M  (Lonza, Basel, Sw itzerland) and th e  cells w ere  
subsequently incubated fo r an add itional 30  min.
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S m art pool siRNA was purchased fro m  T h erm o  Scientific Dharm acon (St Leon-Rot, 
G erm any) and consisted, specifically, o f n on-targe ting  #1  siRNA contro l pool (Cat. No. D- 
0 0 1 2 0 6 -1 3 -0 5 ) and hum an APP targe tin g  siRNA SM ARTpool (Cat. No. M -0 0 3 7 3 1 -0 0 ). The  
siRNA's w e re  reconstitu ted  in R N ase-free w a te r  to  a 5 p M  stock. For each transfec tio n , th e  
siRNA stock (2 .5  pi) was th en  d ilu ted w ith  47 .5  pi U ltra M E M . In a separate  tu b e , D h arm afect 
1 reagent (1 p i) (Therm o Scientific, St Leon-Rot, G erm any) was d ilu ted  w ith  4 9  pi U ltra M E M . 
Both tubes w e re  incubated at room  te m p e ra tu re  fo r 5 min and th en  com bined  p rior to  a 
fu rth e r  20  m in incubation at room  te m p e ra tu re . The D harm afect: siRNA com plexes w ere  
th en  d ilu ted  by th e  addition o f 4 0 0  pi o f an tib io tic  and fungizone free  RPM I containing 10%  
(v /v ) FBS.
The previously equ ilib rated  D u l4 5  cells w ere  rem oved fro m  th e  incubator and th e  
existing m edium  discarded prior to  transferring  a 50 0  pi a liquot o f D harm afect: siRNA 
com plexes to  each w ell. The cells w ere  grow n fo r 24  h prior to  th e  start o f copper 
tre a tm e n ts .
For th e  copper tre a tm e n t o f siRN A-transfected D u l4 5  cells copper: glycine  
com plexes w e re  p repared  by dissolving solid CuCI2 2H 20  to  a final 10  m M  concentra tion  in a 
100  m M  glycine solution. This copper: glycine stock solution (or 100  m M  glycine alone as a 
contro l) w as added d irectly to  th e  existing 5 0 0  pi o f D harm afect: siRNA com plexes on cells to  
achieve final m eta l concentrations o f 0  o r 20 0  p M . The tre a te d  cells w ere  th en  incubated fo r  
an add itiona l 4 8  h before analysing cell p ro liferation  o r harvesting cells and m edium  fo r 
pro te in  analysis.
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2.4% Protein analysis
2.4.1. Preparation of concentrated conditioned medium 
samples and cell lysates
C onditioned m edium  was rem oved from  cells and centrifuged  a t 1 5 0 0  g  fo r 5 min in 
o rd e r to  rem ove cell debris. The supernatants w ere  th en  co ncentra ted  in centrifugal 
concentrators (Sartorius, Epsom, UK) to  a final vo lum e o f 2 0 0 -5 0 0  pi befo re , w h e re  required, 
d eterm in in g  to ta l p ro tein  concentrations (section 2 .4 .2 .) and equalizing p rotein  levels 
b etw ee n  sam ples before  freezing  a t -20°C  pending fu rth e r analysis.
The cell m onolayers w ere  th en  w ashed in situ  w ith  20  ml o f PBS. The initial PBS was 
th en  rem oved and th e  cells w e re  scraped into a fresh 10 ml o f th e  sam e b u ffe r before  
transferring  th em  into a 50  ml Falcon tu be . Residual cells w ere  w ashed from  th e  cu lture flask  
in a fu rth e r 10 ml o f PBS and trans ferred  into th e  sam e Falcon tu b e . Cells w e re  pelle ted  by 
centrifugation  a t 15 00  g fo r 3 m in th en  resuspended in 1-2 ml o f lysis b u ffe r (0 .1  M  Tris, 0 .15  
M  NaCI, 1% (v /v ) T riton  X -100 , 0 .1%  (v /v ) N on idet P -4 0 ,10 m M  1 , 10 -ph en anth ro lin e , pH 
7.4 ). Resuspensions w ere  th en  sonicated on half p ow er fo r 30  seconds using a probe  
sonicator (MSE, Craw ley, UK). An a liquot (1 ml) o f sam ple was th en  transferred  to  an 
ep p en d o rf tu b e  and centrifuged  a t 1 1 ,600  g fo r 10  m in. The su p ern atan t constituting th e  cell 
lysate was transferred  to  a fresh ep p en d o rf tu b e  and to ta l p ro tein  concentrations  
d eterm in ed  (section 2 .4 .2 .) b efo re  equalizing protein  levels b etw een  sam ples and freezing  at 
-2 0  °C pending fu rth e r analysis.
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2.4.2. Bicinchoninic acid (BCA) protein assay
Bovine serum  album in  (BSA) protein  standards w e re  prepared  and 10 pi o f each was  
standard  p ip e tte d  in to  th e  w ells o f a 9 6 -w e ll p la te  (Corning, N ew  York, USA) as indicated  
below :
•  Standard  A: 0 .2  m g /m l W ells A1 and A2
•  Standard  B: 0 .4  m g /m l W ells A3 and A4
•  S tandard  C: 0 .6  m g /m l W ells A5 and A6
•  S tandard  D: 0 .8  m g /m l W ells  A7 and A8














Sucrose - 0 .3 7  g
1 M Tris/HCI pH 8 .8 1.39 ml 1.39 ml
1.5 M Tris/HCI pH 8 .8 -
3 0 %  acrylam ide 0 .8 %  Bis (Universal 
Biologicals, Cam bridge, UK)
0 .88  ml 2 .1 0  ml
1 .5 %  (w /v )  am m onium  persulphate 100 pi 220  pi
Distilled w ater 1.36 ml -
10 %  (w /v )  SDS 37  pi 37  pi
Table 2.1. The composition of resolving gels used in SDS-PAGE
Solution Volume
1 M Tris/HCI pH 6 .8 1.25 ml
3 0 %  acrylam ide  




1 .5 %  (w /v )  
am m onium  
persulphate
0 .50  ml
Distilled w a te r 7 .65  ml
10 %  (w /v )  SDS 100 pi
Table 2.2. The composition of stacking gel used in SDS-PAGE
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Distilled w a te r  (10  fil) was included in w ells A l l  and A 12 as a b lank contro l and cell 
lysate and conditioned  m edium  sam ples (3 pil) w ere  placed in duplicate w ells starting a t B l. 
BCA w orking  reag en t (a 50 :1  ratio  o f BCA stock solution (P ierce, Illinois, USA) and 4%  (w /v )  
CuS 0 4.5H 20 )  w as added to  all w ells in 200  pil volum es. The p la te  w as gen tly  tap p ed  to  mix 
and rem ove a ir bubbles and subsequently incubated fo r 30  min at 37 °C. Absorbance  
readings a t 5 7 0  nm w e re  th en  taken  using a p late read er (Anthos 2 0 2 0  m icro tite r p late  
p h o to m ete r, version 2 .0 .5  o r V ic to r2 1 4 20  m ultilabel counter, PerkinElm er, W alth a m , 
M assachusetts). C oncentra tion  calibration curves w ere  constructed using th e  BSA standards  
and concentrations o f th e  sam ples w ere  ex trapo la ted .
2.4.3. Sodium dodecylsulphate - polyacrylamide gel
electrophoresis (SDS-PAGE)
Unless o therw ise  sta ted , SDS-PAGE was p erfo rm ed  using 7 -1 7  % acrylam ide  
resolving gels m ade up as d eta iled  in Table 2.1 . N ,N ,N ',N '-T e tram eth y le th y len ed iam in e  
(TEM ED) (3 |^l) was added to  both solutions fo llo w ed  by gen tle  mixing by inversion. Resolving 
gels w e re  poured using a g rad ien t m ixer and peristaltic pum p. A layer o f w a te r-sa tu ra ted  
isobutanol w as applied  to  th e  gel and polym erisation was a llow ed  to  proceed fo r 30 m in, 
a fte r w hich th e  w a te r-sa tu ra ted  isobutanol was rem oved from  th e  resolving gel surface. The  
stacking gel (Table 2 .2 .) was poured and allow ed to  set fo r a fu rth e r 30  m in.
Protein  sam ples w e re  d ilu ted  at a ratio  o f 2:1 sam ple to  dissociation b u ffe r (3 .5  ml 1 
M  Tris/HCI pH 6 .8 ,1 0 %  (w /v ) SDS, 80 m M  d ith io th re ito l, 20%  (v /v ) glycerol, 0 .05  mg 
brom ophenol blue, d ilu ted  to  a to ta l vo lum e o f 25 ml using distilled w a te r) and boiled fo r 3 
m in. Samples w e re  th en  loaded into gel wells in 30  \x\ volum es. Low o r high m olecular w eigh t 
standards (GE H ealthcare, Buckingham shire, UK) w ere  prepared  and loaded in th e  sam e w ay.
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Gels w ere  th en  run in running b u ffe r (1 x Tris/glycine/SD S, G en eflow  Ltd, Fradley, UK) at 45  
m A per gel (constant curren t) fo r ap p ro xim ate ly  lh .
2.4.4. Immunoblotting
Follow ing SDS-PAGE, proteins w e re  transferred  fro m  th e  gel to  an Im m obilon-P  
tra n s fer m e m b ra n e  (M illip o re , M assachusetts, USA) in Tow bin  b u ffe r (20  m M  Tris, 150  m M  
glycine, 20%  (v /v ) m ethano l) a t 115 V  fo r 1 h. The m em b ran e  was th en  w ashed fo r 5 m in in 
PBS and blocked by incubation in 5% (w /v ) skim m ed m ilk p ow d er in PBS-T (PBS + 0 .1%  (v /v )  
T w e e n -2 0 ) fo r 1 h at room  te m p e ra tu re  on a ro tating  p la tfo rm . The m em b rane w as th en  
w ashed fo r a fu rth e r 5 m in in PBS-T prior to  an overnight incubation w ith  prim ary an tibody  
at 4  °C (Table 2 .3 ). The fo llow ing  m orning th e  m em b rane was w ashed fo r 3 x 10 m in in PBS-T.
Antibody Dilution
A nti-p-actin 1 /5 0 0 0
Anti-APP 6E10 1 /2 5 0 0
A n ti-A D A M IO 1 /2 0 0 0
A n ti-A D A M 1 7 1 /2 0 0 0
Anti-APP (C -term inal) 1 /7 5 0 0
Anti-sAPPP 1 /3 0 0 0
Anti-FLAG M 2 1 /2 0 0 0
Anti APP 22C11 1 /1 0 0 0
A n ti-neuron  specific enolase NSE-P2 1 /2 0 0 0
Anti-ER K l 1/1 0 ,0 0 0
Anti-E -cadherin 1 /2 0 0 0
A n ti-V im en tin 1 /2 0 0 0
Anti-Caveolin 1 /2 0 0 0
Table 2.3. Primary antibody dilutions
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The m em b ran e  was th en  incubated w ith  th e  secondary peroxidase-conjugated  
an tibo d y fo r a fu rth e r 1 h at room  te m p e ra tu re . It was th en  w ashed fo r 3 x 10 min w ith  PBS 
p rior to  d eve lo p m en t using Enhanced Chem ilum inescence (ECL) reagents (P ierce, Illinois, 
USA) according to  th e  m anufacturer's  instructions.
All p rim ary  antibodies w ere  d ilu ted  in PBS-T containing 2 % (w /v ) BSA unless 
otherw ise  stated . The concentrations o f p rim ary antibodies used are  d e ta iled  in Table 2 .3 . All 
Secondary an tibody peroxidase conjugates w ere  also d ilu ted  in PBS-T containing 2 % (w /v )  
BSA. Rabbit an ti-m o use and goat an ti-rab b it secondary w ere  both used a t 1 /4 0 0 0 . The rabb it 
an ti-go at secondary an tibody was used at 1 /1 0 ,0 0 0 .
2.4.5. Immunoblotting Stripping and re-probing Western Blots
A fte r initial antigen d etection , th e  Im m obilon-P  transfer m em b ran e  was subm erged  
in stripping b u ffe r (1 0 0  m M  |3-m ercaptoethanol, 2%  (w /v ) SDS, 62 .5  m M  Tris, pH 7) and 
incubated at 50  °C fo r 30  min w ith  occasional m ixing. The m em branes w e re  th en  w ashed in 
PBS-T fo r 2 x 10 m in a t room  tem p . Finally, th e  m em b rane was blocked and th e  
im m u n ob lo tting  protocol repeated  as already described (section 2 .4 .4 .).
2.4.6. Amido black staining
M em b ran es  w ere  stained w ith  am ido black solution (0 .1%  (w /v ) am ido  black, 1%  
(v /v ) acetic acid, 40%  (v /v ) m ethano l) fo r 2 m in o r until p ro te in  bands becam e visible. 
M em b ran es  w ere  destained by running under cold w a te r fo r 30  seconds.
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2.5. Lipid raft isolation
Cells w e re  g row n to  confluence in T75 cm 2 flasks and th en  harvested as described in 
section 2 .4 .1 . b ut using M es -b u ffe red  saline (MBS; 25 m M  M es, 0 .1 5  M  NaCI, pH 6 .5 ) in place 
o f PBS. Any excess liquid was rem oved from  th e  resu ltant cell pellets by inverting  th e  tubes  
fo r 30  min befo re  tap p in g  o u t th e  rem ain ing liquid. The p elle t w as th en  incubated on ice fo r  
30  m in in th e  cold room  and th e  rem ain ing steps w ere  p erfo rm ed  at 4  °C. The p elle t was  
resuspended in 2 ml o f MBS containing 0.5%  (v /v ) Triton  X -100 . The cells w ere  th en  
hom ogenised by passing through a 21G needle 15 tim es. Solubilized cells (2 m l) w ere  
com bined w ith  2 .2  ml o f 90%  sucrose (w /v ) in MBS and mixed w ell by inversion. A 2 ml 
a liquot o f 5%  (w /v ) sucrose in MBS was th en  placed in an u ltracen trifu g e tu b e  before  
in jecting 2 m l o f 35%  (w /v ) sucrose in MBS beneath  th e  initial sucrose layer. The solubilized  
cell sam ple (n o w  in ap p ro xim ate ly  45%  (w /v ) sucrose) (1 m l) was th en  in jected b eneath  th e  
sucrose g rad ien t and th e  gradients w ere  centrifuged at 14 0 ,0 0 0  g fo r 1 8 -2 4  h (4°C) in an SW - 
55Ti ro to r. Individual fractions (0 .5  m l) w ere  then  harvested from  th e  gradients from  th e  
base upw ards using a 1 ml syringe and a 21G needle.
2.6. Cel! viability and morphology analysis
2.6.1. Methanethiosulfonate (MTS) cell viability assay
C ellT iter 96® AQ ueous One Cell P ro liferation Assay (m ethaneth io su lfo n ate; MTS) 
solution (Prom ega, W isconsin, USA) 20 pi) was added to  each cell cu lture p late w ell. The  
plate  was w rap p ed  in fo il and re turned  to  th e  incubator fo r 30  m in -  2 h. The absorbance  
readings a t 49 2  nm  w e re  th en  taken  using a p late read er (Anthos 2 0 2 0  m icro titer p late  
p h o to m ete r, version 2 .0 .5  o r W allac V icto r2 1420  m ultilabel counter, PerkinElm er, W a lth a m , 
M assachusetts).
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2.6.2. Cell morphology documentation using optical microscopy
The Nikon eclipse TE200 optical m icroscope (Surrey, UK) was used in conjunction  
w ith  a Nikon COOLPIX P6000 digital cam era (Surrey, UK) to  take  photographs o f cell 
m orphology. Dendricity  fac to r analysis was p erfo rm ed  by calculating th e  area and p e rim e te r  
o f ten  random ly selected cells (using points o f a superim posed grid to  choose individual cells 
fo r analysis) fro m  tw o  individual T75 cm 2 cell cu lture flasks, using im age J so ftw are . These 20  
data points fo r each cell typ e  w ere  then  utilised to  calculate dendric ity  (Inverse shape) fac to r  
using th e  fo llow ing  equation : P2/ 4 tiA  w hen  P = p e rim e te r o f cell and A = area o f cell.
2.7. Immobilized m etal chelate affinity chrom atography 
(IMAC)
Chelating sepharose fast flo w  resin (GE H ealthcare, Buckingham shire, UK) slurry was  
resuspended by shaking th e  co n ta iner fo r 10 seconds and transferred  into plastic m ini 
colum ns (1 .5  m l) (Jena Bioscience, Jena, G erm any) so th a t th e  meniscus was located 0 .5  cm  
above th e  filte r  giving a colum n vo lum e o f approxim ately  192 pi. The colum n w as th en  
w ashed w ith  4  x 1 ml volum es o f distilled w a te r  and prim ed w ith  2 x 1m l volum es o f 0 .2  M  
CuS 0 4.5H 20  o r 0 .2  M  M n C I2.4H 20 .  Unbound m etal was then  w ashed from  th e  colum ns w ith  
4  x 1 ml volum es o f distilled w a te r, 4  x 1 ml vo lum es o f wash b u ffe r (0 .02  M  sodium  aceta te , 
0 .5  M  NaCI, pH 4) and 4  x 1 ml volum es o f binding buffer (0 .15 M  NaCI, 10 m M  sodium  
phosphate, pH 7). Sam ple (100  pi) was th en  applied to  th e  colum n, from  w hich poin t the  
run -through  was collected. Columns w ere  w ashed w ith  2 x 770  pi volum es o f binding b u ffe r  
and a to ta l o f 1 .4  ml run through was collected. The rem aining binding b u ffe r was discarded  
and th en  2 x 7 7 0  pi volum es o f e lu tion  b u ffe r (0 .15  M  NaCI, 10  m M  sodium  phosphate, 10  
m M  im idazole, 50  m M  EDTA, pH 7) w ere  applied  to  th e  colum n. Eluate (1 .4  m l) w as collected  
from  this point.
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2.8. S tatistical analysis
Statistical significance was d e term in ed  using M icro so ft Excel to  p erfo rm  Students t- 
tests. Results show n are  e ith e r standard deviation  o r standard e rro r o f th e  m ean (as 
indicated in th e  Figure legends). Sam ple population num bers are  also indicated in th e  Figure 
legends.
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3. Characterisation of constitutive 
wild-type APP expression and 
proteolysis in cell lines
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3.1. Introduction
The overarching aim  o f this p ro ject w as to  investigate th e  relationships b e tw ee n  APP 
and copper in th e  ageing brain. In this respect, th e  p rotein  was to  be studied in re lation  to  
tw o  conditions associated w ith  th e  ageing brain; A lzheim er's disease and brain m etastatic  
prostate  cancer. Thus, th e  initial part o f th e  pro ject involved th e  characterisation  o f APP 
expression and proteolysis in cell m odels re levant to  th e  tw o  disease conditions.
In re la tion  to  A lzheim er's disease, th e  key cell line used w as th e  hum an  
neuroblastom a line, SH-SY5Y, originally isolated from  a bone m arro w  neuroblastom a  
m etastasis o f a 4  year old fem ale  (27 5 -2 77 ). As fa r as prostate cancer was concerned, th re e  
p aren t cell lines w e re  em ployed . LNCaP cells are an androgen sensitive PCa cell line 
originally isolated in 1977  fro m  th e  le ft supraclavicular lym ph node o f a 50  year old 
Caucasian m ale w ith  confirm ed  PCa m etastasis (277, 278). D u l4 5  cells are  a horm one  
insensitive m etas tatic  PCa cell line derived from  th e  brain o f a Caucasian m ale (277 , 279 ) and  
PC-3 cells, w hich are also horm one insensitive, are derived from  a bone m etastasis o f a 
prostate  adenocarcinom a in a 62 year old Caucasian m ale (277 , 280).
3.2. APP expression and proteolysis
In o rd er to  investigate APP expression in cells and th e  release o f its p ro teo ly tic
fragm ents, cells w e re  grown to  confluence and incubated in reduced serum  (O p tiM E M )
m edium  in o rd er to  a llow  th e  release o f proteolytically cleaved proteins into conditioned
m edium . Cell lysates and concentrated  conditioned m edium  samples w ere  th en  prepared
and subjected to  im m u n ob lo tting  w ith  th e  indicated antibodies as described in th e  M ateria ls
and M eth o ds section. In addition to  the various parent cell lines, SH-SY5Y and D u l4 5  cells
stably transfected  w ith  APP695 w ere  incorporated into th e  analysis in o rd er to  gain an
indication o f w hich APP isoforms w ere  expressed endogenously in th e  cells (and because
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la te r studies w ou ld  requ ire  th e  over-expression o f th e  p ro te in ). The w ild -typ e  (W T)-A PP695 
construct has been characterised previously (281) and D u l4 5  and SH-SY5Y cells w e re  stably  
transfec ted  w ith  th e  construct using th e  lipo fectam ine and e lectro p oration  m ethods  
described in th e  M ate ria ls  and M eth o ds section.
First, lysates fro m  th e  various cell lines w ere  equalised in term s o f p ro tein  co nten t 
b efo re  analysing APP ho loprote in  expression levels. Equal am ounts o f pro tein  fro m  each cell 
typ e  w ere  im m u n o b lo tte d  w ith  a com m ercial anti-APP C -term inal antibody (Sigm a-Aldrich, 
Poole, UK) raised against a synthetic im m unogen corresponding to  am ino  acids 6 7 6 -6 9 5  o f 
th e  APP cytosolic dom ain . The results {Fig. 3.1A)  revealed m ultip le  bands around th e  110  kDa 
region probably corresponding to  m ultip le APP isoforms and glycoform s. APP was highly 
expressed in all th re e  untransfected  PCa cell lines being detec ted  at th e  highest level in PC-3 
lysates. In fact, th e  p rotein  was detected  at h igher endogenous levels in th e  th re e  PCa cell 
lines th an  in th e  SH-SY5Y lysates. A P P 6 g s  in stably-transfected D u l4 5  cells was clearly  
d etec ted  a t a lo w er m olecular w eigh t than  th e  bulk o f th e  endogenous protein  suggesting  
th a t th e  la tte r w as constitu ted  prim arily by th e  larger KPI-containing APP isoforms. The sam e  
w as tru e  fo r th e  APP69 5 -transfec ted  SH-SY5Y cells except th a t levels o f endogenous APP695 
w e re  m ore p reva len t in these cells than  in th e  D u l4 5  cell line. Equal p ro tein  loading o f 
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Figure 3.1. APP expression levels in cell lysates. Equal am ounts o f pro te ins from  cell lysates w ere resolved 
by SDS-PAGE and im m u n o b lo tted  according to  the  M ateria ls  and M ethods section. A. Detection o f APP in 
cell lysates using the  anti-APP C -term inal an tibody. B. D etection o f (3-actin in cell lysates using the  anti-|3- 
actin an tibody . The vertica l lines on b lots ind icate  a lignm en t o f samples from  distal lanes run on the  same 
im m u n o b lo t. The results are represen ta tive  o f th ree  repeat experim ents.
Next the non-amyloidogenic processing o f APP was examined by analysing the 
am ount o f sAPPa released into conditioned medium using the monoclonal anti-APP 6E10 
antibody which recognises an epitope w ith in  amino acids 3-8 (EFRHDS) o f the A(3 domain.
The results [Fig. 3.2) show tha t sAPPa was detected as tw o bands in the conditioned medium 
from  untransfected SH-SY5Y cells. The fact tha t the lower o f these tw o  bands represented 
sAPP695a  was verified by the enhanced intensity o f this band in medium from  the APP695- 
transfected SH-SY5Y cells.
The endogenous sAPPa released from  all three PCa cell lines was clearly derived 
from  the larger KPI-containing isoforms (APP751 and APP770) as the bands were larger than 
the sAPP695a  band detected in the medium from  both D ul45  and SH-SY5Y cells stably 
transfected w ith  the la tter APP isoform. When comparing the levels o f sAPPa generated 
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Figure 3.2. sAPPa shedding into conditioned culture m edium . Cells w ere grow n to  confluence and the 
m edium  replaced w ith  serum  free  m edium  fo r  24 hours. Conditioned m edium  was collected and 
concentra ted (M a te ria ls  and M ethods). SDS-PAGE and im m unob lo ts  w ere then  perfo rm ed (M ateria ls and 
M ethods). A. Detection o f sAPPa in cond itioned  media using the  anti-APP 6E10 an tibody. B and C. M ultip le  
im m unob lo ts  w ere quan tified  and the  levels o f SAPP75 1/ 7 7 0CX (B) and sAPP695a  (C) are expressed relative to  
the  am ounts o f so luble APP released from  the  WT-APP69 5 over-expressing SH-SY5Y cells. Results are means 
± S.D. (n=3). The vertica l line on the  b lo t indicates a lignm en t o f samples from  distal lanes run on the  same 
im m unob lo t.
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lowest levels of this fragm ent with PC3 and D u l45  cells both generating considerably higher
levels.
N ext, th e  am ylo idogenic processing o f APP was exam ined by im m u n ob lo tting  th e  
conditioned  m ed iu m  samples w ith  an tibody 1A9 w hich specifically detects th e  C -term inal 
n eo ep ito p e g en era ted  on sAPPp fo llow ing  f3-secretase cleavage o f th e  holoprote in  (2 8 2 ). The  
results (Fig. 3 .3 )  show  th a t, in th e  case o f th e  SH-SY5Y cells, sAPPp was gen era ted  a t roughly  
eq u iva len t levels fro m  both A P P 6 9 5  and A P P 7 5 1 / 7 7 o  w ith  th e  identity  o f th e  fo rm e r being  
verified  by a massive increase in th e  intensity o f this band in conditioned m edium  from  th e  
APP69 5 -tran s fec ted  SH-SY5Y cells. In term s o f th e  PCa cell lines, sAPPp was v irtually  absent 
fro m  th e  conditioned  m edium  o f untransfected  D u l4 5  and PC-3 cells. H ow ever, small 
am ounts o f sAPP695p did appear to  be present in th e  m edium  from  LNCaP cells. As expected, 
th e  sam e fra g m en t was detec ted , a lbeit at low  levels, in th e  m edium  from  APP695-transfec ted  
D u l4 5  cells. It is interesting  to  note th a t, w h ilst com parab le levels o f sAPP695a  w e re  detec ted  
in th e  conditioned  m edium  from  stably transfected  D u l4 5  and SH-SY5Y cells (Fig .3.2),  th e  
level o f sAPPp g en era ted  from  APP695 in th e  D u l4 5  cells was much low er than  th a t seen in 
m edium  fro m  th e  SH-SY5Y transfectants  (Fig. 3 .3 ).  O f sim ilar notew orth iness was th e  fact 
th a t levels o f sAPPp gen era ted  fro m  th e  endogenous KPI-containing isoform s in D u l4 5  cells 
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Figure 3.3. sAPPp in conditioned cell culture medium . Cells w ere grow n to  confluence and the  m edium  
replaced w ith  serum  free m edium  fo r  24 hours. Conditioned m edium  was collected and concentra ted 
(M ateria ls and M ethods). SDS-PAGE and im m unob lo ts  w ere then  perfo rm ed (M ateria ls  and M ethods). A. 
Detection o f sAPPp in cond itioned  m edium  was achieved using the  anti-sAPPP an tibody, 1A9. M u ltip le  
im m unob lo ts  w ere quantified  and the  levels o f sAPP75 1/7 7oP (B) and sAPP695p (C) are expressed re lative  to  
the  am ounts o f soluble APPP released from  the  WT-APP69 5 over-expressing SH-SY5Y cells. Results are means 
± S.D. (n=3). The vertica l line on the  b lo t indicates a lignm ent o f samples from  distal lanes run on the  same 
im m unob lo t.
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3.3. The effect of d ihyd ro testo ste rone  on APP expression  and 
pro teo lysis in LNCaP cells
LNCaP cells are an androgen sensitive cell line in which various PCa-associated 
proteins have been shown to  increase in response to  hormone trea tm en t (278). As such, the 
e ffect o f d ihydrotestosterone (DHT) on the expression and proteolysis o f APP in th is cell line 
was also examined. Confluent cells were incubated w ith  the indicated concentrations o f DHT 
fo r 24 h and cell lysates and concentrated conditioned medium prepared as described in the 
Materials and M ethods section.
In itially, equal amounts o f protein from  cell lysates were im m unoblotted w ith  the 
anti-APP C-terminal antibody. The results show an apparent dose-dependent increase in APP 
expression [Fig. 3.4A). Equal protein loading o f lysates was confirmed by an actin 
im m unoblot (Fig. 3.4B).
-97  kDa 
-45  kDa
-30  kDa
Figure 3.4. The effect of DHT on APP expression in LNCaP cells. Cells w ere g row n to  confluence and the 
m edium  was replaced w ith  serum  free  m edium , containing 0, 1 ,1 0  o r 100 nM DHT, fo r  24 hours. Cells 
w ere harvested and lysates prepared (M ateria ls and M ethods). SDS-PAGE and im m unob lo ts  w ere then 
perfo rm ed (M ateria ls  and M ethods). A. Detection o f APP in cell lysates using the  anti-APP C-term inal 
an tibody. B. Detection o f P-actin in cell lysates using the  anti-P -actin  an tibody. The results are 
represen ta tive  o f th ree  repeat experim ents.
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The conditioned medium from  the control and DHT-treated cells was then 
im m unoblotted  w ith  antibody 6E10 in order to  determ ine the levels o f shed sAPPa. 
However, no significant alterations in the levels o f sAPPa fo llow ing DHT trea tm ent could be 
determ ined [Fig. 3.5). Similarly, no differences in the levels ofsAPPp in conditioned medium 
were observed fo llow ing  DHT trea tm en t when the samples were im m unoblotted w ith  
antibody 1A9 (Fig. 3.6).
o
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Figure 3.5. The effect of DHT on sAPPa shedding from LNCaP cells. Cells w ere grow n to  confluence and the  
m edium  was replaced w ith  serum  free  m edium , con ta in ing  0,1,10 or 100 nM DHT, fo r  24 hours. 
C onditioned m edium  was collected and concentra ted (M ateria ls  and M ethods). SDS-PAGE and 
im m unob lo ts  w ere then  perfo rm ed (M ateria ls  and M ethods). A. Detection o f sAPPa in cond itioned  m edia 
using the  anti-APP 6E10 an tibody. B. M ultip le  im m unob lo ts  were quantified  and the  results expressed 
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Figure 3.6. The effect of DHT on sAPP(J release from LNCaP cells. Cells w ere g row n to  confluence and the  
m edium  was replaced w ith  serum  free  m edium  conta in ing 0,1,10 or 100 nM  DHT, fo r  24 hours. Conditioned 
m edium  was collected and concentra ted (M ateria ls and M ethods). SDS-PAGE and im m unob lo ts  w ere then 
perfo rm ed (M ateria ls  and M ethods). A. Detection ofsAPPP in the  cond itioned  m edium  was achieved using 
the  anti-sAPPP an tibody, 1A9. M u ltip le  im m unob lo ts  w ere quantified  and the  levels o f sAPP751/770p (B) and 
sAPP695p (C) are expressed re lative  to  the  am ounts in the  un trea ted  contro ls. Results are means ± S.D.
(n=3); n.s. = no t s ign ificant.
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3,4, ci-secretase expression
In o rd er to  fu rth e r understand th e  proteolysis o f APP in th e  various cell lines 
em ployed  and because both A D A M 10  and A D A M 17  have previously been im plicated  in both  
AD and prostate  cancer (2 8 3 -2 8 6 ) th e  levels o f these proteins w e re  next analysed in cell 
lysates.
3.4.1. ADAM10 expression
In itia lly  th e  cell lysates w ere  im m u n ob lo tted  w ith  a com m ercial A D A M 10  an tibody  
raised against a synthetic  pep tide representing  am ino acids 7 3 5 -7 4 9  in th e  C -term inal region  
o f m urine A D A M 10  (see M ateria ls  and M eth o ds). As such, this an tibody should d e tec t both  
th e  im m a tu re , p rodom ain  containing fo rm  o f A D A M 10  and th e  m ature  fo rm  o f th e  enzym e. 
The sam ples w ere  run against a positive control o f HEK cells trans ien tly  transfected  w ith  fu ll- 
length bovine A D A M 10  (see M ate ria ls  and M eth o ds) w hich was detec ted  as tw o  bands at 98  
kDa and 70  kDa as previously observed (287) {Fig. 3 .7 ).  Im m atu re  A D A M 10  was barely  
d etec tab le  in SH-SY5Y and PC3 cells but was clearly present in lysates from  both LNCaP and  
D u l4 5  cells. Interestingly , w hen  APP695 was over-expressed in th e  D u l4 5  cells, levels o f 
A D A M 10  w ere  seen to  decrease. M a tu re  A D A M 10 was only d etec ted  a t appreciable levels in 
th e  lysates o f th e  untransfected  D u l4 5  cells (Fig. 3 .7 ).  N otably, both th e  im m ature  and  
m ature  form s o f A D A M 10  w e re  slightly sm aller in th e  sam ple cell lysates than  in th e  bovine  
A D A M 10 - transfec ted  HEK cell lysate control perhaps due to  differences in th e  m olecular 
w eigh t o f th e  pro te in  b etw een  species or to  differences in glycosylation. N ote th a t these  
samples w ere  th e  sam e ones as used earlier in this chapter; th e  corresponding actin control 
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Figure 3.7. ADAM 10 expression in cell lysates. Cells w ere grow n to  confluence and the  m ed ium  was 
replaced w ith  serum  free  m edium  fo r  24 hours. Cells w ere harvested and cell lysates prepared (M ateria ls  
and M ethods). SDS-PAGE and im m unob lo ts  w ere then  perfo rm ed (M ateria ls  and M ethods). D etection o f 
AD AM 10 in cell lysates was achieved using the  an ti-A D A M IO  C-term inal an tibody. The vertica l line on the 
b lo t indicates a lignm ent o f samples from  distal lanes run on the  same im m unob lo t.
3.4.2. ADAM17 expression
Next, the lysates were im m unoblotted using a commercial anti-ADAM17 antibody 
raised against a synthetic peptide corresponding to  amino acids 807-823 o f the human 
protein. Similarly to  ADAM10, the samples were run alongside HEK cells over-expressing 
ADAM17 as a positive control in which the protein was detected as a 110 kDa im m ature form  
and ~100 kDa mature form  consistent w ith  previous findings (288) {Fig. 3.8). M ature 
ADAM17 was detectable in all o f the cell lines, w ith  a particularly high abundance in the 
hormone-insensitive PC-3 cells (Fig. 3.8). Similarly, imm ature ADAM17 was present in all o f 
the cell lines examined w ith  the exception o f the hormone-sensitive LNCaP cells. Again, the 
corresponding actin control is shown in Fig. 3.1.
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Figure 3.8. ADAM 17 expression in cell lysates. Cells were grown to  confluence and the  m ed ium  was 
replaced w ith  serum  free  m ed ium  fo r  24 hours. Cells w ere harvested and cell lysates prepared (M ateria ls  
and M ethods). SDS-PAGE and im m unob lo ts  were then  perfo rm ed (M ateria ls  and M ethods). D etection o f 
ADAM 17 in cell lysates was achieved using the  anti-ADAM 17 an tibody. The vertica l line on the  b lo t 
indicates a lignm ent o f samples from  distal lanes run on the  same im m unob lo t.
3.4.3. The effect of dihydrotestosterone on ADAM10 and
ADAM 17 expression in LNCaP cells
Next, the possible effects o f DHT on ADAM expression were examined in the 
hormone sensitive LNCaP cells. The cell lysate samples from  Fig. 3.4. were in itia lly 
im m unoblotted w ith  the ADAM10 antibody. However, no detectable change in ADAM10 
expression levels was observed [Fig. 3.9). Similar results were observed when the samples 
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Figure 3.9. The effect of DHT on ADAMIO expression in LNCaP cells. Cells w ere g row n to  confluence and the  
m ed ium  was replaced w ith  serum  free  m edium , con ta in ing  0 ,1 , 10 o r 100 nM  DHT, fo r  24 hours. Cells w ere 
harvested and cell lysates prepared (M ateria ls  and M ethods). SDS-PAGE and im m unob lo ts  w ere  then  
pe rfo rm ed  (M ateria ls  and M ethods). A. D etection o f AD A M IO  in cell lysates using the  an ti-A D A M IO  C- 
te rm in a l an tibody. The vertica l line on the  b lo t indicates a lignm ent o f samples from  distal lanes run on the  
same im m u n o b lo t. B. M u ltip le  im m unob lo ts  w ere quantified  and the  results expressed re la tive  to  the  
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Figure 3.10. The effect of DHT on ADAM17 expression in LNCaP cells. Cells were g row n to  confluence and the 
m ed ium  was replaced w ith  serum free m edium , conta in ing 0 ,1 ,1 0  or 100 nM DHT, fo r  24 hours. Cells w ere 
harvested and cell lysates prepared (M ateria ls and M ethods). SDS-PAGE and im m unob lo ts  w ere then  
p e rfo rm ed  (M ateria ls  and M ethods). A. Detection o f ADAM 17 in the cell lysates was achieved using the  
anti-A D A M 17 C-term inal an tibody. The vertica l line on the  b lo t indicates a lignm ent o f samples from  distal 
lanes run on the  same im m unob lo t. B. M ultip le  im m unob lo ts  were quantified  and the  results expressed 
re lative  to  the  un trea ted  con tro l. Results are means ± S.D. (n=3). n.s. = no t significant.
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The hum an neurob lastom a, SH-SY5Y cells, expressed both endogenous APP69 5 and  
APP7 5 1 /7 7 0  w hereas  th e  endogenous expression in th e  PCa cell lines was restricted to  th e  KPI- 
containing isoform s o f th e  p ro te in  {Fig. 3 .1 ).  O f th e  th re e  PCa cell lines studied, APP 
expression was particu larly  high in th e  horm one-insensitive D u l4 5  and PC3 cells. H ow ever, 
in th e  LNCaP cells th e  expression o f th e  p rotein  w as fu rth e r increased fo llow ing  DHT 
tre a tm e n t {Fig. 3 .4 ).  The constitu tive shedding o f sAPPa from  th e  various cell lines largely  
re flected  th e  expression levels o f th e  various isoforms in cell lysates, w ith  LNCaPs clearly  
shedding th e  low est am o u n t o f th e  p rotein  am ongst th e  PCa cell lines {Fig. 3 .2 ).  Notably, 
h ow ever, w hilst th e  expression o f th e  APP holoprote in  appeared  horm one sensitive in th e  
LNCaP cells, its shedding into  conditioned  m edium  was not {Figs. 3 .5  and 6).  sAPPp 
gen era tion  by th e  various PCa cells was notably very low  and was not responsive to  DHT  
tre a tm e n t in LNCaP cells {Figs. 3 .3  and 6).
In te rm s o f A D A M  expression, A D A M IO  was d etec ted  in all o f th e  cell lines studied  
and was m ost highly expressed in LNCaP and D u l4 5  cells {Fig. 3.7).  H ow ever, th e  expression  
o f th e  enzym e was n ot affected  by DHT in th e  fo rm e r cell line {Fig. 3 .9 ).  Im m atu re  and  
m atu re  A D A M 17  w e re  d e tec ted  at re latively high levels in all o f th e  cell lines studied w ith  
th e  exception th a t th e  im m a tu re  fo rm  was notably absent in LNCaP cells {Fig. 3.8).  Like 
A D A M IO , th e  expression o f A D A M 17  in LNCaP cells was not affected  by DHT tre a tm e n t {Fig. 
3.10).
Collectively, these data  provided a firm  foundation  fo r fu tu re  experim ents designed  
to  investigate th e  link b e tw ee n  APP and copper in th e  various cell lines and confirm ed th a t  
th e  stable expression o f APP695 in both SH-SY5Y and D u l4 5  cells had been successful.
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4. The effects of copper on 
endogenous APP expression and 




C opper has previously been shown to  influence th e  expression, tra ffick ing  and  
A D A M -m e d ia te d  proteolysis o f APP in various cell lines (1 6 3 ,1 6 8 , 28 9 ). F urtherm o re , APP 
and copper have both , ind ep en d en tly , been positively associated w ith  th e  p ropensity fo r  
prostate  cancer ep ithe lia l cells to  m etastasize (2, 267). Thus, in th e  cu rren t study, th e  
p oten tia l relationships b e tw ee n  copper levels and APP expression/proteolysis in th e  prostate  
cancer cell lines LNCaP, PC-3 and D u l4 5  w ere  investigated.
LNCaP, PC-3 and D u l4 5  cells w ere  grown to  confluence before being w ashed in situ 
w ith  O p tiM E M  (10  m l). The cells w ere  then  incubated in copper chloride d ilu ted  in O p tiM E M  
(10  m l) to  th e  concentrations sta ted . A fte r 24  h, th e  cells w ere  harvested and lysates and  
concentra ted  conditioned  m edium  w ere  prepared as described in th e  M ate ria ls  and  
M eth o d s  section. The sam ples w e re  th en  im m u n ob lo tted  fo r fu ll-length  APP and its 
pro teo ly tic  fragm ents. The e ffe c t o f copper on cell viability was also m o n ito red  using th e  
MTS assay as described in M ate ria ls  and M ethods.
4.2. The effect o f copper on LNCaP cell viability
In itially , th e  e ffec t o f copper on th e  viability o f LNCaP cells w as exam ined . Cells w ere  
g row n to  confluence and th en  incubated fo r 24 h in th e  presence o f 0 -5 0 0  piM copper 
chloride a fte r w hich cell v iab ility  was d eterm ined  using th e  MTS assay. The results {Fig. 4 .1)  
show  th a t copper concentrations up to  50  |iM  w ere  not cytotoxic. H ow ever, a t 20 0  [iM  
copper th e re  was a d ram atic  decrease in cell v iability  to  25 .52  ± 1.27%  o f contro l levels 
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Figure 4.1. The effect of copper on LNCaP cell viability. Cells w ere seeded at 2000 cells per w ell and g row n 
to  confluence. CuCI2 2H20  was added at 0 ,1 ,1 0 , 50, 200 o r 500 pM  concentra tions, and the  cells w ere 
fu rth e r incubated fo r  24 hours. Cell v iab ility  was then de term ined using the  MTS assay (see M ateria ls  and 
M ethods). Results are expressed re lative  to  the v iab ility  o f the  un trea ted  con tro ls  and are means ± S.D. 
(n= 3 ). * * * * *  = p<0.0005; * * * * * *  = p<0 .0 0 0 0 1 ; n.s. = no t s ign ificant.
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4.3. Tlie effect of c ^cr on the expression and shedding  of 
endogenous APP in LNCaP cells
Next, th e  copper tre a tm e n t o f LNCaP cells described in th e  preceding section was  
rep eated  but, this tim e , th e  cells and conditioned  m edium  w ere  analysed in te rm s o f APP 
expression and proteolysis. Due to  th e  massive decreases in cell v iability  observed at h igher 
co p per concentrations {Fig. 4 .1 )  very little  protein  was detec ted  in cell lysates p repared  fro m  
th e  20 0  and 50 0  p M  co p p er-trea ted  cells. Thus, it was not feasible to  adjust all o f th e  lysate  
sam ples on th e  basis o f equal p ro te in . Instead, th e  cells from  th e  first fo u r tre a tm e n ts  w e re  
equalised on a pro te in  basis, w hereas th e  200  and 50 0  p M  copper tre a te d  cells w e re  le ft un­
equalised.
Initially, equal lysate volum es w ere  resolved by SDS-PAGE and im m u n o b lo tted  using 
th e  APP C -term inal an tibody in o rd er to  d etec t th e  fu ll-length  protein . The results, [Fig. 4 .2A)  
revealed  a slight increase in APP expression in lysates prepared from  cells tre a te d  w ith  10  
and 5 0  p M  copper. H ow ever, APP expression was not d etec ted  at h igher m etal 
concentrations due to  considerable decreases in overall pro tein  levels as a consequence o f 
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Figure 4.2. The effect of copper on APP expression in LNCaP cells. Cells w ere g row n to  confluence and the  
m edium  was replaced w ith  serum  free  m edium  containing 0 , 1 ,1 0 , 50, 200 o r 500 pM  CuCI2 2H 2 0 . A fte r 24 
h, the  cells w ere harvested and lysates prepared (M ateria ls and M ethods). Equal volum es o f the  lysates 
were then  resolved by SDS-PAGE and im m unob lo tted  (M ateria ls and M ethods). A and C. Detection o f fu ll-  
length APP in cell lysates using the  anti-APP C-term inal antibody. B and D. Detection o f p-actin in cell lysates 
using the  anti-P -actin  an tibody . E and F. Q uantifica tion o f m ature  APP7 5 1 /7 7 0  (E) and im m a tu re  APP7 5 1 /7 7 0  (F) 
levels fro m  con tro l and copper (50 pM ) trea ted  cells. Results are means ± S.D. (n=3). n.s. = no t s ign ificant.
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Due to  copper concentrations o f 10 and 50  p M  initially appearing to  enhance APP 
expression in LNCaP cells (Fig. 4 .2A),  a fu rth er experim ent was conducted in an a tte m p t to  
va lid ate  this result. H ere, confluen t flasks o f cells w ere  tre a te d  in trip licate  w ith  0 or 50  p M  
copper concentrations and th e  cell lysates w ere  subsequently im m u n ob lotted  once m ore  
w ith  th e  anti-APP C -term inal antibody. The results (Fig. 4.2C)  in itially appeared  to  show  an 
increase in th e  levels o f m ature  KPI-containing APP isoforms fo llow ing copper tre a tm e n t  
(n o te  th a t LNCaP cells prim arily  express KPI-containing APP isoforms and not APP695 so 
im m unob lots  o f cell lysates are not confused by th e  presence o f m ultip le m olecular w eigh t 
APP isoform s). H ow ever, w hen these changes w ere  quantified , th ey  w ere  d eem ed not 
significant (Fig. 4.2E).  Sim ilarly, no changes in th e  cell-associated levels o f im m ature  KPI- 
containing APP isoforms w ere  observed fo llow ing copper tre a tm e n t (Figs. 4 .2C  and 2F).
N ext th e  conditioned m edium  samples from  cells trea ted  w ith  0 -5 0 0  p M  copper 
concentrations w e re  im m u n ob lo tted  w ith  th e  anti-APP antibody 6E10 in o rd er to  d eterm in e  
th e  e ffec t o f th e  m etal on APP shedding from  LNCaP cells. The results (Fig. 4.3A)  app ear once 
m o re to  show  a slight increase in sAPPa levels in conditioned m edium  at copper 
concentrations o f 10 and 50 p M  (note  th a t th e  conditioned m edium  samples in this instance  
w ere  loaded in term s o f equal vo lum e as opposed to  equal pro tein  levels). W hen  a fu rth er  
exp erim en t was conducted using trip lica te  trea tm en ts  o f 0 and 50  p M  copper, th e re  again  
appeared  to  be a slight increase in sAPPa generation  in th e  presence o f copper (Fig. 4.3B). 
H ow ever, these changes could not be deem ed significant (Fig. 4.3C).
These data suggest th a t, at sub-toxic copper concentrations, th e re  may be marginal 
increases in e ith e r th e  expression or m aturation  o f APP in LNCaP cells, resulting in enhanced  
shedding o f th e  p rotein  from  th e  cell surface over a 24 h period. H ow ever, any such changes 
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Figure 4.3. The effect of copper on soluble APP production from  LNCaP cells. Cells w ere g row n to  
confluence and the  m edium  was replaced w ith  serum free m edium  conta in ing 0 ,1 ,1 0 , 50, 200 o r 500 pM  
CuCI2 2H 2 0 . A fte r 24 h, the  cond itioned  m edium  was collected and concentra ted (M ateria ls  and M ethods). 
Equal volum es o f the  m edium  samples were then resolved by SDS-PAGE and im m unob lo tted  (M ateria ls  and 
M ethods). A and B. D etection o f soluble APP in cond itioned  m edium  using the anti-APP an tibody  6E10. C. 
Q uantifica tion  o f soluble APP levels in m edium  from  con tro l and copper (50 pM ) trea ted  cells. Results are 















4.4, The effect of copper on PC-3 cell viability
Next, the effects o f copper on the v iab ility  o f the hormone-insensitive prostate 
cancer cell line, PC-3, were examined. The cells were grown to  confluence and then treated 
fo r 24 h w ith  copper concentrations ranging from  0-500 piM before analysing cell v iab ility  
using the MTS assay (Materials and Methods). The results (Fig.4. 4) demonstrated a dramatic 
reduction in PC-3 cell v iab ility  fo llow ing trea tm ent w ith  200 or 500 |iiM copper (32.75 ±
9.71% and 18.31 ± 3.14% of control v iab ility  levels, respectively). As observed previously w ith  
LNCaP cells, copper concentrations o f 50 |iM  and lower were not cytotoxic.
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Figure 4.4. The effect of copper on PC-3 cell viability. Cells w ere seeded a t 2000 cells per w e ll and g row n to  
confluence. CuCI2 2H20  was added a t 0 ,1 ,1 0 , 50, 200 or 500 pM  concentra tions, and the  cells w ere fu rth e r 
incubated fo r  24 hours. Cell v iab ility  was then de term ined  using the  MTS assay (see M ateria ls  and 
M ethods). Results are expressed relative to  the  v iab ility  o f the  un treated contro ls and are means ± S.D. 
(n=3). * = p<0.05; n.s. = n o t significant.
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4.5. The effect of copper on the expression and shedding of
endogenous APP In PC-3 cells
As w ith  th e  LNCaP cells previously, PC-3 cells w ere  grown to  confluence and th en  
tre a te d  fo r 24  h w ith  0 -5 0 0  p M  copper concentrations. The effects o f th e  m etal on APP 
expression and proteolysis w ere  th en  exam ined by im m unob lotting . In this case, as protein  
levels in those cells tre a te d  w ith  th e  highest copper concentrations w ere  d etec tab le , lysates 
w e re  all equalised on a p rotein  basis.
O ne o f th e  key lim itations w ith  this section o f th e  study is th a t this particu lar 
ex p e rim e n t was only p erfo rm ed  on one occasion, w ith  lim ited  replicates, m aking it d ifficu lt 
to  d raw  any firm  conclusions from  th e  data. How ever, th e  results {Fig. 4 .5A)  do, in this 
instance, app ear to  show  a co p per-re la ted  decrease in th e  levels o f cell-associated APP, w ith  
th e  actin im m u n ob lo t confirm ing equal protein  loading {Fig. 4.5B). Conversely, th e  shedding  
o f sAPPa into conditioned  m edium  appeared  to  increase w ith  increasing copper 
co ncentra tion  {Fig. 4 .6 )  perhaps suggesting th a t th e  decreased levels o f cell-associated APP 
m ight result from  enhanced shedding o f th e  protein.
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Figure 4.5. The effect of copper on APP expression in PC-3 cells. Cells w ere g row n to  confluence and the  
m ed ium  was replaced w ith  serum  free  m edium  contain ing 0 ,1 ,1 0 , 50, 200 or 500 pM  CuCI2 2H2 0 . A fte r 24 
h, th e  cells w ere  harvested and lysates prepared (M ateria ls and M ethods). Equal volumes o f the  lysates 
were then  resolved by SDS-PAGE and im m unob lo tted  (M ateria ls and M ethods). A. Detection o f fu ll- leng th  
APP in cell lysates using th e  anti-APP C-term inal antibody. B Detection o f [3-actin in cell lysates using the 
anti-(3-actin an tibody.
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Figure 4.6. The effect of copper on soluble APP production from  PC-3 cells. Cells w ere g row n to  confluence 
and the  m edium  was replaced w ith  serum free  m edium  conta in ing 0 ,1 ,1 0 , 50, 200 o r 500 pM  CuC!2 2H2 0. 
A fte r 24 h, the  cond itioned  m edium  was collected and concentrated (M ateria ls and M ethods). Equal 
vo lum es o f the  m edium  samples w ere then  resolved by SDS-PAGE and im m unob lo tted  using the  anti-APP 















4.6. The effect of copper on D u l4 5  cell viability
Next, the effects o f copper on the viab ility  and endogenous APP 
expression/proteolysis o f D u l45  cells was examined. The v iab ility  assay results (Fig. 4.7) 
clearly show that, as fo r LNCaP and PC-3 cells no copper-associated cytotoxicity was 
observed at concentrations o f the metal below 200 pM. However, once this metal 
concentration was reached, there was a drastic drop in cell v iab ility  (43.24 ± 18.44% the level 
o f the untreated control). A t 500 pM copper, cell v iab ility  was a mere 17.77 ± 5.81% of the 
untreated control.
[Cu CI22H20 ]  (pM )
Figure 4.7. The effect of copper on D u l45  cell viability. Cells w ere seeded at 2000 cells per w e ll and grown 
to  confluence. CuCI2 2H20  was added at 0 ,1 ,1 0 , 50, 200 or 500 pM  concentrations, and the  cells were 
fu rth e r incubated fo r  24 hours. Cell v ia b ility  was then  de term ined  using the MTS assay (see M ateria ls and 
M ethods). Results are expressed re lative  to  the  v iab ility  o f the  un treated contro ls and are means ± S.D. 
(n=3). * = p<0.05; * * *  = p<0.005; n.s. = no t s ignificant.
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4.7, The effect of copper on the expression and shedding of 
endogenous APP in B n l4 5  cells
D u l4 5  cells w ere , once m ore, grow n to  confluence and th en  tre a te d  w ith  copper fo r  
24  h. H ow ever, on this occasion, th e  cells and conditioned m edium  w ere  harvested and  
im m u n o b lo tted  in o rd er to  d e te rm in e  th e  effects o f th e  m etal on APP expression and  
proteolysis. Initially , equal vo lum es o f cell lysates (equal pro tein  co nten t) w ere  
im m u n o b lo tted  using th e  anti-APP C-term inal antibody. The results {Fig. 4 .8A)  show  an 
increase in APP expression at m etal concentrations o f 10, 50  and 200  p M  (re la tive  to  th e  
u n trea ted  contro l). H ow ever, a t 20 0  p M  copper, levels o f th e  APP ho loprote in  appeared  to  
ta il off, perhaps consistent w ith  th e  decreased cell viability observed at these m etal 
concentrations {Fig. 4.7).  As this initial experim ent was only perfo rm ed  on a single occasion, 
and in o rd er to  confirm  a copper-associated increase in APP expression, a repeat experim ent 
was p erfo rm ed  using m ultip le  cultures tre a te d  w ith  e ith er no copper or  a 50  p M  m etal 
concentra tion . The results {Fig. 4.8C-F) show a clear increase in APP expression in th e  
presence o f copper. The levels o f m a tu re  cell-associated APP w ere  enhanced 2 .7 4  ± 0 .49 -fo ld  
w hilst th e  increase in im m atu re  APP expression in th e  presence o f copper w as less 
pronounced a t 1 .29 ± 10 .5 -fo ld .
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Figure 4,8. The effect of copper on APP expression in D u l45  cells. Cells w ere grow n to  confluence and the  
m edium  was replaced w ith  serum  free  m edium  conta in ing 0 , 1 ,10, 50, 200 o r 500 pM  CuCI2 2H 20 . A fte r 24 
h, the  cells w ere harvested and lysates prepared (M ateria ls and M ethods). Equal volum es o f the  lysates 
w ere then  resolved by SDS-PAGE and im m unob lo tted  (M ateria ls and M ethods). A and C. Detection o f fu ll-  
length APP in cell lysates using the  anti-APP C-term inal an tibody. B and D. Detection o f [3-actin in cell lysates 
using the  an ti-p -actin  an tibody. E and F. Q uantifica tion o f m ature  APP7 5 1 /7 7 0  (E) and im m atu re  APP7 5 1 /7 7 0  (F) 
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Figure 4.9. The effect of copper on soluble APP production from D u l45  cells. Cells w ere g row n to  
confluence and the  m edium  was replaced w ith  serum free m edium  containing 0 ,1 , 10, 50, 200 o r 500 pM  
CuCI22H20 . A fte r 24 h, the  cond itioned  m edium  was collected and concentrated (M ateria ls  and M ethods). 
Equal vo lum es o f the  m edium  samples were then resolved by SDS-PAGE and im m unob lo tted  (M ateria ls  and 
M ethods). A and B. D etection o f soluble APP in cond itioned m edium  using the anti-APP an tibody  6E10. C. 
Q uantifica tion  o f soluble APP levels in m edium  from  con tro l and copper (50 pM ) trea ted  cells. Results are 
means ± S.D. (n=3). n.s. = no t significant.
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N ext, th e  conditioned  m edium  from  D u l4 5  cells tre a te d  w ith  th e  initial 0 -5 0 0  ^iM 
copper concentra tion  range was im m u n ob lo tted  w ith  antibody 6E10 in o rd er to  d etec t 
sAPPa. The results (Fig. 4.9A)  appeared  to  show an increase in APP shedding a t copper 
concentrations o f 20 0  and 500  p M . These m etal concentrations w ere  clearly cytotoxic (Fig.
4 .7 )  and so, in o rd er to  confirm  th a t APP shedding was not enhanced at sub-toxic copper 
concentrations, a fu rth e r exp erim en t was conducted w h ereby trip licate  cell cultures w ere  
tre a te d  w ith  e ith e r 0 o r 50  p M  m etal concentrations. The results (Fig. 4 .9B an d  9C) 
confirm ed th a t sub-toxic copper concentrations did not enhance APP shedding despite th e  
previously observed e levated  APP expression levels at this particu lar m etal concentration  
(Fig. 4.8C-F).
4 .8 . Summary
The first conclusion to  be draw n from  this section o f th e  study is th a t LNCaP, PC-3 
and D u l4 5  cells all d em o n stra ted  identical susceptibility to  copper toxicity (Figs. 4.1, 4 .4  an d
4.7 )  w ith  only copper concentrations o f 200  and 500  p M  showing significant decreases in cell 
viability .
The LNCaP cells show ed no change in APP expression w hen th ey  w ere  tre a te d  w ith  
sub-toxic copper concentrations (Fig. 4 .2 )  w ith  a corresponding lack o f change in APP 
shedding (Fig. 4 .3 ).  In contrast, PC-3 cells showed a copper-associated decrease in APP 
expression (Fig. 4 .5 )  possibly resulting from  enhanced shedding o f th e  protein  (Fig. 4.6).
In co m p lete  contrast to  both o f the a fo rem entioned  cell lines, D u l4 5  cells w ere  the  
only cell type to  show  a clear and highly significant increase in APP expression in response to  
copper (Fig. 4 .8 ).  Interestingly, this change was not reflected in APP shedding (Fig. 4.9).  
N otably, how ever, sAPPp levels w ere  not determ ined , raising th e  possibility o f enhanced APP
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processing via th e  am yloidogenic pathw ay due to  increased APP expression in th e  presence  
o f copper.
Collectively, these data show th a t th e  brain m etastatic  p rostate cancer ep ithe lia l cell 
line, D u l4 5 , was th e  only one o f th e  th re e  lines studied to  respond to  copper by increasing  
APP expression. This observation is o f particu lar note given th e  fact th a t th e  brain exhibits  
particu larly  high copper concentrations com pared to  all organs o th e r than  th e  liver (290, 
291), raising th e  possibility th a t these cells m ight use APP as a defence against copper 
toxicity  in th e  fo rm e r organ.
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5. The effect of full-length APP 
construct expression on Dul45 cell 
viability in the presence of copper
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5.1. fatrodnetiQ.il
APP has previously been shown to  bind copper at a site w ith in  th e  E l dom ain  (292) 
and, m ore recently, w ith in  th e  E2 dom ain (159) o f th e  prote in . In add ition, free  AP-peptides  
bind copper (293 ), a lthough it is not known w h e th e r th e  sam e dom ain w ith in  intact APP can 
also bind th e  m eta l. Previous research has dem onstra ted  th a t this copper binding propensity  
o f APP m ay be involved in copper efflux from  cells (1 5 6 ,1 7 0 )  and, th e re fo re , may be 
p ro tective  against copper-induced cytotoxicity.
As prostate cancer cells metastasizing to  th e  brain w ill, no doubt, en co u nter much  
higher copper concentrations w ith in  this organ (290, 291) than  those at th e ir point o f origin  
in th e  p rostate gland. The curren t study exam ined th e  ability o f APP to  p ro tect brain  
m etastatic  D u l4 5  cells against copper toxicity. Specifically, this ch ap ter exam ines th e  e ffect 
o f fu ll-length  APP isoform  expression levels on th e  viability o f D u l4 5  cells in th e  presence o f  
copper.
5.2. Endogenous APP transcrip t analysis in O ul45  ceils
Previous data (C hapter 3) established th a t D u l4 5  cells endogenously expressed  
d etec tab le  (by im m unob lotting ) levels o f only th e  larger KPI-containing APP isoforms. 
H ow ever, APP75i  and APP770 co-m igrated on gels during th e  a fo rem ention ed  im m unob lotting  
experim ents and, th e re fo re , could not be identified  independently . Thus, in o rd er to  fu rth e r  
elucidate  endogenous APP isoform expression in this cell line, an RT-PCR analysis o f 
endogenous APP transcrip t expression was perform ed.
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Table 5.1. RT-PCR primers employed in the current study
Transcript
Analysed
Forward Primer Reverse Primer
APP 5 '-TG AAG AC AAAGTAGTAG AAGT-3' 5'-ACCTGGGACATTCTCTCTCGGTGCTTGGC-3'
A c tin 5'-TGAAGTGTGTGACGTGGACATCCG-3' 5 '-GCTGT CACCTT CACCGTT CCAG -3'
D u l4 5  cells w ere  grown to  ~80%  confluence and RNA was subsequently extracted  as 
described in M ateria ls  and M eth o ds . RT-PCR was carried out using th e  prim ers deta iled  in 
Table 5 .1 .  The APP prim ers had previously been shown to  am plify  th e  th re e  m ajor APP 
isoform  transcripts (294) producing fragm ents o f 337, 505 and 562 base pairs fo r APP695, 
APP75i and APP770, respectively.
The results [Fig. 5.1)  clearly show th a t, as expected, th e  m ajor endogenous APP 
transcripts in D u l4 5  cells w ere  APP75i and APP770 constituting 31 .28  ± 2.67%  and 65 .1  ± 
2.43%  o f th e  to ta l APP transcripts, respectively. M in o r am ounts o f APP695w ere  also d etected  
as confirm ed  by th e  co-m igration o f a fa in t band in th e  untransfected samples w ith  a much  
m ore intense band a t around 337  base pairs in samples extracted from  APP695 o ver­
expressing cells [Fig. 5 .1A).  In fact, the APP6 9 5 transcripts represented 3 .62 ± 1.87%  o f th e  
to ta l APP transcripts in D u l4 5  cells [Fig. 5 . IB ) .  Equal levels o f RNA in th e  untransfected  and 
APP695 over-expressing samples w ere  confirm ed by perform ing an actin RT-PCR [Fig. 5.1C) 
w hich g enerated  th e  expected 44 9  base pair fragm ent.
121
APPttq
A P P 7 5 1
APP695
Actin
















Figure 5.1. Endogenous APP transcript expression in D u l45  cells. Cells were g row n to  80% confluence and 
harvested fo r  mRNA extrac tion  (see M ateria ls and M ethods). RT-PCR was then  perfo rm ed using the  APP 
and actin prim ers deta iled  in Table 5.1 and the  reaction products were resolved by agarose gel 
e lectrophoresis . A. APP tran sc rip t expression in untransfected and APP69 5 over-expressing cells. B. M ultip le  
APP RT-PCR gels w ere quantified  by dens itom etric  analysis. C. Actin RT-PCR analysis.
- 5 0 0  bp  
- 3 0 0  bp
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5,3. Over-expression of AFP isoform constructs in D ul45 cells
Having confirmed that all three major APP isoform transcripts were endogenously 
expressed in Dul45 cells, the effects of over-expressing these isoforms on cell viability in the 
presence of copper were then examined.
D ul45 cells were first stably transfected w ith pIRES hyg plasmid containing cDNA 
encoding APP695, APP751 or APP770 (Fig. 5.2) using the Nucleofector 2b device as described in 
Materials and Methods. Following antibiotic selection, cell lysates were prepared and equal 
amounts of protein from each transfectant were resolved by SDS-PAGE and immunoblotted 
w ith the anti-APP C-terminal antibody in order to detect full-length APP. The results (Fig. 5.3) 
clearly show that all three APP isoforms were successfully over-expressed albeit at varying 
levels.
As the detection of different APP isoforms in cell lysates is confused by the presence 
not just o f multiple isoforms but also multiple glycoforms, the conditioned medium from the 








Figure 5.2. Schematic showing the APP isoform constructs used in the current study. A. APP695 contains 
ne ither the KPI domain nor the OX-2 domain. B. APP7S1 does not contain the OX-2 domain. C. APP770 
possesses both the KPI and the OX-2 domain.
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soluble APP ectodom ain fragments which consist almost exclusively o f fu lly  glycosylated APP 
isoforms. In itia lly the medium samples were im m unoblotted w ith  antibody 6E10 in order to  
detect sAPPa. The results [Fig. 5.4A) show tha t the APP-transfected cells produced 
significantly more to ta l sAPPa than the mock-transfected cells. The same samples were also 
im m unoblotted w ith  antibody 1A9 in order to  detect sAPPp [Fig. 5.4B). W hilst there was a 
significant increase in to ta l sAPPp levels shed from  the APP695-transfected cells, it is 
interesting to  note tha t sAPPp originating from  the endogenous KPI-containing isoforms was 
actually reduced in these cells relative to  the mock-transfected cells, perhaps suggesting a 
com petition  between isoforms fo r the active site o f BACE1. Also o f interest was the fact tha t 
the levels o f sAPP(3 shed from  APP751- or APP770-transfected cells were much greater 
(between 10- and 20-fold higher) than those shed from  either the mock- or APP695- 
transfected cells.
M atu re  APP75^/77o 
Im m ature  APP7 5 i / 77o 
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Figure 5.3. APP isoform over-expression in D u l45  cells. Cells w ere grow n to  confluence and the  m edium  
was replaced w ith  serum  free  m edium  fo r  24 h. The cells were then harvested and lysates prepared 
(M ateria ls and M ethods). SDS-PAGE and im m unob lo ts w ere then perfo rm ed (M ateria ls and M ethods). A. 
Detection o f fu ll length APP in cell lysates using the  anti-APP C-term inal an tibody. B. Detection o f p- actin in 
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Figure 5.4. Soluble APP produced by D u l45  cells over-expressing APP isoform constructs. Cells were 
grow n to  confluence and the  m edium  was replaced w ith  serum free  m edium  fo r  24 h. Concentrated 
cond itioned  m edium  samples w ere prepared and subjected to  SDS-PAGE and im m u n o b lo ttin g  as described 
in M ateria ls  and M ethods. A. D etection o f sAPPa in cond itioned media using the  anti-APP 6E10 an tibody. 
M u ltip le  6E10 im m unob lo ts  w ere quantified  and displayed graphically. B. D etection o f sAPP|3 in 
cond itioned  media using the  anti-APP 1A9 an tibody. M u ltip le  1A9 im m unob lo ts  were also quantified  and 
displayed graphica lly. Results are means ± S.D. (n=3) and displayed as a percentage o f to ta l sAPP produced 
by D u l4 5  APP6 9 5 cells, due to  low  (and variable) levels produced by the  D u l4 5  pIRES hyg cells creating large 
e rro r. Significance was tested  against the  D u l4 5  pIRES hyg con tro l. * = s ign ificant at p<  0.05.
5.4. The effect of APP isoform over-expression on D ul45  cell 
viability in the presence of copper
Having analysed the expression and proteolysis o f the various APP isoform 
constructs, the ir effects on D ul45 cell v iab ility in the presence o f the various copper 
concentrations were then examined. Mock- or APP isoform-transfected cells were seeded at 
2 0 0 0  cells per well and equilibrated overnight before adding glycine-complexed copper at 
metal concentrations ranging from  0-200 pM. These copper concentrations are 
physiologically relevant in the brain as synaptic copper levels are estimated to  be 100-250
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p M  (295 , 296). The D u l4 5  cells w ere  th en  cultured fo r 7 days w ith  th e  m edium  being  
replaced w ith  fresh copper-containing m edium  on day 4. MTS cell v iab ility  assays w ere  
p erfo rm ed  on day 0 (5 h a fte r initial copper add ition) and day 7 as described in M ate ria ls  and  
M eth o ds .
The results from  these v iability  experim ents [Fig. 5 .5)  are expressed as percentage  
viability  o f th e  n o n -m e ta l-trea ted  controls. As w ould  be expected, th e re  was no d iffe rence in 
viability  regardless o f w h e th e r or not th e  cells had been tre a te d  w ith  copper at day 0  [Fig. 
5.5A).  H ow ever, a fte r seven days o f g row th , th e  viability o f th e  m ock-transfected  cells was  
reduced to  65 .42  ± 3.26%  and 51 .72  ± 4 .54%  o f th e  u n treated  cells in th e  presence o f 150  
and 20 0  p M  copper respectively [Fig. 5.5B). W hen  th e  cells w ere  stably transfected  w ith  
APP69 5 , this decrease in viability was largely ab lated  w ith  viability  being 97 .13  ± 1.33%  and 
9 3 .45  ± 2 .34%  o f th e  u n treated  controls in th e  presence o f 150  and 200  p M  copper 
respectively. In fact, a t a copper concentration o f 150 p M , all th ree  o f th e  m ajo r APP 
isoform s significantly enhanced th e  viability o f th e  D u l4 5  cells relative to  th e  m ock- 
transfec ted  cell v iability  at th e  sam e m etal concentration [Fig. 5.5B). The pattern  was also 
sim ilar at 20 0  p M  copper, except th a t APP77o did not im prove v iability  at this m etal 
concentration . N otably, APP695 was clearly the m ost effective isoform in term s o f p reventing  
a copper-induced reduction in cell viability.
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Figure 5.5. The effects of APP isoform construct over-expression on D u l45  cell viability in the presence of 
copper. Cells w ere seeded at 2000 cells per w ell and equ ilib ra ted overn igh t under norm al g row th  
cond itions (37 °C, 5% C 02). G lycine-com plexed copper was added to  fina l m etal concentra tions o f 0; 5 0 ,15 0  
and 200 pM  in 100 pi o f com ple te  RPMI; the  cells were then grown over a 7 day period w ith  m edium  being 
replaced w ith  fresh m eta l-con ta in ing  m edium  at day 4. The MTS cell v iab ility  assay was pe rfo rm ed on day 0 
(w ith in  5 h o f adding the  m eta l) (A) and on day 7 (B). Results are means ± S.E. (n=12). Significance was 
tested against the  D u l4 5  pIRES hyg con tro l. * = s ignificant at p<  0.05; * *  - s ign ificant at p<0.01; * * * * *  = 
s ign ificant at p<  0.0005; * * * * * *  = p<0.0001. Unless o therw ise stated, d ifferences w ere no t s ign ificant.
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5,5. The effect of ablating endogenous APP expression on 
D u i4 5  cell viability in tne  presence of copper
As over-expression o f APP695 pro tected  D u l4 5  cells from  copper induced toxicity {Fig. 
5.5 ),  th e  e ffe c t o f knocking dow n endogenous APP expression on cell v iab ility  in th e  presence  
o f copper was also exam ined. For this purpose th e  fo llow ing  siRNA's w ere  purchased from  
T h erm o  Scientific Dharm acon (St Leon-Rot; G erm any) and em ployed in th e  study: N on­
targe tin g  #1  siRNA control pool (Cat. No. D -0 01 206 -13 -05 ) and hum an APP targeting  siRNA 
SM ARTpool (Cat. No. M -0 0 3 7 3 1 -0 0 ).
Cells w e re  seeded in com plete  grow th m edium  in 24 -w e ll plates and allow ed to  grow  
overnight. siRNA transfections w ere  com m enced th e  fo llow ing  m orning and glycine- 
com plexed copper was added 24 h post transfection (M ateria ls  and M ethods). Follow ing an 
additional 48  h culture period, MTS cell viability assays w ere  perform ed. Parallel cell 
incubations w e re  perfo rm ed  fo r th e  im m unob lot analysis o f APP expression and proteolysis.
As these experim ents w ere  perfo rm ed  in 24 w ell plates th e  protein yield in lysate 
and conditioned  m edium  samples was too  low to quantify  and, as such, equal volum es o f 
sam ples (ra th e r than  equal p ro tein  am ounts) w ere  resolved on gels.
The results {Fig. 5.6A)  show th a t th e  APP siRNA tre a tm e n t reduced th e  expression o f 
APP to  23 .21  ± 4 .8 5  % th a t o f th e  control siRNA tre a tm e n t. A sim ilar decrease in th e  levels o f 
sAPPa was observed in conditioned m edium  (31 .15  ± 3.45%  o f control siRNA tre a tm e n t) {Fig. 
5.6C).  The corresponding MTS assays (Fig. 5.7)  showed th a t depleting APP levels in th e  
presence o f copper reduced cell viability by 9 .6  ± 1.76%  com pared to  th e  control siRNA- 






























- 4 5 kDa 
- 30 kDa
Figure 5.6. APP expression and proteolysis in siRNA transfected D u l45  cells. Cells w ere seeded in to  a 24- 
w ell p la te as stated in M ateria ls  and M ethods. A fte r an overn igh t g row th  period, the  cells w ere transfected 
w ith  25 nM con tro l o r APP-targeting siRNA (M ateria ls and M ethods). G lycine-com plexed copper (200 pM ) 
was added to  wells 24 h post-transfection . Follow ing fu rth e r 48 h incubation, cells and cond itioned m edium  
w ere harvested and prepared fo r im m unob lo tting  as per M ateria ls and M ethods. A. D etection o f APP in 
lysates using the  anti-APP C -term inal antibody. B. Detection o f P-actin in lysates using the  anti-P -actin  
an tibody. C. Detection o f sAPPa in cond itioned  m edium  using the anti-APP 6E10 an tibody. Im m unob lo ts 
w ere quantified  and the  results expressed relative to  the con tro l siRNA trea tm ent. Results are means ± S.E. 
(n= 1 2 ) from  4  independen t experim ents. * * * * * *  = s ignificant at p < 0 .0 0 0 1 .
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Figure 5.7. Viability of siRNA transfected D u l45  cells. Cells w ere seeded in to  a 24-w ell p late as stated in 
M ateria ls  and M ethods. A fte r an ove rn igh t g row th  period, the  cells were transfected  w ith  25 nM con tro l o r 
APP-targeting siRNA (M ateria ls  and M ethods). G lycine-com plexed copper (200 pM ) was added to  wells 24 h 
post-transfection . Follow ing fu rth e r  48 h incubation, MTS assays were carried ou t as stated in M ateria ls and 
M ethods. MTS assay results w ere analysed relative to  the  con tro l siRNA trea tm e n t. Results are means ± S.E. 
(n=15) from  3 independen t experim ents. * * * * * *  = s ign ificant at p< 0.0001.
5.6. Summary
The RT-PCR analysis o f D ul45 cell RNA confirmed tha t the m ajor APP isoforms in this 
cell line were APP75i and APP770 [Fig. 5.1). However, unlike the im m unoblotting  analysis 
performed previously, the RT-PCR analysis confirmed the presence o f m inor amounts o f 
APP695 transcripts in D ul45  cells.
The three major APP isoforms were then successfully stably over-expressed in D ul45  
cells and the ir effects on cell v iab ility  in the presence o f copper were m onitored. The results 
[Fig. 5.5) clearly show tha t all three isoforms were capable o f enhancing viability in the 
presence o f the metal, w ith  APP695 being clearly the most effective isoform in this respect. 
When siRNA was used to deplete the endogenous expression o f APP in D ul45  cells, the ir 
v iab ility  in the presence o f copper was slightly decreased [Fig. 5.7). Notably, the decrease in 
cell v iab ility associated w ith  the depletion o f endogenous APP was nowhere near the
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increase in viability  observed w hen th e  protein  was over-expressed, perhaps suggesting a 
d egree o f redundancy o f APP in this functional capacity.
Collectively, these data confirm  th a t D u l4 5  cells are able to  utilise APP in o rd er to  
enhance th e ir  v iab ility  in th e  presence o f physiologically re levant (to  th e  brain) copper 
concentrations.
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6. The APP cytosolic domain is a 
prerequisite for enhanced Dul45 




The results presented in th e  previous chapter clearly d em onstra te  th a t APP6 9 5 was 
able to  enhance th e  v iability  o f th e  brain m etastatic  prostate cancer cell line, D u l4 5 , in th e  
presence o f copper. The curren t chapter begins to  exam ine th e  prerequisites w ith in  th e  APP 
m olecule necessary fo r this effect. Specifically, th e  role played by the cytosolic dom ain o f th e  
p ro te in  is exam ined . This part o f th e  APP m olecule contains a YENPTY m o tif w hich is typical 
o f tyros ine kinase receptors and has been shown to  in teract w ith  a range o f in tracellu lar 
ad ap to r proteins, som e o f w hich elicit dow nstream  signalling events such as th e  MAPK  
p ath w ay  (rev iew ed  in (50)). The effects o f deleting or m utating  this part o f th e  m olecule on 
th e  v iab ility  o f D u l4 5  cells in th e  presence o f copper are exam ined.
6.2. The expression and proteolysis of APP cytosolic domain 
m u tan t constructs in B u l45  ceils
In o rd er to  investigate th e  role o f the APP cytosolic dom ain in enhancing th e  v iability  
o f D u l4 5  cells in th e  presence o f copper, a range o f cytosolic dom ain m u tan t constructs  
w e re  designed and stably expressed in th e  cell line {Fig. 6.1).  The APP695AICD construct {Fig. 
6 . IB )  lacked th e  cytosolic dom ain  o f th e  protein being truncated  C -term inally  to  L648. A 
series o f tyrosine point m utation  constructs w ere  also generated  (APP695-682, APP695-6 8 7  and 
APP695-6 8 2 /6 8 7 )  in o rd er to  exam ine th e  effects o f phosphorylation w ith in  th e  YENPTY m o tif 
on cell v iab ility  {Figs. 6.1C-E).
The various APP constructs w ere  stably transfected into D u l4 5  cells (see M ateria ls
and M eth o d s ) and th e ir  expression and proteolysis w ere  subsequently m onitored  by
im m u n ob lo tting . Initially, equal am ounts o f protein from  cell lysates w ere  resolved by SDS-
PAGE and im m u n ob lo tted  using th e  anti-APP antibody 6E10 (APP695AICD does not possess
th e  in trace llu lar dom ain  ep itope recognised by the APP C-term inal antibody used in previous
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chapters). The results (Fig. 6.2) clearly show that all of the constructs were successfully 
expressed albeit that the APP695AICD construct was expressed at a significantly lower level 
than the other constructs. Interestingly, the over-expression of the APP695 constructs 
appeared to affect the expression of the two larger endogenous isoforms indicating that APP 
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Figure 6.1. Schematic representing APP intracellular domain mutant constructs. A. W ild-type APP695 B. 
APP695AICD was truncated C-term inally to  L648 and, therefore, lacks the cytosolic domain o f its w ild-type 
counterpart. C-E. Single o r double tyrosine to  glycine mutations were introduced at positions 682 and/or 
687.
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Figure 6.2. APP intracellular domain m utant over-expression in D u l45  cells. Stably transfected  cells w ere 
g row n to  confluence and the  m edium  was replaced w ith  serum free m edium  fo r  24 h. Lysates were 
subsequently prepared and equal am ounts o f pro te in  from  each were im m unob lo tted  (M ateria ls  and 
M ethods). A. Detection o f APP in cell lysates using the anti-APP an tibody, 6E10. M u ltip le  6E10 im m unob lo ts  
w ere quantified  by dens itom e tric  analysis and the results shown are means ± S.D. (n=3). Significance was 
tested against the  m ock-transfected con tro l. * = s ignificant at p<  0.05; * * * * *  = s ign ificant a t p<  0.0005. 
Unless o therw ise  ind icated, the  results are no t sign ificantly d iffe ren t. B. D etection o f (3-actin in cell lysates 
using the anti-P -actin  an tibody.
135
Next, the generation o f soluble APP from  the various cytosolic domain m utant 
constructs was examined by im m unoblotting  equal volumes o f concentrated conditioned 
medium w ith  the anti-APP antibody 6E10 {Fig. 6.3). The w ild-type APP695 cells generated 
significantly more to ta l sAPPa than the mock-transfected cells, as would be expected, and 
the generation o f this proteolytic fragm ent was largely unaffected by the removal o f the 
entire  APP cytosolic domain (APP695AICD) or the m utation o f tyrosine residues w ith in  the 
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Figure 6.3. Soluble APP generation by D u l45  cells over-expressing APP intracellular domain mutants.
Stably transfected cells w ere grow n to  confluence and the m edium  was replaced w ith  serum free  m edium  
fo r  24 h. Conditioned m edium  was subsequently prepared and equal volumes o f each sample were 
im m u n o b lo tted  using the  anti-APP an tibody 6E10 (M ateria ls and M ethods). M u ltip le  6E10 im m unob lo ts  
w ere quantified  by dens itom etric  analysis and the  results shown are means ± S.D. (n=3). Significance was 
tested against the  m ock-transfected con tro l. * = s ign ificant a t p<  0.05; * *  = s ign ificant at p<  0.01; * * *  = 
s ign ificant at p<  0.01. Unless o therw ise indicated, the  results are no t s ign ificantly d iffe ren t.
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6.3. The effects of APP cytosolic domain m utations on the 
viability o fD u l4 5  cells in tlie presence of copper
In o rd er to  exam ine th e  role played by th e  APP cytosolic dom ain  in th e  en h an cem en t  
o f D u l4 5  cell v iab ility  in th e  presence o f copper, th e  stably transfected  cells w ere  seeded out 
and cu ltured  overn ight before adding glycine-com plexed m etal at concentrations o f 0 - 2 0 0  
|aM. MTS viability  assays w ere  perfo rm ed  at both 5 h and 7 days a fte r th e  addition o f copper. 
The results {Fig. 6.4A)  show a slight initial drop in viability fo llow ing  th e  addition o f copper to  
th e  various APP-transfected cells. H ow ever, a fte r seven days {Fig. 6.4B) th e  viability o f m ock- 
transfected  cells tre a te d  w ith  150  and 200  p M  copper had decreased to  63 .25  ± 3 .38%  and 
4 9 .9 8  ± 3.33% , respectively, o f th e  untreated  controls. In contrast, th e  v iability  o f th e  w ild - 
typ e  APP695-transfected  cells at th e  same m etal concentrations rem ained  a t 9 4 .88  ± 1.43%  
and 9 1 .4 8  ± 3.42% , respectively, o f th e  untreated  controls. Thus, th e  w ild -typ e  APP clearly  
enhanced cell v iability  in th e  presence o f copper. How ever, in th e  case o f th e  APP695AICD  
m u tan t and all o f th e  tyrosine m utants, th e  ability o f APP to  p rotect against copper-induced  
reductions in cell v iability  was clearly ablated {Fig. 6.4B).
6.4. APP regela tes the raft association of caveoIin-1
APP proteolysis is linked to  the association o f the protein  w ith  cholestero l and  
sphingolipid-rich lipid rafts (87 ). It is possible th a t rem oving th e  cytosolic dom ain o f APP, as 
in th e  case o f th e  APP6 95AICD construct, w ould a lter its raft association. In o rd er to  
investigate th is possibility, mock-, APP6 9 5 - and APP6 9sAICD-transfected D u l4 5  cells w ere  
grow n to  confluence and solubilised in Triton X -100 at 4  °C. Lipid rafts w ere  subsequently  
prepared  using buoyant sucrose density gradient centrifugation as described in M ateria ls  
and M eth o ds . A fte r harvesting, th e  individual gradient fractions w ere  analysed in term s of
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Figure 6.4. The effects of APP intracellular domain m utant over-expression on D u l45  cell viability in the  
presence of copper. Cells were seeded at 2000 cells per w e ll and equ ilib ra ted ove rn igh t under norm al 
g row th  cond itions (37 °C, 5% C 02). G lycine-complexed copper was added to  fina l m etal concentra tions o f 0, 
5 0 ,15 0  and 200 pM  in 100 pi o f com plete RPMI; the cells w ere then grown over a 7 day period w ith  
m edium  being replaced w ith  fresh m eta l-conta in ing m edium  at day 4. The MTS cell v iab ility  assay was 
pe rfo rm ed on day 0 (w ith in  5 h o f adding the m etal) (A) and on day 7 (B). Results are means ± S.E. (n=9). 
Significance was tested against the  m ock-transfected contro l. * = s ignificant at p<  0.05; * *  = s ign ificant at 
p<0.01; * * *  = s ign ifican t at p<  0.005; * * * *  = s ign ificant at p<  0.001; * * * * *  = s ign ificant at p<  0.0005;
* * * * * *  = s ign ifican t at p < 0.0001. Unless o therw ise stated, d ifferences were no t significant.
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5
th e ir protein content. The results (Fig. 6.5) are expressed in terms o f a percentage 
d istribu tion  o f protein throughout the gradients and show no difference in the d is tribution 
regardless o f which protein was over-expressed in the cells.
Next, the d is tribution o f APP itse lf th roughout the sucrose gradient fractions was 
determ ined by im m unoblotting w ith  anti-APP antibody, 6E10. The results (Fig. 6 .6 ) clearly 
show tha t all forms o f the protein were distributed equally throughout the gradients w ith 
none being detected in the raft fractions.
o Mock
-o,A PP 695A IC D
APP695
L o w -d en s ity  
ra f t  fra c tio n s
F rac tio n  n u m b e r
Figure 6.5. Analysis of protein distribution in sucrose gradients prepared from  D u l45  cells transfected 
w ith either vector alone, w ild-type APP695 or APP695AICD. Lipid rafts were prepared as described in 
M ateria ls  and M ethods and ind iv idua l fractions were harvested (1 -  bo ttom  o f gradient, 9 -  to p  o f 
grad ient). Protein concentra tions w ith in  the  fractions were determ ined using the  BCA assay (M ateria ls and 
M ethods). The results are expressed in te rm s o f percentage d is tribu tion  th ro u g h o u t the  gradients and are 
means ± S.D. (n=3).
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Figure 6.6. Analysis of APP distribution in sucrose gradients prepared from  D u l45  cells transfected with  
either vector alone, w ild-type APP695 or APP695AICD. Lipid rafts were prepared as described in M ateria ls 
and M ethods and ind iv idua l fractions were harvested (1 -  bo ttom  o f grad ient, 9 -  top  o f gradient).
Fractions were resolved by SDS-PAGE and subsequently im m unob lo tted  w ith  anti-APP an tibody, 6E10 
(M ateria ls  and M ethods) (A-C). M ultip le  im m unob lo ts from  each cell type w ere quantified  by dens itom etric  
analysis (D) and the  results are expressed in term s o f percentage d is tribu tion  th ro u g h o u t the  gradients and 
are means ± S.D. (n=3).
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Figure 6.7. Analysis of caveolin-1 distribution in sucrose gradients prepared from D u l45  cells transfected 
w ith either vector alone, w ild-type APP695 or APP695AICD. Lipid rafts were prepared as described in 
M ateria ls  and M ethods and ind iv idual fractions were harvested (1 -  b o ttom  o f grad ient, 9 -  to p  o f 
g rad ien t). Fractions were resolved by SDS-PAGE and subsequently im m unob lo tted  w ith  anti-caveo lin -1  
an tibody (M ateria ls  and M ethods) (A-C). M ultip le  im m unoblo ts  from  each cell type w ere quantified  by 
d ens itom e tric  analysis (D) and the  results are expressed in term s o f percentage d is tribu tion  th ro u g h o u t the 
g rad ients and are means ± S.D. (n=3). Significance was tested against the  mock transfected con tro l. * = 
s ign ifican t a t p<  0.05; * * * * * * =  s ignificant at p<  0.0001. Unless o therw ise stated, d ifferences w ere no t 
s ign ificant.
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Finally, th e  individual sucrose gradient fractions w ere  im m u n ob lo tted  w ith  an 
an tibo d y against th e  ra ft m arker protein, caveolin-1 (83, 298). W hilst th e  m ajority  o f 
caveolin-1 was actually  found in th e  non-ra ft fractions o f th e  m ock-transfected D u l4 5  cells 
{Fig. 6 .7A an d  C), 20 .64  ± 6.04%  was present, collectively, in fractions 5 and 6 consistent w ith  
a low -density  ra ft localisation. How ever, in th e  case o f th e  w ild -typ e  APP695-transfected  cells, 
only 3 .9 1  ± 1.55%  o f caveolin-1 was located in these low -density fractions suggesting th a t  
APP m ay actually disrupt lipid rafts in D u l4 5  cells. Conversely, cells expressing the  
APP695AICD construct exhib ited  m ore caveolin (re lative to  th e  mock transfectants) in 
fractions 5 and 6 suggesting th a t th e  ectodom ain a n d /o r transm em brane dom ain o f APP 
m ight actually serve to  enhance th e  raft association o f caveolin-1.
6,5. Potential in tracellu lar signalling pathways influenced by 
APP over-expression
From th e  preceding w ork  it was apparent th a t th e  cytosolic dom ain  o f APP and, 
specifically tyrosines 682  and 687, w ere  prerequisites fo r the ability o f th e  protein to  
enhance D u l4 5  cell v iab ility  in th e  presence o f copper. The same region o f th e  protein  has 
previously been im plicated  in th e  regulation o f various kinase-m ediated signalling cascades 
including those o f E rk l and 2 (299). Thus, in the current study, th e  e ffect o f over-expressing  
w ild -typ e  APP and th e  various cytosolic dom ain m utants on E rk l expression was exam ined.
The results {Fig. 6.8A)  dem onstrate a 58 .97  ± 6.5%  reduction in E rk l m onom er  
expression in th e  w ild -typ e  APP695-transfected D u l4 5  cells relative to  mock transfectants. 
This a ffect was ab lated  in cells transfected w ith  th e  APP695AICD construct and those  
transfected  w ith  any o f th e  th ree  tyrosine m utant constructs. An actin im m unob lot 
confirm ed equal protein  loading {Fig. 6.8B).
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Figure 6.8. ERK1 expression in D u l45  cells over-expressing APP intracellular domain mutants. Stably 
transfected  cells w ere g row n to  confluence and the  m edium  was replaced w ith  serum free  m edium  fo r  24 
h. Lysates w ere subsequently prepared and equal amounts o f p ro te in  from  each were im m unob lo tted  
(M ateria ls  and M ethods). A. Detection o f E rk l in cell lysates. M u ltip le  E rk l im m unob lo ts w ere quantified  by 
dens itom e tric  analysis and the  results shown are means ± S.D. (n=3). Significance was tested against the 
m ock-transfected con tro l. * * *  = s ignificant at p < 0.005. Unless o therw ise indicated, the  results are no t 
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Figure 6.9. ERK1 expression in D u l45  cells over-expressing APP isoforms. Stably transfected cells were 
g row n to  confluence and the  m edium  was replaced w ith  serum free m edium  fo r 24 h. Lysates were 
subsequently prepared and equal am ounts o f p ro te in  from  each were im m unob lo tted  (M ateria ls and 
M ethods). A. Detection o f E rk l in cell lysates. M u ltip le  E rk l im m unoblo ts were quantified  by dens itom etric  
analysis and the  results shown are means ± S.D. (n=3). Significance was tested against the  m ock-transfected 
con tro l. * * *  = s ign ificant a t p<  0.005. Unless o therw ise indicated, the  results are no t s ign ificantly  d iffe ren t. 
B. Detection o f (3-actin in cell lysates using the  anti-P -actin antibody.
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Follow ing th e  observed reduction in E rk l m o n om er expression in APP695 -transfected  
D u l4 5  cells, and because th e  ab ility  o f th e  la tte r protein to  enhance viability in th e  presence  
o f copper was specific to  th e  695 am ino acid isoform , th e  e ffec t o f th e  larger KPI-containing  
APP isoform s on E rk l expression was also subsequently investigated. As previously observed, 
th e  results {Fig. 6.9A)  show th a t w ild -typ e  APP695 decreased E rk l expression re lative to  th e  
m ock-transfected  contro l. H ow ever, this effect was specific to  th e  695 am ino acid APP 
isoform  w ith  no such change being observed in cells over-expressing e ith er APP75i  o r 770. An 
actin im m u n o b lo t confirm ed equal protein loading {Fig. 6.9B).
6 .6 . Summary
All o f th e  APP695 cytosolic dom ain m utants w ere  over-expressed successfully in 
D u l4 5  cells, a lbeit th e  APP695AICD construct at a noticeably low er level {Fig. 6.2).  
Furtherm o re , all o f th e  constructs yielded sim ilar am ounts o f soluble APP {Fig. 6.3).  How ever, 
only w ild -typ e  APP695 was able to  prom ote cell viability in th e  presence o f copper w ith  this 
e ffec t being ab lated  by e ith er com plete  deletion o f th e  cytosolic dom ain or th e  m u tation  o f 
individual tyrosine residues w ith in  th e  YENPTY m o tif {Fig. 6.4).
Interestingly, w hilst th e  rem oval o f the APP cytosolic dom ain  did not a lte r th e  
association o f APP itself w ith  lipid rafts, th e  w ild -type protein  actually p revented  caveolin-1  
association w ith  these m em b rane structures w ith  th e  APP695AICD construct exhibiting the  
opposite effect {Fig. 6.7).
Finally, th e  cytosolic dom ain o f APP and th e  tyrosine residues w ith in  th e  YENPTY 
m o tif app ear to  be involved in th e  expression o f E rk l in D u l4 5  cells w ith  th e  expression o f 
th e  la tte r pro tein  being im paired by this region o f th e  APP m olecule {Fig. 6.8);  an effect 
w hich was also specific to  th e  695 am ino acid isoform o f APP {Fig. 6.9).
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Collectively, these data show th a t th e  YENPTY m o tif w ith in  th e  cytosolic dom ain  o f 
APP is linked to  th e  ab ility  o f th e  p rotein  to  enhance D u l4 5  cell v iability  in th e  presence o f 
copper and th a t th e  regulation o f E rk l expression m ay be linked to  this ability.
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7. The APP ectodomain and 
enhanced Dul45 cell viability in the 
presence of copper
147
s #  t r  pL f  v  */ . i .  fetrocmction
The data in th e  preceding chapter indicate th a t th e  APP cytosolic dom ain  is a 
prerequis ite  fo r th e  ability o f th e  protein to  enhance D u l4 5  cell v iability  in th e  presence o f 
copper. In th e  current chapter, th e  role o f th e  APP ectodom ain  in this phenom enon was  
investigated.
First, th e  role o f th e  N -te rm inal copper binding site in th e  E l dom ain o f th e  APP 
ectodom ain  (45) was exam ined. M eta l binding w ith in  this copper binding dom ain (CuBD) has 
previously been im plicated in th e  reduction o f intracellu lar copper levels in yeast (156 ) and  
in pro tection  against copper-m ediated  neurotoxic effects in m ice fo llow ing  intrah ippocam pal 
in jection o f peptides mim icking this region o f APP (172). Histidine residues at positions 147, 
149 and 151 o f th e  APP protein have been specifically im plicated in th e  co-ord ination  o f 
copper and th e  m u tatio n  o f these residues has previously been shown to ab late  the  
functions re la ted  to  its m etal binding capacity (156). In th e  current study, th e  effect o f 
histidine to  alanine m utations at these sites on the ability o f APP to  enhance D u l4 5  cell 
viability  in th e  presence o f copper was exam ined.
Second, th e  ability o f th e  soluble APP ectodom ain (as opposed to the  
m em b rane-an ch ored  fu ll-length  protein) to  enhance D u l4 5  cell viability in th e  presence o f 
copper was exam ined. The soluble APP ectodom ain has previously been shown to  exhib it 
functions ind ep en d en t o f the cytosolic dom ain o f th e  protein, including g row th  prom oting  
activ ity (124 ). Furtherm ore, most o f th e  detrim enta l effects seen in APP knockout cells can 
be reversed by application o f sAPPa suggesting th a t this fragm en t carries th e  m ajor  
m olecu lar prerequisites fo r APP functional activity (121).
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7,2. The expression and proteolysis of the APP copper binding 
domain construct in Dul45 ceils
In order to investigate the role of the N-terminal APP CuBD in enhancing the viability 
of Dul45 cells in the presence of copper, an APP construct which should, in theory, be 
deficient in metal binding at this site, was designed. The APP695ACuBD construct contained 
three histidine to alanine mutations at positions 147,149 and 151 (Fig. 7.1). This construct, 
along w ith wild-type APP695, was stably transfected into Dul45 cells (see Materials and 
Methods) and the expression and proteolysis of the constructs were subsequently 
monitored by immunoblotting analysis. Initially, equal amounts of protein from cell lysates 
were resolved by SDS-PAGE and immunoblotted using the anti-APP C-terminal antibody. The 
results (Fig. 7.2) confirmed that both constructs were successfully over-expressed w ith wild- 
type APP695 being detected at an 8.51 ± 2.45-fold higher level than the endogenous protein. 
Notably, however, the level of APP695ACuBD detected in cell lysates was significantly lower 






Figure 7.1. Schematic representing the APP N-terminal copper binding domain deficient construct. A.
W ild-type APP695 B. The APP695ACuBD construct contained three histidine to  alanine mutations at positions 
147, 149 and 151.
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Figure 7.2. APP N-term inal copper binding domain mutant over-expression in D u l45  cells. Stably 
transfected  cells w ere g row n to  confluence and the medium was replaced w ith  serum free  m edium  fo r 24 
h. Lysates were subsequently prepared and equal amounts o f pro te in  from  each were im m unob lo tted  
(M ateria ls  and M ethods). A. Detection o f APP in cell lysates using the  anti-APP C-term inal antibody. 
M u ltip le  APP im m unob lo ts  w ere quantified  by densitom etric  analysis and the  results shown are means ± 
S.D. (n=3). Significance was tested against the m ock-transfected con tro l. * = sign ificant at p<  0.05. B. 
Detection o f (3-actin in cell lysates using the  anti-P-actin antibody.
Equal volumes o f the conditioned medium collected from  these cell types was then 
im m unoblotted and analysed fo r production o f soluble APP metabolites, using the anti-APP 
6E10 and 1A9 antibodies as probes fo r sAPPa and sAPPP, respectively. The results [Fig. 7.3A) 
show tha t the w ild-type APP695 and APPggsACuBD transfected cells produced 2.04 ± 0.27- and 
1.35 ± 0.28-fold more sAPPa, respectively, than the mock-transfected cells; perhaps
150
reflecting the elevated fu ll-length protein expression observed in the w ild-type APP695- 
transfected cells (Fig. 7.2A). The level o f sAPP(3 produced by the w ild-type APP695-transfected 
D u l45  cells was massively increased compared to  the mock transfectants (Fig. 7.3B). 
Notably, however, the m utation o f the CuBD in the APP695ACuBD-transfected cells appeared 
to  completely prevent sAPPp generation (Fig. 7.3B), suggesting a role fo r copper binding in 
the production o f this APP metabolite.
A
- 9 7 kDa
Mock APP69SACuBD
D u l4 5
Figure 7.3. Soluble APP generation by D u l45  cells over-expressing the APP695ACuBD construct. Stably 
transfected cells were grow n to  confluence and the m edium  was replaced w ith  serum free m edium  fo r  24 
h. C onditioned m edium  was subsequently prepared and equal volumes o f each sample were 
im m unob lo tted . A. Detection o f sAPPa in cond itioned m edium  using the anti-APP antibody, 6E10. M u ltip le  
6E10 im m unob lo ts  were quantified  by densitom etric  analysis and the  results shown are means ± S.D. (n=3). 
Significance was tested against the  m ock-transfected contro l. * = significant a t p<  0.05; * * *  = s ignificant at 
p<  0.005. B. Detection o f sAPPp in cond itioned m edium  using antibody 1A9.
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7.3. The effect of E l caj; j o r  IE domain m utations on the 
viability E 145 cells in the p resence of copper
In o rd e r to  exam ine th e  role o f th e  APP E l copper binding dom ain  in m aintain ing  
D u l4 5  cell v iab ility  in th e  presence o f copper, the stably transfected  cells w ere  seeded out 
and cu ltured  overnight before adding glycine-com plexed m etal at concentrations o f 0 ,1 5 0  
and 20 0  p M . MTS viability  assays w ere  perform ed at both 5 h and 7 days a fte r  the addition  
o f copper.
The results {Fig. 7.4A) show an initial drop in viability fo llow ing  th e  addition  o f 
copper to  th e  various cell types, particularly in th e  m ock-transfected cells. A fte r seven days 
{Fig. 7.4B)  th e  viability  o f m ock-transfected cells trea ted  w ith  150 and 20 0  p M  copper had 
decreased to  4 0 .45  ± 2.56%  and 15 .46 ± 0.32% , respectively, o f th e  u n treated  controls. In 
contrast, th e  viability o f th e  w ild -typ e  APP695-transfected cells at th e  same m etal 
concentrations rem ained  at 68 .38  ± 1.08%  and 51 .06  ± 1.89% , respectively, o f th e  untreated  
controls. These initial data confirm ed the previously observed ability o f w ild -typ e  APP695 to  
p ro m o te  D u l4 5  cell viability in th e  presence o f copper. Notably, how ever, at seven days, the  
m u tatio n  o f th e  APP E l CuBD partially ablated the effect o f the w ild -typ e  protein  at 200  p M  
copper and com plete ly  ab lated its effect at 150 p M  copper (Fig. 7.4B). These data clearly 
ind icate th a t an intact copper binding dom ain in the E l dom ain o f APP is a prerequisite fo r  
its ab ility  to  p ro m o te  D u l4 5  cell viability in th e  presence o f copper.
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Figure 7.4. The effect of APP695ACuBD mutant over-expression on D u l45  cell viability in the presence of 
copper. Cells w ere seeded at 2000 cells per w ell and equ ilib ra ted  overn igh t under norm al g row th  
cond itions (37 °C, 5% C 02). G lycine-complexed copper was added to  fina l metal concentra tions o f 0, 150 
and 200 pM  in 100 pi o f com plete RPMI; the  cells were then grow n over a 7 day period w ith  m edium  being 
replaced w ith  fresh m eta l-con ta in ing  m edium  at day 4. The MTS cell v iab ility  assay was perfo rm ed on day 0 
(w ith in  5 h o f adding the  m etal) (A) and on day 7 (B). Results are means ± S.E. (n=9). Significance was tested 
against the  m ock-transfected c o n tro l. . * = significant at p<  0.05; * * *  = s ignificant at p<  0.005; * * * * *  = 
s ign ifican t a t p<  0.0005; * * * * * *  = s ignificant at p<  0.0001. Unless o therw ise stated, d ifferences were no t 
s ign ificant.
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7 .4. The role of the soluble APP ectodomain in promoting
Du 145 cell viability in the presence of copper; stab le over­
expression of sAPPa
These studies w ere  perfo rm ed  in o rder to  d eterm ine  w h e th e r th e  soluble form s o f 
APP (as opposed to  th e  fu ll-length  m em brane-anchored  protein) w ere  capable o f prom oting  
D u l4 5  cell v iab ility  in th e  presence o f copper. Initially, a truncated  APP construct analogous 
to  sAPPa was g enera ted  w ith  a v iew  to  over-expressing this form  o f th e  protein  in D u l4 5  
cells. The construct generated  in this instance was based on th e  770  am ino acid isoform  of 
APP, and in this respect it should be noted that, chronologically, these experim ents w ere  
p erfo rm ed  before  th e  data in Chapter 5 was obtained pertaining to  an APP695 isoform - 
specific en h an cem en t o f cell v iab ility  in th e  presence o f copper.
In full length APP770, th e  alpha cleavage site is betw een residues Lys687 and Leu688  
(30 0 ). The soluble APP770 construct (APP770S) was m ade by m utating th e  codon fo r residue  
Leu688 (which w as originally T T G ') into a 'TAG' stop codon and was subsequently stably  
expressed in D u l4 5  cells using lipofectam ine transfection as described in M ateria ls  and 
M eth o ds . It should be noted th a t th e  original fu ll-length APP770 construct used to  generate  
th e  APP770S construct also possessed a FLAG epitope tag im m ediately C-term inal to  th e  signal 
sequence (i.e. a fte r A la l7 )  th ereb y  enabling detection o f both full-length and soluble  
derivatives o f th e  construct using an anti-FLAG antibody.
Following transfection, th e  secretion o f soluble APP into conditioned m edium  from  
D u l4 5  cells was com pared to  th a t in m edium  conditioned on SH-SY5Y cells previously also 
stably transfected  w ith  th e  APP770S construct in our laboratory. Im m unoblotting  th e  
conditioned  m edium  w ith  th e  anti-FLAG antibody {Fig. 7.5A)  detected a band at 
ap p roxim ately  106 kDa in the SH-SY5Y conditioned m edium  as w ould be expected fo r the
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molecular mass o f sAPPcr. However, the same band was absent from  medium conditioned 
on the APP770S-transfected D ul45  cells. Instead, an extremely intense band was detected in 
this conditioned medium at 25 kDa and, notably, the same band was completely absent from  
mock-transfected D u l45  cells (Fig. 7.5A).
When the cell lysates from the various transfectants were im m unoblotted w ith  the 
anti-FLAG antibody (Fig. 7.5B) a lesser amount o f the 25 kDa protein fragm ent was also 
detected in the APP770S-transfected D ul45  cells and was, again, absent from  the mock- 
transfected D ul45  cell lysates.
S o lub le  APP
B
-9 7  kDa
-3 0  kDa
Figure 7.5. Detection of the soluble APP770 construct using the anti-FLAG antibody. D u l45  cells were 
transfected using the  lipo fectam ine  technique (M ateria ls and M ethods). Cells were grown to  confluence 
and the  m edium  was replaced w ith  serum free m edium  fo r 24 h. Conditioned m edium  and cell lysates 
were prepared and SDS-PAGE and im m unob lo tting  perform ed according to  M ateria ls and M ethods. A. 
D etection o f the  FLAG tag in cond itioned m edium . B. Detection o f the FLAG tag in cell lysates.
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In order to  fu rthe r characterise the 25 kDa fragm ent detected in the APP770S- 
transfected D ul45  cells, the same conditioned medium and lysate samples were 
im m unoblotted using the anti-APP antibody, 22C11 (M illipore, W atford, UK) which 
specifically recognises amino acids 66-81 w ith in  the APP ectodomain. The results (Fig. 7.6A) 
show tha t 22C11 also detected an intense 25 kDa fragm ent in medium conditioned on the 
APP770S-transfected D ul45 cells. As observed previously using the anti-FLAG antibody, lower 
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Figure 7.6. Detection of the soluble APP770 construct using the antibody 22C11. D u l4 5  cells were 
transfected  using the  lipo fectam ine technique (M ateria ls and M ethods). Cells were grow n to  confluence 
and the  m edium  was replaced w ith  serum free m edium  fo r 24 h. Conditioned m edium  and cell lysates 
w ere prepared and SDS-PAGE and im m unob lo tting  perform ed according to  M ateria ls and M ethods. A. 
Detection o f APP in cond itioned m edium  using antibody 22C11. B. Detection o f APP in cell lysates using 
an tibody 22C11.
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From the data shown in Figs. 7.5 and 7.6 it was apparent that, although the APP77oS 
construct behaved as expected in SH-SY5Y cells, a truncated version o f the construct, 
possibly derived by proteolytic digestion, was detected in D ul45  cells. Thus, in order to  
determ ine w hether pro teo lytic digestion was involved, a degradation assay was performed. 
Cell lysate from  untransfected D ul45 cells was prepared in the absence o f protease 
inhibitors and was subsequently incubated at 37°C over a 24 h tim e course w ith  conditioned 
medium containing the 106 kDa APP770S construct from  SH-SY5Y cells. Incubations were 
perform ed w ith  both boiled and unboiled lysates in order to  detect any inactivation o f 
endogenous D ul45  cell p ro teolytic activity. The results, however, (Fig. 7.7) showed no 
degradation o f the 106 kDa sAPPa band over the experimental tim e course.
H o u rs
- 9 7  kD a
- 3 0  kD a
Figure 7.7. Lack of soluble APP770 degradation by D u l45  cell lysates. Lysates were prepared from  
untransfected D u l4 5  cells and a liquots o f th is lysate (boiled and unboiled) were incubated at 37 C fo r  the 
indicated tim es w ith  concentra ted cond itioned m edium  from  APP7 7oS-transfected SH-SY5Y cells. The FLAG 
tag in the  sAPPa present in the  SH-SY5Y conditioned m edium  was then detected w ith  the anti-FLAG 



































Collectively, th e  data presented in this section show th a t th e  APP770s construct, 
although behaving as expected in SH-SY5Y cells, was aberrantly  processed in D u l4 5  cells to  
produce a 25 kDa N -te rm inal fragm ent. How, exactly, this fragm en t was generated  rem ains  
to  be d e term in e d . How ever, in th e  context o f th e  curren t study, th e  use o f th e  APP770S 
construct to  d e term in e  th e  effect o f th e  soluble APP ectodom ain  on D u l4 5  cell viability in 
th e  presence o f copper was clearly not a viable approach.
7.5. The role of the soluble APP ectodomain In prom oting
B itl45  cell viability in  the presence of copper; i n h i b i t i o n  o f  
endogenous ectodomain generation
As an a lternative  approach to  investigate th e  involvem ent o f soluble APP in 
prom oting  D u l4 5  cell viability in th e  presence o f copper, th e  e ffect o f a -  and (3-secretase 
inhibitors was investigated.
Initially, confluent w ild -type APP6 9 5 over-expressing D u l4 5  cells w ere  incubated fo r  
24  h in serum  free  m edium  in th e  presence or absence o f th e  a-secretase inhibitor 
G 1254023X  (A g ift from  Ishrut Hussain, GlaxoSmithKline, Harlow ) (20 p M ) in o rder to  
d em o n stra te  effective shedding inhibition by th e  com pound. The results (Fig. 7.8A)  showed  
no significant change in cell-associated APP levels w hen lysates w ere  prepared from  inh ib itor 
tre a te d  and u n treated  cells and im m unoblotted  using th e  anti-APP C-term inal antibody. 
W hen  th e  conditioned  m edium  from  cells was im m unob lotted  w ith  antibody 6E10 (Fig. 7.8B) 
a reduction in sAPPa generation to  73 .79 ± 9.84%  th a t o f controls was observed in the  
m edium  o f G 12 540 23 X -trea ted  cells, consistent w ith  a partial inhibition o f a-secretase  
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Figure 7.8. Inhibition of APP a-secretase activity by G1254023X in wild-type APP695-transfected D u l45  
cells. D u l4 5  cells w ere transfected w ith  the  w ild -type  APP695 construct using the lipo fectam ine  technique 
(M ateria ls  and M ethods). Cells were grow n to  confluence and the m edium  was replaced w ith  serum free 
m edium  and incubated in the  absence o r presence o f G1254023X (20 pM ) fo r  24 hours. Conditioned 
m edium  and cell lysates w ere prepared and SDS-PAGE and im m unob lo tting  perfo rm ed according to  
M ateria ls  and M ethods. A. Detection o f APP in cell lysates using anti-APP C-term inal an tibody. B. Detection 
o f sAPPa in cond itioned m edium  samples using anti-APP antibody, 6E10. C. Detection o f sAPPp in 
cond itioned  m edium  samples using the an tibody 1A9. Im m unoblots were quantified  and the  results 
expressed relative to  the  DMSO trea ted  contro l. Results are means ± S.D. (n=3). * = sign ificant at p<  0.05. 


















observed fo llow ing im m unoblotting o f conditioned medium samples w ith  antibody 1A9 (Fig. 
7.9C).
Having established tha t G1254023X inhibited sAPPa generation in D ul45 cells (albeit 
only partially), the v iab ility  o f APP695 over-expressing cells in the presence o f copper was 
examined in the absence or presence of the inhibitor. The stably transfected cells were 
seeded and cultured overnight in the absence/presence o f inh ib ito r before adding glycine- 
complexed metal at concentrations o f 0 or 200 pM. MTS viability assays were perform ed at 
both 5 h and 7 days a fte r the addition o f copper and the inh ib ito r was incorporated into 
medium where required fo r the duration o f these incubations (Fig. 7.9). A fter seven days o f 
growth, only m inor changes in cell viability in the presence o f copper could be detected 
between the inh ib ito r treated and untreated cells (Fig. 7.9B), suggesting tha t ADAM- 
mediated cleavage o f APP is not a prerequisite fo r the ability o f the protein to  enhance 
D u l45  cell v iab ility  in the presence o f copper.
■ DMSO■ DMSO
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Figure 7.9. The effect of APP a-secretase inhibition on the viability of APP695-transfected D u l45  cells in 
the presence of copper. Cells were seeded at 2000 cells per w ell and equ ilib ra ted overn igh t under norm al 
g row th  cond itions (37 °C, 5% C 02) in the absence or presence o f G1254023X (20 pM ). G lycine-com plexed 
copper and o f G1254023X (20 pM ) was added to  fina l m etal concentrations o f 0 and 200 pM  in 100 pi o f 
com ple te  RPMI; the  cells w ere then grown over a 7 day period w ith  m edium  being replaced w ith  fresh 
m eta l- and in h ib ito r-  conta in ing m edium  at day 4. The MTS cell v iab ility  assay was perform ed on day 0 
(w ith in  5 h o f adding the  m etal) (A) and on day 7 (B). Results are means ± S.D. (n=3). * = s ign ificant at p<  
0.05. Unless o therw ise  stated, d ifferences were no t significant.
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Next, th e  e ffect o f p-secretase inhibition on th e  ability o f APP to  enhance D u l4 5  cell 
viability  in th e  presence o f copper was investigated. The ability o f P-secretase inh ib itor IV 
(Calbiochem , M erck -M illip o re , Darm stadt, G erm any) to  effectively inhibit p-secretase activity  
in w ild -typ e  APP695-transfected  D u l4 5  cells was initially investigated by incubating confluen t 
cells in serum  free  m edium  fo r 24 h in th e  absence or presence o f th e  com pound (10 0  n M ). 
Subsequent im m u n ob lotting  o f cell lysates {Fig. 7.10A)  w ith  the anti-APP C-term inal an tibody  
show ed no change in fu ll-length  cell-associated APP levels fo llow ing inh ib itor tre a tm e n t. 
Sim ilarly, no changes in th e  level o f sAPPa in conditioned m edium  w ere detected  using 
antibody 6E10 {Fig. 7.10B). How ever, blotting conditioned m edium  samples w ith  an tibody  
1A9 {Fig. 7.10C) showed an 85 .9  ± 7.35%  decrease in sAPPp generation fo llow ing inh ib itor  
tre a tm e n t.
Having clearly established th a t p-secretase inh ibitor IV virtually ab lated sAPPp 
generation  in w ild -typ e  APP695 over-expressing D u l4 5  cells, th e  effect o f th e  com pound on 
th e  viability  o f these cells in th e  presence o f copper was then  exam ined. These experim ents  
w ere  perfo rm ed  (w ith  th e  exception o f d ifferen t inh ibitor concentrations) in an identical 
m ann er to  th a t already described fo r th e  G 1254023X  inhibitor. The results {Fig. 7.11)  showed  
no change in cell v iability  regardless o f w h e th e r th e  p-secretase inhibitor was present or 
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Figure 7.10. Inhibition of APP P-secretase activity by p-secretase inhibitor IV in D u l45  cells. Cells were 
grow n to  confluence and the m edium  was replaced w ith  serum free m edium  and incubated in the  absence 
or presence o f p-secretase in h ib ito r IV (100 nM) fo r 24 h. Conditioned m edium  and cell lysates were 
prepared and SDS-PAGE and im m unob lo tting  perform ed according to  M ateria ls and M ethods. A. Detection 
o f APP in cell lysates using anti-APP C-term inal antibody. B. Detection o f sAPPa in cond itioned m edium  
samples using anti-APP antibody, 6E10. C. Detection o f sAPPp in cond itioned m edium  samples using 
an tibody 1A9. Im m unoblo ts were quantified  and the results expressed relative to  the DMSO treated 
con tro l. Results are means ± S.D. (n=3). * * *  = s ignificant a t p < 0.005. Unless o therw ise stated, d ifferences 
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Figure 7.11. The effect of APP p-secretase inhibition on the viability of APP695-transfected D u l45  cells in 
the presence of copper. Cells were seeded at 2000 cells per w ell and equ ilib ra ted overn igh t under norm al 
g row th  cond itions (37 °C, 5% C 02) in the  absence or presence o f P-secretase in h ib ito r IV (100 nM ). G lycine- 
com plexed copper was added to  fina l m etal concentrations o f 0 and 200 pM w ith  P-secretase in h ib ito r IV 
(100 nM ) in 100 pi o f com ple te  RPMI; the  cells were then grow n over a 7 day period w ith  m edium  being 
replaced w ith  fresh m eta l- and in h ib ito r- containing m edium  at day 4. The MTS cell v iab ility  assay was 
pe rfo rm ed  on day 0 (w ith in  5 h o f adding the metal) (A) and on day 7 (B). Results are means ± S.D. (n=3). 
Unless o therw ise  stated, d ifferences were no t significant.
7.6. The role of the soluble APP ectodomain in prom oting
Du 145 cell viability in the presence of copper; the effect of 
recom binant sAPPp
In order to  confirm  tha t sAPPp generation was not a prerequisite fo r the ability of 
APP695 to  enhance cell v iab ility in the presence o f copper an additional experiment was 
conducted. Here, a truncated APP695 construct analogous to  sAPPp was utilised in which the 
codon encoding D597 (C-terminal to the p-secretase cleavage site) was mutated to a stop 
codon. As soluble APP had previously been shown to  be aberrantly processed in Dul45 cells 
(section 7.4) the sAPPp695 construct was initia lly stably transfected into HEK cells and its 
secretion into conditioned medium monitored by im m unoblotting. The results (Fig. 7.12A) 
show tha t the construct was clearly detected in conditioned medium using antibody 1A9 and
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Figure 7.12. Detection of soluble APP derivatives in conditioned medium from  mock- and APP695p- 
transfected HEK cells. HEK cells were stably transfected using the lipo fectam ine m ethod (M ateria ls and 
M ethods). C onfluent cells w ere then  incubated fo r 24 h in serum free m edium . Conditioned m edium  
samples w ere prepared and im m unob lo tted  as described in M ateria ls and M ethods. A. Detection o f sAPPp 
in cond itioned  m edium  using an tibody 1A9. B. Detection o f sAPPa in cond itioned m edium  using anti-APP 
an tibody, 6E10.
the same band was absent from  mock-transfected cells. When the same conditioned 
medium samples were im m unoblotted w ith  anti-APP antibody 6E10 in order to  detect 
sAPPa, no difference was detected between the mock- and sAPP695p-transfected cells (Fig. 
7.12B).
Having confirmed tha t the sAPP69sP construct was secreted into the conditioned 
medium o f HEK cells and could be detected using antibody 1A9, similar batches o f medium 
from  both mock- and sAPP695(3-transfected HEK cells were concentrated 50-fold by 
centrifugal filtra tion  and then re-diluted to the ir original volume in order to  neutralise the 
acidity o f the medium and in order to  remove any low molecular weight toxins. This 
rediluted medium was then used to culture untransfected Dul45 cells during the ir treatm ent 
w ith  copper as previously described. In this way the effect o f copper on cells grown in the 
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Figure 7.13. The effect of recombinant sAPPp on the viability of D u l45  cells in the presence of copper.
Cells w ere seeded at 2000 cells per w ell and equ ilib ra ted  overn ight under norm al g row th  cond itions (37 °C, 
5% C 02). G lycine-com plexed copper was added to  fina l m etal concentrations o f 0 and 200 pM in 100 pi o f 
com ple te  RPMI; th e  cells w ere then  grow n over a 7 day period w ith  m edium  pre-cond itioned on e ithe r 
mock- or sAPPp695-transfected  HEK cells. The m edium  was replaced w ith  fresh preconditioned, m eta l- 
con ta in ing  m edium  at day 4. The MTS cell v iab ility  assay was perform ed on day 0 (w ith in  5 h o f adding the 
m etal) (A) and on day 7 (B). Results are means ± S.D. (n=3). Unless o therw ise stated, d ifferences w ere no t 
sign ificant.
MTS assay data (Fig. 7.13), again, showed no effect o f sAPP(3 on the viability o f cells 
in the presence o f copper.
7,7. Summary
The over-arching aim o f the work presented in the current chapter was to 
investigate the potentia l role played by the APP ectodomain in the enhancement o f D ul45 
cell v iab ility  in the presence o f copper. Initially, the role of the E l copper binding domain o f 
APP was examined in this respect. The APP695CuBD construct generated fo r this purpose was 
successfully over-expressed in Dul45 cells (Fig. 7.2) and appeared to  be processed by a- 
secretase in a manner analogous to  its w ild-type counterpart (Fig. 7.3A). However, notably, 
the m utation o f the E l CuBD clearly prevented [3-secretase-mediated processing o f the 
protein (Fig. 7.3B). It was subsequently demonstrated that, whereas w ild-type APP695 clearly 
enhanced D ul45  cell viability in the presence of copper, the m utation o f the E l CuBD 
prevented this phenomenon (Fig. 7.4). It is therefore clear that copper binding to the El
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dom ain  o f APP is a prerequis ite  fo r th e  ab ility o f th e  protein to  enhance D u l4 5  cell viability. 
The la te r experim ents in this chapter clearly show th a t sAPPp had no im pact on cell viability. 
This precludes th e  possibility th a t th e  lack o f sAPPp a n d /o r A(3 generated  from  the  
APP695CuBD construct was responsible fo r its lack o f ability to  p rom ote cell viability.
Next, th e  ability o f soluble APP derivatives to  enhance D u l4 5  cell viability in th e  
presence o f copper was exam ined. Initially, a ttem p ts  w ere  m ade to address this point by 
over-expressing a truncated  APP construct analogous to  sAPPa in D u l4 5  cells. How ever, th e  
resu ltan t protein  was aberrantly  processed in D u l4 5  cells to  generate a 25 kDa N -te rm inal 
fra g m en t (which could be detected  using antibody 22C11) (Fig. 7.6) despite the construct 
being secreted as th e  expected 106 kDa fragm en t in SH-SY5Y cells (Fig. 7.5).
As an a lterna tive  approach to  exam ining th e  role o f soluble APP derivatives, a -  and 
P-secretase inhibitors w ere  em ployed. H ow ever, despite these compounds effectively  
inh ibiting sAPPa or sAPPp generation  (to  differing degrees) (Figs. 7.8  and 7.10)  little  or no 
effec t o f these com pounds on th e  viability o f w ild -type APP695 over-expressing D u l4 5  cells 
was observed in th e  presence o f copper. Similarly, recom binant sAPPp was unable to  
pro m o te  th e  viability o f D u l4 5  cells in the presence o f copper (Fig. 7.13).
In sum m ary, it is clear th at, w hilst an intact APP E l CuBD is a prerequisite fo r the  
pro te in  to  enhance D u l4 5  cell viability in th e  presence o f copper, the generation o f soluble, 
secretase-cleaved, APP derivatives is quite clearly not a requ irem ent in this respect.
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8. APP-induced morphological 
changes in Dul45 cells
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8.1. In troduction
During th e  preceding research it was noted th a t, w hen D u l4 5  cells w ere  transfected  
w ith  th e  APP695 isoform , a m orphological change was observed, clearly distinguishing th em  
fro m  m ock-transfected  cells. The current chapter investigates th e  biological basis fo r these  
m orphological changes and how  th ey  m ight re late to  prostate cancer pathogenesis.
8.2. The effect of APPegs over-expression on D ul45  cell 
m orphology
D u l4 5  cells w ere  stably transfected w ith  e ith er vector alone (m ock) or APP695 and 
cell m orphology was subsequently visualised at 35%  confluency. Parallel cultures w ere  also 
grow n in o rd er to  confirm  APP over-expression by im m unoblotting . The results {Fig. 8 .1A-D)  
confirm  th a t th e  APP69 5 -transfected  D u l4 5  cells over-expressed the desired protein and th a t  
th ey  generated  m ore sAPPa and sAPPp than th e  m ock-transfected cells. In term s o f cell 
m orphology, th e  m ock-transfected D u l4 5  cells had a fla t ep ithelial type m orphology, tend ing  
to  g row  in small focal groups {Fig. 8.1E), w hereas th e  APP695-transfected  cultures contained  
cells w ith  several neurite-like  extensions {Fig. 8 .1F ). Thus, it was apparen t th a t APP695 was  
capable o f inducing clear morphological changes in D u l4 5  cells.
8.3. APPegs-induced morphological changes in D ul45 cells are 
not associated with neuroendocrine differentiation
Having shown th a t APP695 was capable o f inducing morphological changes in D u l4 5  
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Figure 8.1. APP695- induced morphological changes in D u l45 cells. A-D. D u l4 5  cells stably transfected w ith  
e ith e r vecto r alone (mock) o r APP69 5 were grown to  confluence and the m edium  was replaced w ith  serum 
free m edium  fo r  24 h. Cells and cond itioned  m edium  were then harvested and prepared fo r 
im m u n o b lo ttin g  as described in M ateria ls and M ethods. A. Detection o f the  APP ho lop ro te in  in cell lysates 
using the  anti-APP C-term inal antibody. B. Detection o f p-actin in cell lysates using the anti-p -actin  
an tibody. C. D etection o f sAPPa in cond itioned m edium  using the anti-APP 6E10 an tibody. D. Detection o f 
sAPPp in cond itioned m edium  using the antibody 1A9. The vertical lines on blots indicate a lignm ent o f 
samples from  dista l lanes run on the  same im m unob lo t. E and F. Light m icroscopy images at 35% 
confluency o f (A) m ock-transfected and (B) APP695-transfected cells. A rrow s indicate neu rite -like  extensions. 
The results are representa tive  o f th ree  repeat experim ents.
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N euroendocrine (NE) d ifferen tiation  is the process by which prostate cancer cells 
d iffe ren tia te  into a cell type capable o f th e  generation and secretion o f m ultip le  
neuropeptides. Prostatic NE cells may, th ere fo re , support the an drogen-independent grow th  
o f tu m o u r cells (301 ). Focal NE d ifferen tiation  o f cells in prostatic carcinomas is fairly  
com m on (302) and is positively associated w ith  tu m o ur progression (303) making this 
process d irectly  re levant to  th e  progression o f prostate cancer. One subtype o f NE 
d iffe ren tia ted  prostatic cells is characterised by cells having a m ultipo lar appearance w ith  
long processes and beaded varicosities (304) sim ilar to  the m orphology o f th e  APP695 over­
expressing D u l4 5  cells in th e  current study. Am ongst o ther proteins, NE d ifferen tiation  is 
associated w ith  th e  increased expression o f neuron-specific enolase (NSE) (302).
In o rd er to  d eterm in e  w h e th e rth e  APP695-induced morphological changes in D u l4 5  
cells represented  NE d iffe ren tiation , mock- and APP695 -transfected cells w ere  grown to  
confluence and cell lysates and conditioned m edium  samples w ere  im m unob lotted  in o rder 
to  d e term in e  NSE expression and secretion levels, respectively. The ta rge t o f th e  NSE-P2 
antibody em ployed  is a hom odim er, th e  expression o f which is enhanced in cells which have 
undergone neuroendocrine d ifferen tiation  (302). The results from  the current study {Fig. 8.2) 
actually show a decrease in th e  expression o f NSE dim er (55 .71 ± 4.07%  o f m ock-transfected  
contro l) and m o n o m er (10 .21  ± 2.06%  o f mock- transfected control) in lysates prepared from  
APP695-transfected  cells {Fig. 8.2A and  B). The level o f NSE secreted into th e  conditioned  
m edium  o f APP695-transfected  cells was also dram atically decreased.
Thus, it would appear that the morphological changes brought about by APP695 in 
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Figure 8.2. Decreased NSE expression and secretion in APP695-transfected D u l45  cells. D u l4 5  cells (mock) 
o r D u l4 5  cells stably transfected w ith  APP695 were grown to  confluence and the m edium  was replaced w ith  
serum  free  m edium  fo r  24 h. Cells and conditioned m edium  were then harvested and prepared fo r 
im m u n o b lo ttin g  as described in M ateria ls and M ethods. A. Detection o f NSE in cell lysates using the  an ti- 
NSE-P2 an tibody. B. Q uantifica tion o f m ultip le  NSE lysate blots showing relative levels o f both m onom eric  
and d im eric  fo rm s o f the  p ro te in . C. Detection o f p-actin in cell lysates using the anti-p-actin  an tibody. D. 
D etection o f NSE in cond itioned m edium  using the NSE-P2 antibody. E. Q uantification o f m u ltip le  NSE blots 
show ing re lative  levels o f the  secreted fo rm  o f the  pro te in . Results are means ± S.D. (n=3). * = s ignificant at 
p<  0.05; * * *  = s ign ificant at p<0.005; * * * * *  = s ignificant at p<0.0005.
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8.4. APp695-indiiced morphological changes in Dh145 cells are 
associated with epitheEia!-to-mesenchymal transition
The transition o f ad h eren t ep ithelial cells to  non-polar m esenchym al cells lacking 
th e ir  in terce llu lar junctions through epithelia l-to -m esenchym al transition  (EM T), perm its  
enhanced cell m ob ility  and invasion (305). Therefore, EM T o f m alignant cells aids metastasis 
and disease progression resulting in a poorer prognosis (306). EM T is associated w ith  
reduced expression o f th e  adhesion protein E-cadherin and a converse increase in vim entin  
expression which, in tu rn , correlates w ith  increased disease severity (307).
In o rder to  d eterm in e  w h e th e r the morphological changes induced by APP6 9 5  in th e  
curren t study correlated  w ith  EM T m arker protein expression, lysates and conditioned  
m edium  from  th e  D u l4 5  transfectants w ere  im m unoblotted  fo r E-cadherin and vim entin . 
The results {Fig. 8.3A)  showed a 59 .53  ± 2.29%  decrease in E-cadherin expression in the  
lysates o f th e  APP695-transfected  cells. Interestingly, this decrease was not reflected in shed 
E-cadherin in th e  conditioned m edium  o f cells [Fig. 8.3B).  The APP695-transfected  D u l4 5  cells 
also expressed significantly m ore vim entin  w ith  a 4 .46  ± 0 .9-fo ld  increase in levels o f the  
protein  in lysates re lative to  th e  m ock-transfected cell lysates (Fig. 8.3C).
Collectively, these changes indicate th a t APP695 is capable o f inducing ep ithe lia l-to - 
m esenchym al transition in D u l4 5  cells.
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Figure 8.3. APP695-transfection is associated with epithelial-to-mesenchymal transition in D u l45  cells.
M ock D u l4 5  cells o r cells stably transfected w ith  APP695 were grown to  confluence and the m edium  was 
replaced w ith  serum  free m edium  fo r 24 h. Cells and conditioned m edium  were then harvested and 
prepared fo r  im m un o b lo ttin g  as described in M ateria ls and M ethods. A. Detection o f E-cadherin in cell 
lysates. B. D etection o f E-cadherin in conditioned m edium . C. Detection o f v im entin  in cell lysates. D. 
D etection  o f P-actin in cell lysates. M u ltip le  im m unoblo ts were quantified  by densitom etric  analysis and the 
results are means ± S.D. (n = 3 ).). Significance was tested against the m ock-transfected con tro l. -  
s ign ifican t a t p<  0.05; * * * * *  = s ignificant at p<  0.0005. W hen significance is no t ind icated, results are not 
sign ifican tly  d iffe ren t.
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8»b» APP- i ' c beer ehi o -liiasrencnymal transition. In
Du 14S cells Is isofbrm specific
In o rd er to  d e term ine  w h e th e r all isoforms o f APP w ere  capable o f inducing EM T in 
D u l4 5  cells, th e  m orphology o f stable transfectants over-expressing APP695, APP751 or APP770 
w as exam ined by light microscopy. The results [Fig. 8.4)  once m ore dem onstra ted  th a t the  
APP69 5 -transfected  cells had an altered  morphology relative to  th e  m ock-transfected cells 
[Fig. 8 .4A  and B) w ith  th e  fo rm er cell type having m ore apparent extensions and a m ore  
elongated  cell body, indicative o f EMT. In contrast, the visual analysis o f APP75i-  and APP770- 
transfec ted  cells suggested a lesser change in morphology (Fig. 8.4C and  D).
In o rd er to  quantify  th e  morphological changes occurring in th e  APP695-transfected  
cells, a dendric ity fac tor analysis o f the light microscope images was perform ed. Dendricity  
fac to r is a m athem atical m easure o f a 2-dim ensional shape using th e  fo llow ing form ula: 
Dendricity (Inverse shape) fac to r = P 2/ 4 t iA  w hen P = perim eter o f cell and A = area o f cell 
(30 8 ). This arb itra ry  value quantifies th e  extension o f processes which causes cells to  
develop a m ore com plex/less rounded shape (309). This analysis dem onstrated th a t the  
APP695-transfected  D u l4 5  cells exhibit a 1 .54 ± 0.39-fold  increase in dendricity factor relative  
to  th e  m ock-transfected controls (Fig. 8.4E). However, th ere  was no increase in dendricity  
fac to r w hen cells w ere  transfected  w ith  KPI-containing isoforms o f APP (Fig. 8.4E).  Thus, it 
appears th a t APP-induced EM T in D u l4 5  cells is specific to  th e  695 am ino acid isoform o f the  
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Figure. 8.4. The effect of APP isoforms on EMT in D u l45 cells. D u l4 5  cells stably transfected w ith  e ither 
vecto r alone o r the  APP isoform s indicated were visualised by light m icroscopy as described in M ateria ls 
and M ethods (A-D). A dendric ity  fac to r analysis was then perform ed on m ultip le  images (E) and results are 
means ± S.E. (n=20). Significance was tested against the m ock-transfected contro l. * * *  = s ign ificant at p<  
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Figure 8 5 The effect of APP C-terminal constructs on EMT in D u l45 cells. D u l45  cells stably transfected 
w ith  e ith e r vecto r alone or the  APP C-term inal constructs indicated were visualised by ligh t m icroscopy as 
described in M ateria ls and M ethods (A-F). A dendric ity fac to r analysis was then perform ed on m ultip le  
images (G) and results are means ± S.E. (n=20). Significance was tested against the  m ock-transfected 
con tro l. * * *  = s ign ificant a t p< 0.005. No indication o f significance means results are no t sign ificantly
d iffe re n t.
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8.6. The Apings cytosolm domain is Involved to. epithelial-to-
m esendiyinal transiti: a In D u i45 cells
Having d eterm ined  th a t th e  ability to  induce EM T in D u l4 5  cells was specific to  the  
APP6 9 5  isoform , th e  m olecular determ inants w ith in  the APP m olecule contributing to  these  
m orphological changes w ere  next exam ined. Initially, th e  involvem ent o f the APP cytosolic 
dom ain  was exam ined by com paring th e  m orphology o f w ild -typ e  APP695-transfected  cells 
w ith  th a t o f th e  cytosolic-dom ain lacking m utant, APPAICD (described previously in Chapter 
6 ). The results {Fig. 8 .5A-C  and G) clearly show that, w hilst w ild -type APP6 9 5  induced EMT, no 
change in m orphology or dendricity factor was observed in th e  APPAICD-transfected cells.
Next, th e  potentia l involvem ent in EMT o f phosphorylatable tyrosine residues in th e
APP6 9 5  cytosolic dom ain  was exam ined. The APP6 9 5  tyrosine 682 residue has an essential role
in d eve lo p m en t and regulating APP function (310, 311) and has been shown to  exhibit
e levated  phosphorylation in an AD brain (312). This tyrosine residue has also been previously
shown to  be both involved in th e  phosphorylation o f the protein (313) and to  interact w ith
specific proteins only w hen phosphorylated, such as GRB2 and she, which upon binding can
influence dow nstream  signalling pathways (109, 299). The APP695 tyrosine 687 residue has
been identified  as a regu lator o f APP processing (314) and has also been found to  exhibit
e levated  phosphorylation in AD brains (315). A range o f proteins interact w ith  the
Y682ENPTY687 m o tif o f APP, such as the she fam ily (316) and Grb2 (317) which are involved in
signalling intracellu larly. M u ta tio n  o f the tyrosine residue at position 687 to glycine (APP695-
687) ab lated th e  ability o f w ild -type APP6 9 5 to  induce EM T in D u l4 5  cells (Fig. 8.5D, E and G)
as did th e  m u tation  o f both residues to gether (APP695-682/687) (Fig. 8 .5F  and G), how ever
m u tatio n  o f th e  tyrosine residue at 682 (APP695"682) caused cells to  exhib it an EM T-like
m orphology, which was not significantly d ifferen t from  the control w hen carrying out
dendric ity  analysis due to  variation (Fig. 8.5A, B, D, and G). Thus, it is apparent th a t specific
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tyrosine residues w ith in  the cytosolic dom ain o f APP are required as a prerequisite fo r th e  
ability  o f th e  p rotein  to  induce ep ithelia l-to -m esenchym al transition.
8.7. The E l copper binding domain is a prerequisite  for APPgqs- 
induced epithelial-to-mesenchymal transition in D ul45 
cells
In o rd er to  fu rth e r elucidate th e  m olecular determ inants w ith in  th e  APP695 m olecule  
contribu ting  to  EMT, th e  m orphology o f m ock-transfected D u l4 5  cells was com pared w ith  
th a t o f cells stably transfected  w ith  e ith er w ild -type APP695 or the previously described E l 
copper-b ind ing  dom ain defic ien t construct, APP695ACuBD. Visual analysis (Fig.8.6A-C) 
confirm ed th a t th e  disruption o f the E l copper binding dom ain prevented th e  m orphological 
changes associated w ith  w ild -typ e  APP695 . These results w ere confirm ed w hen a dendricity  
analysis was perfo rm ed  which, again, showed th a t only w ild -type APP695 induced EM T- 
associated m orphological changes in D u l4 5  cells {Fig. 8.6D). Thus, it w ould appear th a t  
copper binding w ith in  th e  E l dom ain o f APP is also a prerequisite fo r ep ithe lia l-to - 
m esenchym al transition  in D u l4 5  cells.
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Figure. 8.6. The effect of APP E l domain copper binding ablation on EMT in D u l45  cells. D u l4 5  cells stably 
transfected  w ith  e ithe r vecto r alone o r the APP constructs indicated were visualised by ligh t m icroscopy as 
described in M ateria ls and M ethods (A-C). A dendric ity factor analysis was then perform ed on m ultip le  
images (D) and results are means ± S.E. (n=20). Significance was tested against the  mock transfected 
con tro l. * = s ign ificant at p ^  0.05. When no significance is indicated, results are no t s ign ificantly d iffe ren t.
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8 M* Attempted, artificial induction of epithelial-to 
m esenchymal transition by enhancing endogenous APP 
expression
Having established tha t the artificial over-expression o f APP695 could induce EMT in 
D u l45  cells, attem pts were then made to  stimulate expression o f the endogenous protein 
w ith  a view to  in itia ting  EMT.
Nerve growth factor (NGF) is a neurotrophin present in the brain involved in 
prom oting survival, growth and differentia tion o f neurons (318) and has previously been 
shown to  increase APP mRNA levels in hamster brain and PC12 cells (319, 320). As Dul45 
cells are a brain metastatic prostate cancer cell line, the effect o f NGF on APP expression in 
these cells was examined in the current study. Untransfected cells were grown in the 
absence or presence o f a range of NGF-(3 (human, recombinant, Sigma-Aldrich, Poole, UK) 
concentrations and the effect on APP expression and proteolysis was subsequently 
m onitored by im m unoblot analysis. Initial results {Fig. 8.7A) appeared to  show an increase in 
the expression o f endogenous APP when cells were treated w ith  NGF-(3 in the concentration 
range 3-20 ng/m l. Such changes were not m irrored in conditioned medium when the anti- 
APP antibody 6E10 was used to  detect the shed form o f the protein (Fig. 8.7C). However, 
when the experim ent was repeated in trip licate using only 0 and 3 ng/m l NGF-(3 
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Figure 8.7. The effect of NGF-p on APP expression and proteolysis in D u l45  cells. Cells were grow n in the 
absence o r presence o f NGF-P (M ateria ls and M ethods) and cell lysates and conditioned m edium  were 
subsequently prepared and subjected to  im m unob lo tting  (M aterials and M ethods). A-C. Cells were treated 
w ith  the  ind icated range o f NGF-P concentrations and cell lysates were subsequently im m unob lo tted  w ith  
anti-APP C-term inal an tibody (A) and anti-p-actin  antibody (B). The conditioned m edium  samples were 
im m u n o b lo tted  w ith  anti-APP antibody, 6E10 (C). D-H. Cells were grown in the absence or presence o f 3 
ng /m l NGF-p and lysates were im m unob lo tted  w ith  anti-APP C-term inal antibody (D), anti- p-actin antibody 
(E) or anti-APP an tibody 6E10 (F). M ultip le  APP-CT antibody (G) and anti-APP 6E10 antibody (H) blots, 
respectively, were quantified  by densitom etric  analysis and the results are means ± S.D. (n=5). Significance 
was tested against the  un trea ted  contro l. Unless otherw ise indicated, the  results are no t sign ificantly 
d iffe ren t.
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Figure 8.8. The effect of HGF on APP expression in D u l45 cells. Cells were grown in the  absence or 
presence o f HGF (M ateria ls and M ethods) and cell lysates were subsequently prepared and subjected to  
im m unob lo tting  (M ateria ls and M ethods). A. Detection o f APP in cell lysates using the anti-APP C-term inal 
antibody. B. Detection o f (3-actin in cell lysates using the anti-P-actin antibody. C. APP C-term inal antibody 
im m unob lo ts were quantified  and the  results expressed relative to  the untreated contro l. Results are 
means ± S.D. (n=3). Significance was tested against the untreated contro l. Unless otherw ise indicated, the  
results are no t s ign ificantly d iffe ren t.
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As NGF tre a tm e n t o f D u l4 5  cells did not have the desired effect, a second 
com pound was tested  fo r its ability to  enhance endogenous APP expression. Hepatocyte  
gro w th  fac to r (HGF) has been linked to prostate cancer disease progression (321) and has 
also been linked to  brain tu m o u r grow th, angiogenesis and a reduced disease prognosis 
(32 2 ). HGF has also previously been shown to enhance APP expression in HEK293 cells (323).
D u l4 5  cells w ere  grown to 80%  confluence before washing tw ice in 
O p tiM E M  and then  adding a fresh 10 ml O p tiM E M . HGF (Gibco, Life Technologies Ltd., 
Paisley, UK) stock solution was m ade up at 0 .33  p g /50  pi o f 0.1%  (w /v ) BSA in PBS and a 
single 50  pi a liquot o f this stock was added to th e  10 ml o f fresh O ptiM E M  in cell cultures. 
Follow ing 48  h incubation, th e  cells w ere  harvested and lysates w ere  prepared and 
im m u n o b lo tted  in o rd er to  exam ine APP expression. How ever, th e  results {Fig. 8.8)  showed  
no HGF-associated change in APP levels.
8,9. Summary
In th e  current chapter th e  effects o f APP695 on D u l4 5  cell m orphology have been  
characterised. Stable expression o f th e  protein induced neurite-like extensions at th e  cell 
p eriphery {Fig. 8.1)  and these changes w ere  shown to  be associated not w ith  
neuroendocrine d iffe ren tia tion  {Fig. 8.2)  but w ith  epithelial-to -m esenchym al transition {Fig.
8.3 ).
The induction o f EM T by APP in D u l4 5  cells was specific to  th e  sm aller 595 am ino  
acid isoform  {Fig. 8 .4 )  and to  a specific tyrosine residue in th e  cytosolic dom ain o f th e  protein  
{Fig. 8 .5 ).  An in tact E l copper binding dom ain {Fig. 8 .6 ) was also shown to  be a prerequisite
fo r th e  e ffect.
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9. The role of copper binding in APP 
proteolysis and the viability of SH- 
SY5Y cells
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The preceding chapters have largely focused on the potential role o f APP in 
regulating th e  viability  o f prostate cancer cells upon metastasis to  th e  brain. In this respect it 
is ap p aren t th a t th e  E l copper binding dom ain o f APP was a prerequisite fo r the enhanced  
viab ility  o f D u l4 5  cells observed in the presence of copper.
In th e  cu rren t chapter, the role o f APP copper binding in relation to Alzheim er's  
disease ra ther than  brain m etastatic prostate cancer is exam ined. Specifically, the effects o f 
histid ine to  alanine m utations w ith in  the E l CuBD or the putative copper binding sites w ith in  
th e  Ap dom ain, on th e  proteolysis o f APP and cell viability w ith in the neuroblastom a cell line 
SH-SY5Y are exam ined.
9.2. The expression and proteolysis of APP&95 copper binding 
m utants  in SH-SY5Y cells
As APP695 is th e  m ajor isoform o f the protein expressed in neurons (324), SH-SY5Y 
cells w ere  initially stably transfected w ith  a range o f APP695 copper binding m utan t 
constructs {Fig. 9.1).  The E l copper binding dom ain m utant, APP69sACuBD {Fig. 9 . IB )  has 
been described previously (Chapter 7). In addition, th ree  fu rth er constructs w ere  em ployed, 
each w ith  a single histidine to  alanine m utation w ithin the A(3 dom ain at positions 602, 609  
or 610  {Fig 9.1C-E).
The various APP constructs w ere stably transfected into SH-SY5Y cells (see M aterials  
and M eth o ds) and th e ir  expression and proteolysis w ere subsequently m onitored by 
im m unob lotting . Initially, equal am ounts o f protein from  cell lysates w ere resolved by SDS- 
PAGE and im m u n ob lotted  using the anti-APP C-term inal antibody. The results {Fig. 9.2)  w ere  
expressed re lative to  th e  levels of APP detected in lysates from  the w ild -type APP695 over-
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expressing cells as the level o f endogenous APP in the mock-transfected cells was extremely 
low relative to  the APP-transfected cell lines. The data clearly show that, in all of the 
transfectants, APP was dramatically over-expressed and no significant difference could be 
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Figure 9.1. Schematic representing APP695 copper binding mutant constructs. A. W ild-type APP695. B. The 
APP69 5ACuBD construct contained three histidine to alanine mutations at positions 147,149 and 151. C-E. 
Three additional constructs were employed, each one containing a single histidine to  alanine m utation at 
position 602, 609 or 610.
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Next, the generation o f soluble APP from  the various APP695 copper binding m utant 
proteins was examined by im m unoblotting equal volumes o f concentrated conditioned 
medium. Im m unoblotting the samples w ith  anti-APP antibody 22C11 (Fig. 9.3A) revealed 
tha t the generation o f sAPP from  the various APP constructs was identical. However, when 
the samples were im m unoblotted using antibody 1A9, a clear decrease in the levels o f 
sAPPp generated from  all o f the histidine to  alanine mutants was detected relative to  the 
w ild-type APP695-transfected cells (Fig. 9.3B). This difference was particularly pronounced in 
the APP695- 6  1 0-transfected cells w ith  levels o f sAPPp generated from  this construct being 
only 37.86 ± 4.77% tha t generated from  the w ild-type protein.
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Figure 9.2. APP695 copper binding domain mutant over-expression in SH-SY5Y cells. Stably transfected cells 
w ere grown to  confluence and the  m edium  was replaced w ith  serum free m edium  fo r 24 h. Lysates were 
subsequently prepared and equal am ounts o f pro te in  from  each were im m unob lo tted  (M ateria ls and 
M ethods). A. Detection o f APP in cell lysates using the anti-APP C-term inal antibody. M u ltip le  APP 
im m unob lo ts  were quantified  by densitom etric  analysis and the results shown are expressed relative to  the 
w ild -type  APP695-transfected cells and are means ± S.D. (n=3). Unless o therw ise indicated, the  results are 
no t s ign ificantly d iffe ren t. B. Detection o f P-actin in cell lysates using the anti-P-actin antibody.
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Figure 9.3. Soluble APP generation by SH-SY5Y cells over-expressing the APP695 copper binding constructs.
Stably transfected cells were grown to  confluence and the m edium  was replaced w ith  serum free m edium  
fo r  24 h. Conditioned m edium  was subsequently prepared and equal volumes o f each sample were 
im m unob lo tted . A. Detection o f sAPP in conditioned m edium  using the anti-APP antibody, 22C11. B. 
D etection o f sAPPp in cond itioned m edium  using antibody 1A9. M u ltip le  im m unoblo ts were quantified  by 
dens itom etric  analysis and the  results shown are means ± S.D. (n=3). Significance was tested against the  
w ild -type  APP695-transfected cells. * = s ignificant at p < 0.05; * *  = s ign ificant at p<  0.01; * * *  = s ignificant at 
p<  0.005. Unless o therw ise indicated, the results are no t sign ificantly d iffe ren t.
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s. £ tie effects o f ' ^95 copper binding m utants on the
viability of SM-SY5Y ceils in the presence of copper
In o rder to  exam ine th e  role o f APP695 copper binding in m aintain ing SH-SY5Y cell 
viability  in th e  presence o f copper, th e  stably transfected cells w ere  grown fo r 72 h in serum - 
fre e  m edium  containing a range o f copper concentrations before analysing cell viability using 
th e  MTS assay (M ateria ls  and M ethods). Note th at, in these experim ents, free copper was 
em ployed  as opposed to  the glycine-com plexed m etal used fo r th e  D u l4 5  cells in Chapters 5- 
7.
The results [Fig. 9.4)  show th a t, a fte r 72 h, th e  viability o f m ock-transfected cells 
tre a te d  w ith  100, 200  and 250  p M  copper had decreased to 83 .27  ± 3 .2 9 ,7 7 .7 6  ± 2 .98  and  
68 .3  ± 3.91% , respectively, th a t o f th e  untreated  controls. How ever, as w ith  the D u l4 5  cells 
(C hapter 5), w ild -typ e  APP695 generally enhanced SH-SY5Y cell viability in th e  presence o f 
copper, particularly at m etal concentrations o f 100 and 200 p M  (95 .28  ± 3 .67  and 9 8 .84  ± 
2.52%  o f th e  u ntreated  controls, respectively). As w ith  th e  D u l4 5  cells, th e  disruption o f 
copper binding by th e  E l CuBD in th e  APP695CuBD m utan t prevented th e  ability o f APP to  
enhance SH-SY5Y cell viability in the presence o f copper {Fig. 9.4).  How ever, m utating  
individual histidine residues w ith in  th e  Ap dom ain o f APP did not prevent the ability o f the  
protein  to  enhance cell viability at low er copper concentrations. In fact, a t a higher m etal 
concentration  o f 250  p M , th e  APP695-602  m u tan t construct appeared to be even m ore  
effective in prom oting cell viability than its w ild -type counterpart.
Collectively, these data indicate th a t copper binding w ithin th e  E l dom ain o f APP695 
as opposed to  th e  Ap dom ain is a prerequisite for the ability o f the protein to  enhance SH- 
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Figure 9.4. The effect of APP695 copper binding mutant over-expression on SH-SY5Y cell viability in the  
presence of copper. Cells w ere seeded from  an 'u ltracon fluen t' T75 flask in to a 24-well p late a fte r d ilu ting  1 
in 150 in DMEM and equ ilib ra ted  overn igh t under norm al g row th cond itions (37 °C, 5% C 02). The fo llow ing  
day, th e  m edium  was replaced w ith  1 0 0  pi o f serum free m edium  containing the  indicated concentra tions 
o f CuS04 .5H20  and cells w ere grow n fo r a fu rth e r 72 h before conducting an MTS v iab ility  assay (M ateria ls 
and M ethods). Results are means ± S.E. (n=15). Significance was tested against the  m ock-transfected 
con tro l. * = s ign ificant at p<  0.05; * * *  = s ignificant at p<0.005 ; * * * *  = p<0.001; * * * * *  = p<0.0005; * * * * * *  = 
p<0.0001. Unless o therw ise  stated, d ifferences were no t significant.
9 .4 , The expression and proteolysis of APP770 copper binding 
m utants in SH-SY5Y cells
As the ability o f APP to  enhance Dul45 cell viability observed in Chapter 5 was 
isoform specific, the effect o f APP770 on SH-SY5Y viability in the presence o f copper was also 
investigated in this respect. A range o f APP770 copper binding mutants analogous to those 
previously generated in APP695 were designed (Fig. 9.5). The amino acid numbering o f the 
three mutated histidine residues in the APP770 E l CuBD construct was the same as tha t in the 
analogous APP695 construct, as the E l domain precedes the KPI and OX-2 domains in terms o f 
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Figure 9.5. Schematic representing APP77D copper binding mutant constructs. A. W ild-type APP770. B. The 
APP7 7 0ACuBD construct contained three histidine to  alanine mutations at positions 147,149 and 151. C-E. 
Three additional constructs were employed, each one containing a single histidine to  alanine mutation at 
position 677, 684 or 685.
domain constructs were 677, 684 or 685 (as opposed to 602, 609 or 610 in the APP695 
constructs).
Stable over-expression of the APP770 copper-binding constructs was confirmed by 
immunoblotting with the anti-APP C-terminal antibody {Fig. 9.6A). Equal protein loading was 
demonstrated via immunoblotting with the anti-(3-actin antibody (Fig. 9.6B).
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Figure 9.6. APP770 copper binding dom ain m utant over-expression in SH-SY5Y cells. Stably transfected  cells 
w ere g row n to  con fluence  and th e  m edium  was replaced w ith  serum  free m edium  fo r  24 h. Lysates w ere 
subsequently  prepared and equal am ounts o f p ro te in  from  each w ere im m u n o b lo tted  (M a te ria ls  and 
M ethods). A. D etection o f APP in cell lysates using the  anti-APP C-term inal an tibody. M u ltip le  APP 
im m u n o b lo ts  w ere  qua n tifie d  by d e ns itom e tric  analysis and the  results shown are expressed re la tive  to  the  
w ild -typ e  APP770-transfec ted  cells and are means ± S.D. (n=3). * *  = s ign ifican t a t p < 0.01. Unless o therw ise  
ind ica ted, the  results are n o t s ign ifican tly  d iffe ren t. B. D etection o f p-actin in cell lysates using the  anti-P - 
actin an tibody.
Next, the generation o f soluble APP from  the various APP770 copper binding m utant 
proteins was examined by im m unoblotting  concentrated conditioned medium. 
Im m unob lo tting  the samples w ith  anti-APP antibody 22C11 (Fig. 9.7A) revealed that, as fo r 
the analogous APP695 constructs, the generation o f sAPP from  the various APP770 constructs 
was identical. However, when the samples were im m unoblotted using antibody 1A9, a clear 
decrease in the levels o f sAPPp generated from  all o f the histidine to  alanine mutants was 
again detected relative to  the w ild -type APP770 over-expressing cells (Fig. 9.7B). This 
d ifference was particularly pronounced in the APP770-685-transfected cells w ith  levels of
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Figure 9.7. Soluble APP generation by SH-SY5Y cells over-expressing the APP770 copper binding constructs.
Stably transfected  cells w ere g row n to  confluence and the  m edium  was replaced w ith  serum free  m edium  
fo r  24 h. C ond itioned  m edium  was subsequently prepared and equal volum es o f each sample were 
im m u n o b lo tted . A. Detection o f sAPPa in cond itioned  m edium  using the  anti-APP an tibody, 22C11. B. 
Detection o f sAPP(3 in cond itioned  m edium  using an tibody 1A9. M u ltip le  im m unob lo ts  were quantified  by 
dens itom e tric  analysis and the  results shown are means ± S.D. (n=3). Significance was tested against the 
w ild -typ e  APP770-transfected  cells. * = s ign ifican t at p < 0.05; * * *  = s ign ificant at p < 0.005. Unless o therw ise  
ind ica ted, the  results are no t s ign ifican tly  d iffe ren t.
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sAPP(3 g en era ted  fro m  this construct being only 2 9 .9 6  ± 23 .78%  th a t g en era ted  fro m  th e  
w ild -typ e  p ro te in . It w ou ld  seem , th e re fo re , th a t th e  d ifferences in proteolysis brought 
a b o u t by th e  various histid ine m utations in th e  curren t study occur in both  APPe95and APP770 
isoform s o f th e  pro te in .
9.5. The effects of APP770 copper binding m utan ts  on the
viability of SH-SY5Y cells in the presence of copper
In o rd er to  exam ine th e  role o f APP770 copper binding in m ain ta in ing  SH-SY5Y cell 
v iab ility  in th e  presence o f copper, th e  viab ility  experim ents previously p erfo rm ed  w ith  th e  
analogous APP695 constructs w ere  repeated  fo r th e  APP770 isoform  expressing cell lines.
The results [Fig. 9 .8 ) show  th a t, a fte r 72 h, th e  viability  o f m ock-transfected  cells 
tre a te d  w ith  20 0  and 250  | iM  copper had decreased to  79 .53  ± 4 .1 6 , and 62 .71  ± 9 .64%  
respectively, th a t o f th e  u n trea ted  controls. How ever, as w ith  th e  APP695 isoform , w ild -typ e  
APP77o g enera lly  enhanced SH-SY5Y cell viability in th e  presence o f copper, particu larly at 
m eta l concentrations o f 200  and 250  p M  (11 0 .65  ± 7 .86  and 107 .35  ± 9 .05%  o f th e  u n trea ted  
controls, respectively). The disruption o f th e  E l CuBD in th e  APP770CuBD m u tan t prevented  
th e  ab ility  o f APP to  enhance SH-SY5Y cell viability in th e  presence o f copper [Fig. 9 .8 ).  As 
w ith  th e  analogous APP695 constructs, th e  APP770-6 7 7  and APP770-6 8 5  constructs had a sim ilar 
propensity to  th e  w ild -typ e  p rotein  to  enhance SH-SY5Y cell v iability  in th e  presence o f 
copper. H ow ever, in th e  case o f th e  APP77o isoform , the m u tation  o f H is609 to  alanine  
ab la ted  th e  ab ility  o f th e  p rotein  to  m ain tain  cell viability.
Collectively, these data indicate th a t th e  roles o f th e  various copper binding histidine 
residues in th e  E l and A 0 dom ains o f APP, in relation to  m aintain ing cell viability, are sim ilar 
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Figure 9.8. The effect o f APP770 copper binding m utant over-expression on SH-SY5Y cell viability in the  
presence of copper. Cells w ere seeded from  an 'u ltra co n flu e n t' T75 flask in to  a 24-w ell p la te  a fte r d ilu tin g  1 
in 150 in DMEM and equ ilib ra ted  ove rn igh t under norm al g row th  cond itions (37 °C, 5% C 0 2). The fo llo w in g  
day, th e  m ed ium  was replaced w ith  100 pi o f serum free m edium  con ta in ing  the  ind icated concentra tions 
o f CuS04.5H20  and cells w ere  g row n fo r  a fu rth e r 72 h before conducting an MTS v iab ility  assay (M ateria ls  
and M ethods). Results are means ± S.E. (n=15). Significance was tested against the  m ock-transfected  
co n tro l. *  = s ign ifican t a t p<  0.05; * * *  = s ign ificant a t p<  0.005. Unless o therw ise  stated, d iffe rences w ere 
no t s ign ificant.
9.6. APP binds copper despite m utation of the El. or Ap copper 
binding dom ains
In order to  determ ine w hether the histidine m utations in the APP constructs 
employed affected metal binding, soluble APP770 shed into the conditioned medium o f SH- 
SY5Y cells expressing the various copper binding domain APP mutants was subjected to 
metal chelate a ffin ity  chromatography (Materials and Methods). The affin ity columns were 
preloaded w ith  e ithe r no metal, copper or manganese. The rationale fo r using manganese
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w as th a t  th e re  exist m any sim ilarities in th e  cell biology o f APP and th e  prion pro te in  (PrP) 
(2 8 1 , 32 5 ) th e  la tte r o f w hich has been shown to  bind both copper and m anganese (326 ).
The results {Fig. 9 .9 )  show  th a t, w hen  th e  affin ity  colum ns w ere  not pre loaded  w ith  
m e ta l, th e  soluble APP g en era ted  from  all o f th e  constructs, as expected, was d etec ted  solely 
in th e  colum n run -through . In fact, th e  sam e was tru e  w hen colum ns preloaded w ith  
m anganese w e re  em ployed , indicating th a t APP does not bind effective ly to  this m eta l. 
H o w ever, soluble APP bound effective ly  to  th e  a ffin ity  colum ns w hen  th ey  had been  
p re lo ad ed  w ith  copper, regardless o f any histid ine to  alanine m utations in e ith e r th e  E l  
CuBD o r th e  Ap dom ain  and was, th e re fo re , only d etec ted  in th e  colum n elu ate .
Thus, w hilst th e  m u tatio n  o f histidine residues w ith in  e ith e r th e  E l CuBD or 
th e  Ap region m ight w ell ab late  copper binding in those specific regions o f th e  p ro te in , such 
m u tatio n s  do n ot en tire ly  p reven t copper binding o f th e  protein  p erse .
9.7. Sum m ary
In th e  cu rren t chapter, th e  effects o f copper binding w ith in  th e  E l and Ap dom ains  
o f APP on th e  proteolysis o f th e  p rotein  in SH-SY5Y cells and th e  viability o f these cells in th e  
presence o f copper have been investigated. The results show th a t th e  introduction  o f 
histid ine to  alanine m utations w ith in  e ith e r th e  E l or AP dom ains o f both th e  695  and 77 0  
am in o  acid APP isoform s had no effect on th e  expression of, or a -secretase-m ed iated  
proteolysis o f th e  p rotein  {Figs. 9.2A, 9.3A, 9 .6A  and 9 .7A). H ow ever, such m utations did 
significantly reduce th e  g enera tion  o f sAPPp from  both APP isoforms w ith  th e  in troduction  o f 
a H 610A  (APP695) o r H 685A  (APP770) m u tatio n  having a particularly dram atic effect in this 
respect {Fig. 9 .3B  and 9.7B).
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Figure 9.9. Binding of APP constructs to  metal affinity spin columns. Serum free m edium  was cond itioned 
fo r  48 hours on SH-SY5Y cells expressing the  ind icated APP constructs (A-F). The m edium  was then 
concentra ted  and passed th ro u g h  m eta l a ffin ity  spin colum ns in the  absence o f metals, presence o f copper 
o r manganese (M a te ria ls  and M ethods). Column run th rough  (RT) and eluate (E) were made up to  equal 
vo lum es and im m u n o b lo tted  w ith  the  22C11 an tibody in o rde r to  de tect soluble APP.
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Both APP695 and APP770 w ere  capable o f enhancing th e  v iab ility  o f SH-SY5Y cells in th e  
presence o f co p per and m u ta tio n  o f th e  E l CuBD in both isoform s ab lated  this function  {Fig.
9 .4 ).  In th e  case o f APP695, th e  in troduction  o f h istid ine to  alanine m utations a t positions 602 , 
609  o r 6 1 0  largely had no e ffec t on th e  ab ility  o f th e  w ild -typ e  p rotein  to  enhance v iab ility  in 
th e  presence o f copper. The situation  was sim ilar fo r th e  APP770 isoform  w ith  m u tatio ns at 
positions 67 7  and 685  largely having no e ffec t on th e  ab ility  o f th e  w ild -typ e  p ro te in  to  
enhance cell v iab ility  in th e  presence o f copper [Fig. 9 .8 ).  H ow ever, th e  H 684A  m u ta tio n  in 
APP770 (analogous to  H 609A  in APP695) did seem  to  p reven t th e  ab ility  o f th e  w ild -typ e  
pro te in  in this respect (th ereb y  d iffering  from  th e  situation w ith  th e  APP6 9 5  isoform ).
Finally, in th e  cu rren t study, APP was able to  bind copper regardless o f any o f th e  
histid ine m u tatio ns introduced {Fig. 9 .9 ).  This indicates th a t th e  protein  was still capable o f  




1 0 .1 . In troduction
The cu rren t study has exam ined th e  ab ility  o f th e  am ylo id  precursor p ro te in  to  
p ro m o te  cell v iab ility  w ith in  th e  en v iro n m e n t o f th e  brain in tw o  diseases associated w ith  
ageing; A lzheim er's  disease and prostate  cancer. The results are discussed in th e  co n text o f 
individual results chapters below .
10.2. Characterisation of constitutive wild-type APP expression 
and  proteolysis in cell lines
An analysis o f APP expression, its proteolysis and its secretases was p erfo rm ed  in 
various PCa cell lines and in SH-SY5Y neuroblastom a cells. This analysis was carried o u t in 
p rep aratio n  fo r subsequent use o f these cell lines in studies re la ting  to  PCa and AD.
O f th e  PCa cell lines, endogenous APP expression and shedding w e re  low est in 
LNCaP cells {Figs. 3 .1A an d  3 .2 ) .This observation is in teresting  given th a t LNCaPs are an early  
stage, h orm o ne sensitive, cell line in w hich APP has previously been shown to  be a key 
androgen recep to r ta rg e t gene and to  p ro m o te  cell p ro liferation  and tum origenesis (233). 
The h igher APP expression and proteolysis in D u l4 5  and PC3 cells, which are derived from  
la te r stage, m o re  aggressive, horm one-insensitive m etastases, m ight add fu rth e r w e igh t to  
th e  arg u m en t th a t APP expression in PCa cells is d irectly linked to  th e ir  pro liferative  capacity. 
In fact, so high w e re  th e  levels o f APP expression in PC3 and D u l4 5  cells th a t th ey  w ere  
com parab le  to  levels o f th e  over-expressed protein  in SH-SY5Y cells {Fig. 3 .1A).  This raises 
th e  possibility th a t, w h en  cells becom e horm one-insensitive (fo r exam ple, in th e  D u l4 5  cells) 
APP expression gets 'stuck on' regardless o f androgen levels and th e  cells p ro lifera te  m ore  
aggressively as a consequence.
200
Levels o f sAPPa g en era ted  by th e  various cell lines generally re flected  th e  expression  
levels o f th e  various APP isoform s [Fig. 3 .2 ).  H ow ever, interestingly, th e  over-expression o f 
w ild -ty p e  APP6 9 5  in SH-SY5Y cells resulted in decreased endogenous APP7 5 1 / 7 7 0 shedding in 
com parison to  th e  m ock-transfected  controls [Fig. 3.2A an d  B). This could suggest th a t in SH- 
SY5Y cells, th e  secretases regulating APP a-shedding  becom e saturated  w hen APP6 9 5  is o ver­
expressed, resulting in a decline in endogenous APP shedding. This im plies th a t th e  o ver­
expressed pro te in  m ay be com peting  w ith  endogenous APP fo r shedding. In teresting ly , a 
sim ilar e ffe c t was not observed w hen  APP6 9 5  was over-expressed in D u l4 5  cells [Fig. 3 .2 ),  a 
cell line w hich expressed m ore endogenous A D A M 10  than SH-SY5Y cells [Fig.3. 7). H o w ever, 
th e  ratio  o f endogenous to  over-expressed APP in D u l4 5  cells was also considerably higher 
th an  in th e  SH-SY5Y cells, perhaps creating less com petition  fo r this a-secretase activ ity.
In te rm s o f th e  sAPP(3 levels secreted from  th e  PCa cell lines, LNCaP cells produced  
slightly m ore th an  th e  D u l4 5  and PC-3 cells [Fig. 3.3),  despite holoprote in  expression and  
sA PPa g en era tion  being low est in th e  fo rm e r cell line. This observation raises th e  possibility  
th a t  am ylo idogenic processing o f APP is perhaps associated particularly w ith  th e  early  stages 
o f PCa but decreases as cells becom e m ore m alignant. This th eo ry  w ould  coincide w ith  th e  
data g en era ted  in regards to  th e  invo lvem ent o f sAPPa (and not sAPP(3) in cell p ro lifera tion  
(11 1 , 1 2 3 ,1 2 5 ) .
W h en  APP6 9 5  was over-expressed in both the D u l4 5  and SH-SY5Y cell lines, th e re  
w as an increase in th e  sAPP6 9 5 p production [Fig. 3.3).  Such an increase was to  be expected  
fo llo w in g  th e  increase in soluble APP substrate presented to  BACE1. Interestingly, in th e  
D u l4 5  cells, endogenous SAPP7 5 1 / 7 7 0 P production was also elevated  [Fig. 3.3).  APP expression  
levels have previously been shown to  regulate th e  expression o f BACE1 (100), m aking it 
possible th a t over-expressing APP in th e  D u l4 5  cells in th e  current study m ay have increased
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BACE1 expression and, consequently , increased th e  gen era tion  o f sAPPp fro m  endogenous  
APP.
10.3. The effects of copper on endogenous APP expression and 
proteolysis in p rosta te  cancer epithelial ceils
In o rd er to  exam ine th e  effects o f copper on APP expression and proteolysis in PCa 
cells, LNCaP, D u l4 5  and PC-3 cells w e re  tre a te d  w ith  a concentra tion  range o f th e  m etal. 
C opper was not toxic to  any o f th e  cell types w hen used at concentrations o f 50  |uM o r low er  
{Figs. 4 .1 , 4 .4  a n d 4 .7 ).  A t m eta l concentrations o f 200  |iM  or higher, all th re e  cell lines 
exhib ited  d ram atica lly  reduced viability . This was likely due to  toxicity ra th er than  decreased  
p ro lifera tion  given th e  short tim e  course em ployed  in these experim ents . The toxic effects o f 
co p per com plexes on cells have previously been a ttrib u ted  to  th e  inhibition o f pro teasom e  
function  and p rom otion  o f apoptosis (327). Furtherm ore , th e  oxidative capacity o f copper 
m ay result in oxidative dam age to  cells (328).
In contrast to  LNCaP and PC-3 cells (w here  copper, a t sub-toxic concentrations, had 
no e ffec t), APP expression w as enhanced in D u l4 5  cells fo llow ing  m etal tre a tm e n t [Fig. 4.8).  
The m echanism  behind this increase in APP expression could be via copper binding to  a 
copper responsive regu latory e le m en t in th e  APP p ro m o ter (163). H ow ever, th e  oxidative  
properties  o f copper alone m ay enhance APP expression, as this e ffect has been shown to  be 
ab la ted  using an tioxidants (16 0 ). W h a te v e r th e  m olecular m echanism s involved, th e  fac t th a t  
serum  and tissue copper concentrations are elevated  in prostate cancer patients (262) raises 
th e  possibility th a t these increased m etal concentrations may serve to  p rom ote APP 
expression in these patients. The fact th a t copper prom oted  APP expression only in D u l4 5  
cells is particu larly  interesting given th e  fact th a t these cells are o f a brain m etastatic  origin 
(279) and this organ is second only to  the liver in term s o f copper concentration. Thus, the
202
copper-induced  expression o f APP in D u l4 5  cells m ay play a role in th e ir  ab ility  to  survive in 
an organ contain ing  exceptionally  high copper concentrations.
10.4. The effect of full-length APP construct expression on 
D uI45  cell viability m the  presence of copper
As co p per had been shown to  p ro m o te  endogenous APP expression in D u l4 5  cells, it 
w as hypothesized th a t th e  pro te in  m ight be able to  p ro m o te  D u l4 5  cell v iab ility  in th e  
presence o f th e  m eta l. Thus, APP was over-expressed in cells in th e  form  o f APP695. The  
m igration  d ifferences b etw een  this isoform and th e  endogenous p ro te in /p ro teo ly tic  
fragm en ts  (APP7 5 1 / 7 7 o) in D u l4 5  cells m ade it easier to  quantify  over-expression o f th e  
em ployed  constructs. A lthough previous sections in th e  curren t study had failed to  d etec t 
any endogenous APP69 5  p ro te in  in D u l4 5  cells, th e  RT-PCR data in th e  current section {Fig. 
5.1 )  clearly show  th a t low  levels o f th e  RNA transcrip t o f this isoform w ere  present. The fact 
th a t th e  larger KPI-containing isoform s o f APP p redom inated  in D u l4 5  cells was not 
surprising given th a t w hilst APP6 9 5  is th e  m ajor isoform in neurons (324 ), th e  KPI-containing  
isoform s p red o m in a te  in o th e r tissues, such as th e  liver, skeletal muscle, heart and lung  
(32 9 ). These results co rre late  w ith  th e  observed APP expression pattern  in D u l4 5  cells, 
w hich orig inate  in prostate  tissue (279).
W h e n  APP69 5 , 7 5 1  or 7 7 0  w ere  over-expressed in D u l4 5  cells, it was clear th a t th e  
fo rm e r isoform  p ro m o ted  cell v iability  in th e  presence o f 150 and 200  p M  copper, w hereas  
th e  o th e r isoform s w ere  less effective  in this respect {Fig. 5.5).  Previous experim ents have  
d em o n stra ted  th a t Tg2576 mouse prim ary cortical neurons contain significantly less copper 
than  w ild -typ e  mice, w hereas APP knockout prim ary cortical neurons contained significantly  
m ore copper th an  cells from  control m ice (163). The T g2576 mice over-express APP69 5  (330), 
rendering  this isoform  responsible fo r th e  observed copper efflux, which could be the
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m echanism  responsible fo r th e  e levated  viability  o f APP695 over-expressing D u l4 5  cells in th e  
cu rren t study.
It m ight also be possible th a t th e  APP695 over-expressed in D u l4 5  cells in th e  curren t 
study, prom otes th e  uptake and safe sequestration o f copper, th e re b y  reducing toxicity  o f 
th e  m eta l. This th eo ry  is supported  by th e  fact th a t HEK293 cells over-expressing APP have  
been shown to  exh ib it enhanced copper uptake and increased levels o f m e ta llo th io n e in -l/ll 
expression; a p ro tein  w hich assists cells in th e  m anagem ent o f in trace llu lar copper ions 
(175 ).
Subsequent experim ents  using siRNA knockdown o f endogenous APP in D u l4 5  cells 
revealed  a slight reduction in viability  in th e  presence o f copper fo llow ing  APP knockdown  
{Fig. 5 .7 ).  H ow ever, this change was not in th e  sam e o rd er o f m agnitude as th a t observed  
w h en  APP was over-expressed in th e  sam e cell line. This discrepancy m ay be explained by 
th e  fac t th a t in th e  over-expression studies th e  cells w ere  exposed to  copper fo r 7 days as 
opposed to  only 48  h (due to  th e  trans ien t nature o f th e  APP knockdow n). There also exists 
th e  possibility th a t APP m ay be partia lly  redundant in re lation  to  its ab ility to  enhance cell 
viability  in th e  presence o f copper. Indeed previous studies have shown th a t a double  
APP/APLP2 knockout, as opposed to  a single APP knockout, was m ore e ffective  at increasing 
copper levels in both cortical neurons (331) and in th e  cerebral cortex and liver o f knockout 
m ice (332).
10,5. The APP cytosolic domain Is a p rerequisite  for enhanced 
B u l4 5  cell viability In the presence of copper
Next, various cytosolic dom ain  APP m u tan t constructs w ere  over-expressed in D u l4 5  
cells, in o rd er to  exam ine th e  role o f this dom ain in th e  ab ility o f th e  m olecule to  enhance
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cell v iab ility  in th e  presence o f copper. All o f th e  constructs w ere  successfully expressed, 
a lb e it th e  APP69 sAICD construct at a seem ingly low er level than  th e  o thers (Fig. 6.2).  N otably, 
th e  sA PPa produced by th e  APP695AICD over-expressing cells was h igher than  th a t gen era ted  
by th e  w ild -typ e  APP695 over-expressing cells, despite th e  low er ap p aren t expression level o f  
th e  fo rm e r construct (Fig. 6.3).  This m ight be th e  result o f increased re ten tio n  o f APP a t th e  
cell surface, as th e  cytosolic dom ain is th ou gh t to  be required fo r endocytosis (53). As a -  
secretase cleavage prim arily  takes place at th e  cell surface (333), this location is likely to  
enhance sA PPa gen era tion . The enhanced a-shedding  o f th e  APP695AICD construct fro m  th e  
cell surface m ight also explain th e  seem ingly low er levels o f this construct d etec ted  in cell 
lysates.
As observed earlier, w ild -typ e  APP695 was able to  enhance th e  v iability  o f D u l4 5  cells
in th e  presence o f copper. H ow ever, th e  rem oval o f th e  cytosolic dom ain  or m u tatio n  o f
individual tyros ine residues w ith in  this dom ain reduced th e  action o f APP in this respect (Fig.
6.4).  T here  are  several possible explanations fo r this observation. First, th e  APP intrace llu lar
d om ain  is involved in interactions w ith  G -prote in -coupled  receptors regulating cellu lar
apoptosis, th e re fo re  th e  d e le tio n /m u ta tio n  o f this region o f APP m ight im pede apoptosis
(10 5 ). The APP in trace llu lar dom ain also interacts w ith  a w ide range o f ad ap to r proteins
(10 8 ), p rim arily  th rough th e  YENPTY m otif, th e  tyrosine residues o f which w ere  m u ta ted  in
th e  cu rren t study. Interactions w ith  these ad ap to r proteins have been associated w ith  cell
g ro w th , p ro life ra tio n , hom eostasis, responses to  stress, apoptosis, cell fa te  d eterm ination
and in regu lation  o f th e  cell cycle (Table 1.1).  A lterations in any o f these pathways as a result
o f im paired  APP cytosolic dom ain function, as in th e  case o f th e  m u tan t constructs, m ight
explain th e  observed decrease in cell viability in th e  presence o f copper relative to  w ild -typ e
A P P-transfected  cells. F urtherm ore , th e  ability o f APP to  generate  AICD w ould  clearly be
p reven ted  in th e  APP695AICD construct, th ere b y  preventing th e  regulation o f gene expression
by this fra g m en t (121 ). The genes regulated by th e  AICD include those involved in cell cycle
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regu lation  and pro lifera tion  (discussed in section 1 .5 .4 .), w hich m ay explain th e  im pact o f  
this m u ta tio n  on cell g ro w th . The YENPTY m o tif in th e  APP cytosolic dom ain  m ay be 
responsib le fo r tra ffick ing  th e  AICD fra g m en t through th e  cell (93), and fo r its in teraction  
w ith  a d a p te r proteins to  fo rm  th e  com plex able to  translocate to  th e  nucleus and regu late  
gene expression (14 2 ). These la tte r points m ight explain th e  im pact o f th e  tyrosine  
m u tatio ns  in th e  cu rren t study on th e  cell v iab ility  results.
In th e  context o f gene expression regulation by th e  APP cytosolic dom ain  (or th e  
AICD), it is notab le  th a t in th e  cu rren t study, th e  over-expression o f w ild -typ e  APP695 in 
D u l4 5  cells repressed ERK1 expression; an effect th a t was isoform -specific {Figs. 6 .8  an d  
6.9 ).  In contrast, all o f th e  APP cytosolic dom ain  m utants studied failed to  elicit a sim ilar 
effe c t, raising th e  possibility o f invo lvem ent o f th e  YENPTY region o f APP in th e  regu lation  o f 
ERK1 expression. A lthough a d irect in teraction  betw een  APP and ERK1 has not been  
previously d em o n stra ted , soluble APP can activate the ERK pathw ay (9 7 ,1 2 6 ,1 2 7 )  and Ap  
has been  associated w ith  n eu ro protection  through ERK1 signalling (146). Binding o f th e  SH2 
and PTB containing ad ap to r proteins to  th e  APP intracellu lar dom ain is also associated w ith  
th e  ERK signalling p ath w ay (109). The APP695 induced reduction in ERK1 expression m ay  
en ab le  D u l4 5  cells to  rem ain  viable in th e  presence o f exogenous copper through a ltered  
regu lation  o f cell cycle progression, cell survival, m etabolism , p ro liferation  and transcription  
by th e  ERK1 signalling p ath w ay (334).
Also o f in te res t in relation to  th e  cytosolic dom ain o f APP, is th e  observation th a t  
w ild -typ e  APP appeared  to  dissociate caveolin-1 from  lipid rafts w hereas th e  APP695AICD 
construct actually appeared  to  enhance caveolin-1 association w ith  rafts {Fig. 6.7).  One  
possible explanation  fo r these contrasting observations is th a t th e  APP ectodom ain and 
cytosolic dom ain  have opposing roles in relation to  caveolin-1 association w ith  rafts. The  
ectod o m ain  m ight p ro m o te  caveolin-1 raft association, w hereas th e  intracellu lar dom ain
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m ight s tim u la te  th e  dissociation o f th e  p rotein  from  rafts, possibly over-rid ing  th e  fo rm e r  
e ffe c t o f th e  ec tod o m ain .
10.6. The APP ectodom ain  and enhanced D«145 cell viability In 
the  presence  of copper
In this section o f th e  study, th e  role o f th e  N -te rm in a l copper binding dom ain  o f APP 
in enhancing  D u l4 5  cell v iab ility  was investigated. W hen  a copper binding APP m u tan t, 
APP695ACuBD, was over-expressed in these cells, th e  expression and a -secre tase -m ed ia ted  
processing o f th e  pro te in  w ere  sim ilar to  th a t o f w ild -typ e  APP695 [Fig. 7.2 an d  7.3A).  
H o w ever, th e  g en era tion  o f sAPPp from  APP695ACuBD was negligible, being th e  sam e as th a t  
g en era ted  by m ock-transfected  D u l4 5  cells {Fig. 6.3B). This suggests th a t copper binding in 
th e  E l dom ain  o f APP is essential fo r th e  production o f sAPPp. This observation is at odds 
w ith  previous studies w hich d em o n stra ted  th a t th e  addition o f copper to  cell cu lture  
m ediu m  reduced cellu lar Ap production and, th ere fo re , presum ably, sAPPp generation  (166, 
168). S im ilarly, studies using APP over-expressing mouse models have shown th a t copper  
reduces CSF Ap and Ap plaque burden (1 7 0 ,1 7 1 ) . How ever, th e  exact m echanism  o f Ap  
reduction  was not d em o n stra ted  in these studies, raising th e  possibility th a t enhanced Ap  
clearance, as opposed to  reduced generation , could have been responsible fo r th e  results  
observed.
Spoerri e t al. (16 5 ) d em o n stra ted  th a t sAPPp production was reduced w hen  APP 
histid ine residues 149  and 151 w ere  m u tated  to  asparagines. How ever, these m utations also 
resu lted  in decreased sAPPa generation; som ething th a t was not observed in th e  current 
study. M o reo ve r, it seem s th e  case th a t th e  rep lacem ent o f histidine residues w ith  
asparagines (as opposed to  alanines, as in this study) resulted in APP folding and trafficking
ab n orm alities . The reduced generation  o f both sAPPp and sAPPa observed by Spoerri et al.
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w as th e re fo re  m ore likely due to  decreased tra ffick ing  o f APP to  th e  cell surface, which  
w ou ld  subsequently reduce endocytosis and access to  secretases.
B aum ko tte r e t  al. (13 4 ) d em o n stra ted  a reduction in A(3 production w ith  prevention  
o f co p per binding at th e  N -te rm in a l APP CuBD, and this was associated w ith  th e  prevention  
o f copper/C uB D  d ep en d e n t d im eriza tio n . This could th e re fo re  be a m echanism  behind th e  
observed  reduction  o f sAPPp in this study.
In th e  cell v iab ility  studies presented , th e  m u tatio n  o f th e  APP E l copper binding  
d om ain  ab lated  th e  ab ility  o f w ild -typ e  APP695to  enhance D u l4 5  cell v iability  in th e  presence  
o f copper {Fig. 7.4).  This m ight w ell indicate th a t copper binding w ith in  this dom ain is a 
p rereq uis ite  fo r prom oting  cell v iability . H ow ever, th e  possibility th a t conform ational 
changes in th e  APP m olecule u nre la ted  to  copper binding w ere  induced by th e  histidine to  
alan ine m utations cannot be en tire ly  excluded. H ow ever, this is ex trem ely  unlikely given th e  
fac t th a t th e  m aturation  and tra ffick ing  o f APP w ere  unaffected  by these m utations (based 
on th e  glycosylation banding patterns o f th e  prote in , and on th e  fact th a t th e  a -secretase- 
m ed ia ted  shedding o f th e  APP6g5ACuBD construct was sim ilar to  th a t o f its w ild -typ e  
co u n te rp art, m eaning th a t tra ffick ing  to  th e  cell surface m ust not have been affected).
The m echanism  by w hich copper binding to  th e  E l dom ain o f APP m ight p rom ote  
cell v iab ility  is unclear. H ow ever, it has previously been dem onstra ted  th a t the E l copper 
binding dom ain  sequence is highly specific fo r Cu(ll) and th a t th e  g eo m etry  o f th e  CuBD is 
highly unfavourab le  in re la tion  to  Cu(l) binding (335 , 336 ). These observations support th e  
possibility th a t APP m ay p refe ren tia lly  tran s fer redox active Cu(ll) to  o th e r proteins, 
fac ilita ting  its sequestration and preventing  th e  generation  o f dam aging ROS. Furtherm ore, a 
p ep tid e  based on th e  APP E l CuBD has been shown to  p ro m o te  copper efflux from  yeast 
cells (156); an effect w hich was ab lated  fo llow ing  th e  m u tation  o f histidine residues 1 4 7 ,1 4 9
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and 151 to  alanines. S im ilar observations have also been d em o n stra ted  in m ice. M ice  
exhib ited  reduced neuro tox ic ity  w hen  an infused CuBD peptide was ad m in is tered  alongside  
co p per (172); an e ffec t w hich was d ep en d en t on th e  C y s l44  residue responsible fo r th e  
reduction  o f Cu(ll) to  Cu(l). A sim ilar tra n s fer o f redox active Cu(ll) to  o th e r proteins, an APP- 
m edia ted  efflux o f Cu fro m  cells a n d /o r  a p otentia l copper detoxification  strategy exhib ited  
by APP m ay have been responsible fo r th e  observed enhanced viab ility  o f D u l4 5  cells in th e  
presence o f th e  m eta l.
In th e  cu rren t study, effo rts  w ere  also m ade to  d e term in e  w h e th e r soluble APP could  
enhance D u l4 5  cell v iab ility  in th e  presence o f copper in th e  sam e w ay as its fu ll-length  
co u n te rp art. In this respect, a tru n cated  construct analogous to  a-secretase -c leaved  APP770 
w as stably transfected  into D u l4 5  cells. H ow ever, despite th e  construct being va lidated  in 
SH-SY5Y cells, th e  resu ltan t p ro tein  w as ab erran tly  expressed a n d /o r processed in D u l4 5  
cells (Fig .7.5). The key transfection  product in D u l4 5  cells consisted o f an ap p ro xim ate ly  25 
kDa frag m en t arising from  th e  N -term inus o f APP, as confirm ed by im m unob lots  using th e  
anti-FLAG and 22C 11 antibod ies (Fig.7.5 and  7.6). It w ould  seem  th a t this fra g m en t was not 
g en era ted  th rough  th e  proteolysis o f th e  m ature , fu lly glycosylated sA P P 770a p ro te in , as 
D u l4 5  cell lysates w e re  incapable o f cleaving th e  la tte r fragm en t w hen secreted into the  
conditioned  m edium  o f SH-SY5Y transfectants {Fig. 7.7).  In this respect, cleavage o f th e  
construct in D u l4 5  cells is likely to  take  place prior to  secretion, possibly as a consequence o f 
th e  lack o f m em b rane anchorage. This raises th e  possibility th a t th e  small am ounts o f the  
endogenous APP 25 kDa fra g m en t observed by o th e r groups (337, 338) result from  a m inor 
pool o f im m atu re  APP cleaved from  th e  m em b rane in th e  endoplasm ic reticulum  (as 
opposed to  th e  m a jo r pool w hich reaches th e  cell surface uncleaved).
As th e  sAPPa construct did not over-express as expected in D u l4 5  cells, th e  effect o f 
inhibiting endogenous sAPPa generation  on cell viability in the presence o f copper was
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exam ined  instead. As such, cells w ere  incubated  in th e  absence or presence o f th e  A D A M  
inh ib itor, G 12 540 23 X  w hilst trea tin g  w ith  copper. H ow ever, sAPPa gen era tion  w as only  
reduced by ap p ro x im ate ly  one q u arter in th e  in h ib ito r-tre a ted  cells [Fig. 7.8) m aking it 
difficu lt to  m ake any d efin itive  conclusions in re lation  to  th e  observed small changes 
observed in cell v iab ility  (Fig. 7.9). S im ilar experim ents  using (3-secretase inh ib itor IV reduced  
th e  gen era tion  o f sAPPp by 85 .9  ± 7.35%  (Fig. 7.10),  but fa iled  to  change cell v iab ility  in the  
presence o f copper (Fig. 7.11).  It th e re fo re  seems ap p aren t th a t m em b rane anchorage o f th e  
APP m olecule is requ ired  in o rd er fo r th e  protein  to  enhance cell v iab ility  in th e  presence o f 
copper. These data are in ag reem en t w ith  earlier results in th e  curren t study indicating th a t  
th e  cytosolic dom ain  o f APP is required in this respect. H ow ever, these results seem  to  
conflict w ith  th e  studies o f o th e r groups w hich have shown th a t fragm ents o f th e  sAPP 
ectod o m ain  w ith  an in tact CuBD pro tect cells from  copper insult (1 7 2 ,1 7 5 ) . This conflicting  
data in regards to  th e  ab ility  o f soluble form s o f APP to  p ro tect against co p per-m ed ia ted  
insult is likely both  ce ll-type and experim enta l condition- type specific.
10.7. APP-fiiduced morphological changes in Du 145 cells
The over-expression o f APP695 in D u l4 5  cells led to  a change in m orphology (Fig.8.1 ), 
w ith  th e  cells appearing  to  have long neuron-like extensions. Such m orphological 
appearance is s im ilar to  th a t seen fo llow ing  neuroendocrine d iffe ren tia tion  (NED) (Fig. 10 .1)  
(33 9 ). NED occurs in m ore than  50%  o f m alignant prostatic tum ours (340), and has been  
associated w ith  a p oo rer prognosis in non-organ confined prostate cancer (301). NED is also 
associated w ith  th e  increased expression o f neuron-specific enolase (NSE) (339). H ow ever, in 
th e  cu rren t study, NSE expression was decreased ra th er than  increased fo llow ing  APP695 
over-expression in D u l4 5  cells (Fig.8.2).  This w ould  indicate th a t th e  m orphological changes 
observed fo llow ing  APP transfection w ere  not linked to  NSE.
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Figure 10.1. NED in D u l45  cells. A. Norm al D u l4 5  cells. B. NED in D u l4 5  cells induced by the  add ition  o f 
5 n g /m l EGF. Image taken and adapted from  Humez e t al. 2006 (339).
A n o th e r phenom enon which could potentially  explain th e  m orphological changes 
linked to  APP6 9 5 in th e  curren t study, is th a t o f ep ithe lia l-to -m esenchym al transition  (EM T). 
E M T brings ab o ut an e levated  population o f m esenchym al cells which lack in terce llu lar  
junctions and th ere fo re  exhib it g rea te r m obility  and invasion, resulting in a poorer prognosis 
in cancer (305 , 306 ). EM T is associated w ith  th e  decreased expression o f th e  cell adhesion  
m olecule, E-cadherin, and conversely an increased expression o f v im entin  (307). Just such 
changes in expression w ere  observed in th e  current study fo llow ing  APP695 over-expression  
in D u l4 5  cells (Fig.8.3),  suggesting th a t th e  protein  enhances EM T and m ight w ell, th e re fo re , 
lead to  a poorer prognosis in PCa. A causal relationship b etw een  APP and EM T has not 
previously been identified . H ow ever, it has been shown th a t hum an proxim al tu b u lar cells 
undergo suspected EM T, concom itant w ith  a tw o-fo ld  increase in APP gene expression  
fo llo w in g  cyclosporine A tre a tm e n t (341). Furtherm ore, th e  nuclear translocation o f the  
A lC D /b ind ing  p artn er com plex can regulate genes such as GSK3(3 and p53 which have, in 
tu rn , been im plicated in th e  regu latory n etw ork controlling EM T (342).
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F urther results in this study show ed th a t both an intact APP cytosolic dom ain  and an 
E l CuBD w e re  requ ired  in o rd er to  induce E M T-like m orphological changes; in add ition, th e  
e ffe c t w as specific to  th e  APP695 isoform  {Figs. 8.4, 8 .5  and  8.6).
10.8. The role of copper binding in AFP proteolysis and the 
viability of SH-SY5Y cells
In o rd er to  exam ine th e  role o f APP copper binding and cell v iab ility  in re lation  to  AD, 
several APP constructs w ere  stably over-expressed in SH-SY5Y cells. The E l CuBD d efic ien t 
construct, APPACuBD, has been described previously. H ow ever, add itiona l constructs w ith  
histid ine to  alanine m u tatio ns w ith in  th e  Ap dom ain o f th e  APP m olecule w ere  also 
expressed. These la tte r m utan ts w ere  generated  fo llow ing  previous evidence th a t copper 
binds to  th e  Ap peptide via these residues (343, 344); it is not known w h e th e r th e  sam e  
residues partic ipate  in copper co -ord ination  in th e  fu ll-length  APP m olecule.
All o f these APP constructs (both  the 695 and 770 m utants) expressed at com parab le  
levels in cell lysates and gave rise to  th e  sam e levels o f shed sAPPa {Figs. 9.2, 9.3, 9 .6  and  
9.7 ).  H ow ever, low er levels o f sAPPp w ere  produced by th e  m u tated  constructs, particu larly  
th e  APPACuBD and APP695-6 1 0 /A P P 770-68 5  constructs {Fig. 9.3, 9.7).  A reduction in sAPPp 
g en era tion  as a consequence o f histidine to  alanine m utations in th e  E l CuBD o f APP was  
also observed e a rlie r in th e  cu rren t study in D u l4 5  cells (discussed in section 10.5). Notably, 
th e  reduction in D u l4 5  cells was m ore dram atic than  th a t observed in SH-SY5Y cells. The  
observed reductions in SH-SY5Y cells in relation to  th e  APP695-610/APP770-68 5  construct 
ind icate th e  particu lar im portance o f copper coordination at H is6 10 /6 85  in P-cleavage o f 
APP. Previous studies have d em o n stra ted  th a t e levated  copper concentrations can result in 
reduced A(3 levels in SH-SY5Y cells (161) and in vivo (171). There is th ere fo re  a possibility th a t 
if th e  m u tated  APP histidine residues in this study p revent the relocation o f copper, the
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resu ltan t e levated  local copper concentra tion  m ay replicate this e ffect. Exam ination o f local 
copper levels w ou ld  enab le  th e  testing  o f this hypothesis.
The m olecu lar m echanism s behind th e  decreased generation  o f sAPP(3 from  th e  
various copper binding m utants are unclear. Certainly, th e  decreased sAPPp generation  fro m  
APP695-6 1 0 /A P P 770-6 8 5  is not likely due to  BACE1 being blocked from  accessing APP by the  
am ino  acid substitu tion, as this residue is th e  fu rth est m u tated  residue from  th e  p-cleavage  
site. H o w ever, it is possible th a t copper binding to  APP and subsequent hom odim erisation  
m ight be requ ired  fo r BACE1 cleavage o f th e  protein  (154 , 345 ). As BACE1 has been shown to  
directly  in te rac t w ith  copper via its cytoplasm ic dom ain (169), it is also possible th a t one o f 
th e  m echanism s em ployed  by BACE1 in o rd er to  com e into contact w ith  APP, is via 
in te rac ting  w ith  th e  copper ion bound to  th e  H is6 10 /6 85  residue o f th e  protein; thus w hen  
th is in te rac tion  is p reven ted , perhaps th e  association b etw een  BACE1 and APP is reduced or 
w eaken ed , consequently decreasing sAPPp production. Further investigation into th e  
co n form atio n  and fu nctio n ality  o f th is APP copper binding region as a co m p o nent o f th e  
h o loprote in  and into  th e  interactions b etw een  copper, th e  APP H is6 10 /6 85  residues and th e  
APP secretases m ay provide an explanation fo r this effect.
The cell v iab ility  results g enerated  using th e  APP695 copper binding m utants suggest 
th a t, as in th e  D u l4 5  studies (discussed in section 10.5); th e  APP695ACuBD m u tan t does not 
enhance th e  viability  o f th e  SH-SY5Y cells, w hereas th e  over-expressed w ild -typ e  APP695 
construct does {Fig. 9 .4 ).  The single histidine m utations w ith in  th e  Ap region o f th e  protein , 
h o w ever do not reduce this positive e ffect {Fig. 9 .4 ).  These results th e re fo re  suggest th a t 
only copper binding in th e  E l CuBD o f th e  p rotein  is involved in prom oting cell viability, an 
e ffe c t w hich has previously been discussed in section 10.5 .
The cell v iab ility  results generated  using th e  APP77o copper binding m utants assigned 
an o th e r am ino acid a role in APP's ability to  enhance SH-SY5Y cell viability in th e  face o f
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exogenous copper stress. The APP77o isoform  indeed p ro m o ted  cell v iability , w hereas th e  
APPACuBD and th e  APP770-6 8 4  m u tan t constructs did not (Fig. 9 .8 ).  Firstly, this dem onstra tes  
th a t in SH-SY5Y cells, th e  beneficial role o f APP on viability  w hen  presented  w ith  exogenous  
copper is not isoform  specific. In th e  D u l4 5  cell studies this effect was lim ited  to  th e  APP695 
isoform  (Fig. 5 .5 ),  d em o n stra tin g  th e  variab le m olecular m echanism s w hich em erge w hen  
using d iffe ren t m odel cell systems.
Secondly, as in d ep en d en t m utations w ith in  th e  N -te rm in a l and Ap regions o f APP 
p reven t th e  ab ility  o f APP770 to  enhance th e  viability o f SH-SY5Y cells fo llow ing  copper 
tre a tm e n t, it suggests th a t these tw o  regions o f th e  protein  m ay act to g e th e r in o rd er to  
coord inate  copper and p reven t th e  observed reduction in viability . Previous evidence  
suggests th a t a co n form atio na l change occurs fo llow ing  copper binding at both th e  E l CuBD 
(292 ) and w ith in  th e  A 3 pep tid e  (346), which m ay also take  place upon copper binding to  the  
A3 region o f th e  fu ll length ho loprote in . This structural change fo llow ing  binding to  one o f 
th e  dom ains m ay bring th e  copper ion into contact w ith  th e  o th e r dom ain, allow ing th e  
in teraction  to  take  place w hich results in th e  SH-SY5Y enhanced v iability  w hen  tre a te d  w ith  
copper. These results identify  a possible physiological function fo r APP in th e  m ain tenance o f 
cell v iability  in th e  presence o f high copper concentrations, which depends on its ability to  
bind copper a t both th e  N -te rm in a l CuBD and w ith in  th e  A3 dom ain  o f th e  protein.
APP has previously been d em onstra ted  to  bind copper a t th e  N -te rm in a l E l CuBD, 
th e  E2 CuBD and via th e  secreted A3 peptide (1 5 7 ,1 5 9 , 293), giving sufficient evidence to  
expect th a t th e  soluble APP ectodom ain  collected from  SH-SY5Y cell conditioned m edium  
w ill bind copper. In o rd er to  dem o n stra te  w h e th e r or not the copper binding constructs used 
lost th e ir m eta l binding ab ility, m etal chelate affin ity  chrom atography was em ployed. None  
o f th e  constructs (including w ild -typ e  APP77q) w ere  able to  bind m anganese in these columns.
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In te rm s o f copper, none o f th e  constructs lost th e ir  ab ility to  bind to  th e  m etal {Fig. 9.9),  
suggesting th a t APP-copper binding sites exh ib it a degree o f functional redundancy.
10,8, Fu ture  directions
Future research directions fo r this w ork  w ou ld  involve th e  fu rth e r elucidation o f the  
specific region o f APP which potentia lly  interacts w ith  copper. A dditional APP constructs, 
containing individual am ino acid m utations w ith in  th e  E l copper binding dom ain  o f APP, 
w ou ld  be d eve loped . These constructs w ou ld  be exam ined using th e  sam e D u l4 5  and SY- 
SY5Y cell systems as in this analysis. Furtherm ore , add itional v iability  assays w ould  be 
em ployed  in o rd er to  d e term in e  w h e th e r APP prom otes cell v iability  by protecting  against 
cell toxicity , or by d irectly  enhancing cell viability .
Once th e  exact region o f APP which interacts w ith  copper is identified , fu rth e r  
investigation into  th e  w ay in which this in teraction  b etw een  APP and copper prom otes cell 
v iab ility  w ould  be carried out. Copper chelation experim ents, using th e  ap propria te  APP 
construct fragm ents, w ould  d e term ine  w h e th e r th e  APP constructs w hich w ere  ineffective at 
p rom oting  cell v iab ility  had lost th e  ability to  bind copper, or w h e th e r th ey  had lost th e ir  
ab ility  to  in te rac t w ith  copper in an a lterna tive  w ay. Additional in vitro  experim ents w ould  
also be used to  exam ine th e  APP conform ational changes which take  place during its 
in te rac tion  w ith  copper. This m ay provide an explanation as to  w hy both th e  intracellu lar 
and ex tracellu la r dom ains o f APP are required in o rder to  p ro m o te  cell v iability  during  
exposure to  copper.
Subsequent progression o f these experim ents into mouse m odels w ould assist in 
d eterm in in g  w h e th e r APP prom otes cellu lar v iability  in th e  face o f copper in vivo. If indeed  
APP does enhance cell viability w ith  elevated  copper concentrations in vivo, this w ork could 
have a m ajor im pact on AD, and particularly PCa research.
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If APP d em onstra tes th e  ab ility  to  p ro tect PCa cells against th e  raised copper levels 
fo un d  in th e  tissues and serum  o f cancer patients, then  APP could p o ten tia lly  be used as a 
b io m a rk er fo r prognosis. In th e  even d istant fu tu re , it m ay becom e viable to  th erapeutica lly  
ta rg e t APP in o rd er to  reduce cancer cell viability , as part o f a personally ta ilo red  cancer 
tre a tm e n t program . In add ition , this fu rth e r insight into th e  m olecular biology o f APP w ill be 
invaluable  w hen  w orking  to w ard s th e  d eve lop m ent o f successful AD tre a tm e n ts .
10.9. Sum m ary
In th e  cu rren t study, th e re  seems to be a link b etw een  m alignancy o f PCa cell lines 
and APP expression, a lb e it th e  n um ber o f cell lines analysed was lim ited. There  was also 
som e evidence to  suggest th a t APP processing via th e  non-am yloidogenic path w ay m ay be 
favou red  over th e  am ylo idogenic path w ay as th e  malignancy o f cells increases. H ow ever, th e  
results also suggest th a t, if particu larly  high levels o f APP expression are evident, th e  a -  
secretases m ay becom e saturated  lim iting fu rth e r sAPPa production and, p otentia lly  forcing  
APP dow n th e  reciprocal am ylo idogenic pathw ay.
The data presented in th e  current study also indicate th a t copper enhances th e  
expression o f endogenous APP in D u l4 5  cells. This increased expression m ay potentia lly  
p ro tec t these brain m etastatic  cells from  th e  high levels o f m etal encountered  in this organ. 
This is supported  by th e  fact th a t th e  over-expression o f w ild -type APP enhanced th e  viability  
o f Du 145  cells in th e  presence o f copper. Furtherm ore, th e  over-expression o f APP in th e  
sam e cell line induced EM T-like changes th ereb y  possibly prom oting th e  m etastatic  potentia l 
o f this PCa cell line.
In term s o f th e  m olecular prerequisites fo r th e  ability o f APP to  enhance D u l4 5  cell 
viab ility  in th e  presence o f copper and to  p ro m o te  EMT, it is apparen t th a t only the 695  
am ino  acid isoform  o f th e  p rotein  induces such changes. Furtherm ore, an intact E l CuBD is
216
requ ired  fo r these abilities, suggesting th a t copper binding to  th e  m olecule plays a d irect role  
in th ese  functional capacities. M e m b ran e  anchorage and, in particular, an intact APP 
cytosolic dom ain  are also requ ired  in these respects. M o re  specifically still, it is ap p aren t th a t  
specific tyros ine residues w ith in  th e  APP cytosolic dom ain are requ ired  fo r th e  protein  to  
exert these effects . The role o f th e  cytosolic dom ain in this context m ay w ell be linked to  
changes in ERK1 expression.
The ab ility  o f APP to  p ro m o te  cell viability in th e  presence o f copper has also been  
investigated  in th e  co ntext o f AD by em ploying th e  neuroblastom a cell line, SH-SY5Y. Here, 
both  APP695 and APP770 enhance viability  fo llow ing  copper tre a tm e n t. This activ ity was, again, 
d ep en d e n t on in tact p u ta tive  copper binding histidine residues in th e  E l CuBD and AP 
dom ain  o f th e  p ro te in .
In conclusion, a possible physiological function fo r APP has been identified , w hich  
involves p rom oting  cell survival in th e  presence o f copper and th e  induction o f EM T-like  
changes. The fo rm e r function  w ill, no doubt, be proved to  have an im p o rtan t role in both  
PCa and AD pathogenesis. The la tte r function m ay w ell identify  fu tu re  th erapeutic  
in te rven tio n  sites fo r th e  tre a tm e n t or prevention  o f m etastatic  PCa.
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